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CHAPTER I 
GENERAL INTRODUCTION 

The management of superficial bladder cancer consists of two 
complementary but separate therapeutic goals: to resect the existing 
tumor(s) and thereafter to take measures to prevent tumor recurrence. 
This recurrence rate is considerable: 50-70%. Besides the high 
recurrence rate of superficial bladder tumors there is the tendency of 
these neoplasms to progress in stage and/or grade. Accumulated 
experience shows that especially high grade lesions as well as 
multicentricity of tumors in space and time are most likely to account 
for tumor progression (19). Intravesical instillation of 
chemotherapeutic agents as an adjuvant therapy after surgery, has been 
used for more than twenty years. These agents do appear to reduce the 
recurrence rate as well as to extend the disease-free period. 
In 1976 a new approach to adjuvant therapy for superficial bladder 
cancer was developed by Morales et al (20). They were the first to use 
Bacillus Calmette-Guérin (BCG), an attenuated strain of Mycobacterium 
bovis, the bovine tubercle bacillus, for non specific active 
immunotherapy. The preliminary results were very promising. In their 
study BCG was administered intravesically as well as intradermally. 
Morales started this new avenue for the treatment of superficial 
bladder cancer, making a linkage between the observations made by Сое 
and Feldman and the results of experiments performed by the research 
group of Zbar and Rapp (7, 23). 
In 1966, Сое and Feldman demonstrated that the bladder is a suitable 
organ for the development of delayed type hypersensitivity reactions. 
In immunized guinea pigs, exposed to an antigenic challenge, strong 
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delayed type hypersensitivity reactions were observed in the skin and 
in the bladder. Responses, observed in the kidney, testis or muscle, 
were particularly weaker or absent. So, the induction of antigen 
specific responses in the guinea pig can be demonstrated by eliciting 
a delayed type hypersensitivity reaction not only in the skin, but 
also in the bladder wall. 
The research group of Zbar and Rapp, in a number of experiments, 
investigated the basic principles for successful nonspecific active 
immunotherapy in a guinea pig tumor system (1). In inbred strain 2 
guinea pigs, the line 10 hepatocarcinoma, a chemically induced tumor, 
could be completely cured by intratumoral injection of Bacillus 
Calmette-Guérin. Not only the primary tumor, but also micrometastases 
in the regional lymph nodes, present at the time of treatment, were 
eradicated. Furthermore, the existence of tumor immunity could be 
demonstrated as BCG-cured animals rejected a second tumor cell 
challenge. Optimum results in antitumor activity were obtained if 
certain basic principles were fulfilled: 
1. Tumor burden must be small. 
2. Direct contact between tumorcells and BCG is essential. 
3. The dose of immunizing agent must be adequate. 
4. Tumors respond better, when confined to the parent organ or, in 
case of metastases, when spread is limited to the regional lymph 
nodes. 
Superficial bladder cancer appears to be ideally suited for non-
specific active immunotherapy with BCG. After endoscopic surgery, 
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which remains the initial and the most effective treatment modality, 
only a small tumor burden or no tumor at all, is left in the bladder. 
Intensive contact between possible residual tumor cells and BCG is 
guaranteed by the intravesical instillation of BCG in a watery 
solution. Also from another point of view, immunotherapy seems to be 
indicated for transitional cell carcinoma of the bladder in patients 
with bladder tumors. Tumor associated antigens were demonstrated which 
may be recognized by the host (5). In addition, patients with advanced 
disease, show impaired immunologic responses (6). So, there seems to 
be an interaction between the immune system and the existence of 
bladder tumors. 
In general the clinical results in cancer immunotherapy with BCG are 
disappointing (14). Partly this is due to the fact that in many BCG 
treated tumors the basic principles, advocated by Zbar and Rapp, were 
not fulfilled. At this moment promising preliminary results may 
indicate a role for BCG in the treatment of colon carcinoma (13) and 
in head and neck cancer (2). Only for superficial transitional bladder 
cancer the effectiveness of BCG has been conclusively established (3, 
10, 16, 17, IB, 20, 21). Favorable results also were obtained in the 
treatment of carcinoma in situ of the bladder (4, 11, 12). 
The studies described in this thesis were performed with the BCG 
preparation produced at the Rijksinstituut voor Volksgezondheid en 
Milieu Hygiëne (National Institute of Public Health and Environmental 
Protection), Bilthoven, the Netherlands. BCG-RIVM is a preparation 
with a stable content and a relatively high ratio viable/dead 
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organisms due to its culture method (9). In contrast to most other BCG 
preparations, such as BCG-Pasteur, BCG-Armand Frappier, BCG-Tice and 
BCG-Connaught, the Dutch BCG-RIVM is produced as a homogeneously 
dispersed culture. This culture method yields less subcellular 
products than the classic way of production. There, BCG is cultured as 
a surface pellicle and a mechanical procedure is needed to grind the 
pellicle to a paste in a ball mill. The role of subcellular debris, 
dead bacilli and disrupted BCG particles is unknown. Although 
differences in immunostimulating properties may be present between BCG 
preparations cultured as a surface pellicle or homogeneously 
dispersed, similar antitumoractivity was exerted by these products in 
an experimental tumor model (22). 
For bladder cancer, considering the previous remarks, the following 
questions were tried to be answered: 
1. What are the local and systemic side effects of this therapy in 
animal and man. 
2. What are the morphological effects and what is the immunological 
impact of intravesical administration of BCG-RIVM in animal and 
man. 
3. Is BCG-RIVM effective in superficial bladder cancer and is the 
efficacy comparable to standard intravesical chemotherapy. 
In the following chapters an effort has been made to find the 
answers. Chapter II presents an overview, in which several aspects of 
BCG and its use for superficial bladder cancer therapy during the last 
decade are depicted. The morphological effects of intravesical 
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administered BCG are known, but not reported frequently (8, 15). 
Therefore, in chapter III the histopathological effects of 
intravesical BCG-RIVM instilled in different doses, were studied in 
various organs of the guinea pig. 
Before using BCG-RIVM for cancer therapy, the toxicity of the agent 
has to be investigated. In chapter IV the local and systemic toxicity 
of intravesically and intradermally applicated BCG-RIVM are 
investigated in the dog. Chapter V presents the results of a similar 
study in 30 patients with superficial bladder tumors, with regard to 
local and systemic side effects. These patients received BCG-RIVM 
intravesically and intradermally. 
BCG has a considerable effect on the immune system in which activation 
and suppression may occur. In the guinea pig and in man the 
immunostimulation, mediated by intravesically administered BCG was 
investigated. Results are reported in chapter VI and VII respectively. 
Finally, it has to be established whether intravesical BCG therapy is 
superior to intravesical chemotherapy, which is an effective adjuvant 
therapy after transurethral resection in superficial bladder cancer. 
In chapter VIII the preliminary results are reported of a prospective 
randomized trial in which intravesical immunotherapy with BCG-RIVM is 
compared to an intravesically used chemotherapeutic agent: 
mitomycin-C, in patients with primary and recurrent papillary 
superficial tumors and carcinoma in situ of the urinary bladder. This 
thesis concludes with chapter IX in which the major conclusions are 
discussed and possible research for the future is suggested. 
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CHAPTER II 
ASPECTS OF NON SPECIFIC IWUNOTHERAPY WITH BCG IN SUPERFICIAL 
BLADDER CANCER: AN OVERVIEW. 

INTRODUCTION 
In 1908 Calmette and Guérin were working on the development of an 
antituberculosis vaccine. They observed, while culturing a highly 
virulent strain of the tubercle bacillus of bovine origin in a mixture 
of beef bile and cooked potatoes, that the culture lost its 
characteristic appearance (57). After a transitory increase of 
virulence, the tubercle bacillus was gradually losing its noxious 
characteristics. Thirteen consecutive years and two hundred and thirty 
one transplantings later the tubercle bacillus had been tamed. It had 
become completely harmless to animals but its antigenetic properties 
were unimpaired. In 1921 the first human was vaccinated with the 
attenuated bovine tubercle bacillus: Bacillus Calmette-Guérin 
(BCG). Since then, more then 500 million vaccinations with BCG to 
prevent tuberculosis were performed (57). The use of BCG for the 
prevention of tuberculosis was the most important issue in the first 
half of this century, but later on, the immunostimulating aspect of 
BCG became of interest. 
Pearl, in 1929, reported on the protective effect of tuberculosis 
against cancer (51). In an autopsy study it was observed that a group 
of patients suffering from tuberculosis significantly showed less 
malignant tumors than a control group. Already during the last decade 
of the nineteenth century Coley determined empirically a therapeutic 
principle for the treatment of neoplasms (48). If different tumors 
were treated with bacterial toxins, provoking an acute infection in or 
nearby the tumor site, tumor regression could be observed. Later, the 
- 21 -
working mechanism was interpreted as being a stimulation of the immune 
system causing tumor eradication. Rosenthal, in several studies in the 
mid thirty's, reported that, when the vaccin was administered to 
animals by various routes, not only a specific local response 
appeared, but also a generalized stimulation of the immune apparatus 
could be observed (55, 56). Old and Clarke in the United States and 
Halpern in France demonstrated in 1959 that BCG was able to inhibit 
tumor growth in experimental tumors (19, 50). 
In man immunotherapy with BCG was first used and reported by Mathé et 
al in 1969 (41). They used BCG as an adjuvant therapy in the treatment 
of acute lymphoblastic leukemia. Due to their promising results a 
number of trials were conducted in the U.S.A. and in Europe. However, 
the initial favorable results by Mathé et al. could not be confirmed 
conclusively by other investigators. 
Morton, in 1970, was the first to use BCG successfully by injecting 
the living bacilli intratumorally, in malignant melanoma (47). The 
intratumoral approach was advocated and verified as effective in the 
line 10 hepatocarcinoma, a chemically induced tumor in the guinea pig, 
by Zbar and Rapp (64). The group of Zbar and Rapp showed the 
conditions necessary to obtain immune modulation using BCG as a cancer 
therapy (see chapter I). It was remarkable, however, that important 
information for the development of immunotherapy with BCG in bladder 
cancer in man was obtained without the use of experimental bladder 
tumors. Bloomberg et al. observed a marked inflammatory reaction in 
the bladder of healthy dogs after intravesical instillation of BCG 
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Cellular infiltrates built up from histiocytes and macrophages were 
present in the bladder wall. This observation, together with the 
results of studies by Сое and Feldman (11) and by Zbar and Rapp (64) 
provided the basis for immunotherapy protocols in bladder cancer. 
Morales in 1976 was the first to use BCG as a therapy for superficial 
bladder cancer in man (45). Now, a decade has past and the 
effectiveness of BCG in superficial transitional cell carcinoma has 
been determined conclusively. However, a number of issues on this 
therapy are still questionable or remain unclear. 
No consensus has been reached about the route of administration, 
treatment schedule, optimal dose, and appropriate strain. 
Some of these problems, which are controversial or indistinct will be 
discussed below. 
THE ROUTE OF ADMINISTRATION 
Five different routes of BCG-administration for the treatment of 
superficial bladder cancer have been used sofar: 
- percutaneous administration 
- intralesional injection 
- oral administration 
- intravesical instillation combined with percutaneous administration 
- intravesical instillation alone. 
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Percutaneous administration of BCG in superficial bladder cancer was 
investigated by Martinez-Pineiro and Muntanola (39, 40). Per week ten 
scarifications measuring 5 cm. in length were administered. At each 
treatment a 0.5 ml dose of lyophilized Pasteur BCG vaccin, containing 
300 mg/ml was used. Only 7 patients were treated and many variable 
factors (different periods of treatment, patients with or without 
residual bladder tumors) made it impossible to estimate the value of 
this intensive therapy, but antitumor effect was observed. 
Intralesional administration was performed by the same authors in two 
patients by injection 37.5 mg of BCG into their bladder tumor. One 
patient developed a serious hypersensitivity reaction, resulting in an 
allergic shock. Thereafter this way of administration was abolished. 
The antitumor effect of oral administration of BCG was studied by 
several investigators (36, 49). Netto and Lemos treated 10 patients 
with muscle invasive bladder cancer using fresh BCG of the Moreau 
strain in high doses. A complete response was obtained in 7 patients. 
Lamm used oral administration of the Tice BCG-strain in muscle 
invasive bladder cancer in patients, who could not be treated by 
radiation or cystectomy. Although tumor regression was observed the 
results were less impressive compared with those from Netto and Lemos 
(36). 
Lamm also investigated the effect of oral administered BCG (200 mg 
Tice-BCG, three times per week) in superficial bladder tumors (34). No 
measurable antitumor effect, however, was observed in patients treated 
that way. 
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The most thoroughly investigated route of administration is the 
intravesical instillation, initially combined with percutaneous 
administration. Morales developed an empirically based therapeutic 
scheme which remained the treatment modality in superficial bladder 
cancer for many years (45). He instilled BCG in a watery solution in 
the bladder once weekly, for 6 consecutive weeks. 
At the same time BCG was administered percutaneously at the anterior 
surface of the thigh by a multiple puncture apparatus. After 10 years 
of experience, reviewing his results, Morales reported a complete 
response in SOS of the patients using BCG as a prophylactive therapy. 
In SBS of patients with residual disease and in 77S of patients with 
carcinoma in situ complete response was achieved (46). Two prospective 
randomized clinical trials, using the Morales treatment schedule, were 
conducted in the U.S.A. (9, 32). Responses were in the same range as 
obtained by Morales. Herr et al. used intravesical and percutaneous 
BCG for the treatment of carcinoma in situ. A complete response was 
noted in 65« of the patients (20, 21). 
Excellent results of intravesical BCG instillation without 
percutaneous administration were reported by Brosman (5). In a 
randomized study patients were treated either with thiotepa 
instillations or with BCG instillations. BCG was administered 
intravesically weekly for 12 consecutive weeks, followed by 
instillations every 2 weeks for 3 months and thereafter every month 
until a recurrent tumor developed or the patient had been treated for 
a total period of 2 years. 
No recurrences have been observed in the BCG-treated group, while 
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40 per cent in the thiotepa group suffered from recurrences. 
Treating carcinoma in situ, 94 per cent of the patients were rendered 
free of tumor (7). Brosman stated that patients do not require 
pre-sensitization or continued intradermal inocculations of BCG as he 
observed that all his patients, when treated with intravesical 
instillations alone converted from a negative PPD skin reaction to a 
positive one, after 9 instillations. A problem in these studies was 
the increasing toxicity of the prolonged instillation therapy. 
At the moment percutaneous supportive inocculation has been abandoned 
by most investigators. It is considered as not essential for the 
antitumor effect of BCG immunotherapy in superficial bladder cancer, 
but the value of percutaneous administration has not been conclusively 
established yet. The significance of this issue is subject of study in 
several prospective randomized clinical trials. So, at the moment 
intravesical administration of BCG alone is accepted in most centres 
to be the best route of administration in treating patients with 
superficial transitional cell carcinoma of the urinary bladder. 
The PPD skin test conversion, which indicates a systemically induced 
immunisation against BCG, seems to show a correlation to treatment 
results (27). 
Most investigators noted that patients, whose PPD skin test converted 
from negative to positive after BCG treatment, were the best 
reaponders to the therapy (10, 18, 27). Badalament et al., however, 
observed that patients with a reactive tuberculin test before and 
after б weeks BCG had significantly less tumor recurrences than 
patients with different PPD skin test results (2). 
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TREATMENT SCHEDULE 
Till 1985 the over-all complete response rate for BCG therapy of 
papillary carcinoma and carcinoma in situ tumors obtained from all 
published reports is approximately 67 per cent (17). 
The cumulative experience with BCG as a non-specific immunotherapy for 
superficial bladder cancer is depicted in table 1. 
Table 1: Cumulative BCG experience in superficial bladder tumors. 
INVESTIGATOR 
PROPHYLAXIS: 
Morales et al. (46) 
Lamm et al. (35) 
Ріпзку et al. (52) 
Brosman et al. (6) 
deKernion et al. (28) 
Haaff et al. (18) 
RESIDUAL: 
Douville et al. (14) 
Morales et al. (46) 
Martinez-Pineiro et al. (39) 
Brosman et al. (6) 
deKernion et al. (28) 
Schellhammer et al. (59) 
Haaff et al. (18) 
CIS: 
Morales et al. (46) 
Lamm et al. (35) 
Brosman et al. (6) 
Herr et al. (21) 
deKernion et al. (28) 
Haaff et al. (18) 
NO. OF PATIENTS 
46 
53 
25 
53 
22 
29 
6 
24 
5 
27 
22 
24 
13 
26 
77 
33 
47 
19 
19 
WITHOUT RECURRENCE (S) 
5055 
12% 
32Ä 
88% 
64Й 
(Л% 
58% 
0% 
63% 
36% 
71% 
69% 
77% 
75% 
94% 
68% 
68% 
68% 
The response rate for prophylaxis after TUR, for residual disease 
after TUR and for carcinoma in situ is presented separately. It must 
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be strained that remarkable differences exist in duration of 
follow-up, used strain, therapeutic regime and route of 
administration. 
It was clearly demonstrated that BCG therapy is superior to standard 
endoscopic resection alone (31, 45) to adjuvant intravesical 
chemotherapy with thiotepa (9) or doxorubicin (35). Although the 
response rate to BCG appears to be superior to other forms of 
intravesical therapy, a considerable number of patients fail when only 
the initially proposed 6 weeks BCG-regimen is used. 
An appropriate adjuvant therapy for those patients failing one course 
of 6 weeks BCG has not been determined yet. At the moment two 
fundamental treatment schedules have become of interest and both 
schedules have presented favorable tumor responses compared with an 
instillation scheme of б weeks only. (5, 7, 10, 18). 
The first schedule is the so called maintenance therapy, first 
advocated by Brosman (5). This treatment regimen consisted of 
intravesical instillations once per week for 6 weeks, biweekly for 3 
months and monthly until recurrence or the completion of a 2-year 
course. The response rate was far more favorable than ever previously 
reported. In a randomized trial patients with superficial bladder 
tumors were treated with thiotepa or BCG intravesically. Twentyseven 
patients were allocated to the BCG group and 12 additional patients 
were treated after they had failed previous thiotepa therapy. These 39 
patients showed no recurrences. In treating 33 patients with carcinoma 
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in situ, 31 patients (94 per cent) were rendered free of tumor (mean 
follow-up 5.2 years). However, the local and systemic toxicity of this 
prolonged therapy was severe and significantly worse than in other 
protocols (33). Regarding the increased toxicity, the maintenance 
therapy as used by Brosman, can be considered in a number of patients 
as an unnecessary over-treatment. On the other hand this therapy may 
be suitable for patients with strongly recurrent tumors, resistant to 
any previous treatment. 
The second treatment schedule has become of interest during the last 2 
years. It was reported that adding a second 6-week course of BCG 
therapy for those patients failing the first course, could improve the 
response rate from approximately 60% after a single 6-week course up 
to approximately 80& following the second 6-week course (10, 18). This 
over-all response rate approaches that reported by Brosman. Moreover, 
the 2-course treatment could spare unnecessary toxicity for those 
patients who respond rapidly to BCG therapy and appears to provide 
adequate therapy for those patients needing more extensive treatment. 
Another point that must be emphasized concerning multiple BCG 
treatments is the inability to identify patients who will not respond 
to BCG and who are at risk for invasive bladder cancer while being 
treated with maintenance BCG therapy or multiple courses of BCG. 
Catalona et al.conducted a risk-to-benifit analysis of repeated 
courses of intravesical BCG therapy (10). Their results suggest that 
many patients who failed 1 course of therapy respond to a second 
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course of 6 weeks. On the other hand the risk of developing invasive 
cancer or metastases in patients who have failed 2 courses exceed the 
prospects of eradicating the superficial cancer with further BCG 
treatment. In 100 consecutive patients treated with repeated 6-week 
courses of BCG they observed a 30 per cent risk of developing invasive 
cancer and a 50 per cent risk of metastatic disease in those patients 
who relapsed after 2 courses of BCG. In other words to treat patients 
with more than 2 courses may be dangerous with regard to development 
of invasive disease. However, it remains unclear whether or not 
patients developing invasive cancer after 2 courses of BCG should have 
done so, if they were treated with maintenance therapy from the start. 
Although most investigators are convinced that a single 6-week course 
of intravesical BCG is a suboptimal therapy, Badalament, however, in a 
prospective randomized study comparing maintenance versus 
non-maintenance therapy, could not demonstrate a significant 
difference between the two groups. Patients receiving maintenance 
therapy had similar recurrence and progression rate as those who were 
treated with a single 6-week course (2). It must be stated, however, 
that patients starting with maintenance therapy did so, 5 to θ weeks 
after completing the initial 6-week course, thus lacking intravesical 
instillation up to two months between the end of the initial 6-week 
course and the start of the maintenance scheme. 
Prognostic factors in each individual patient should be considered in 
order to decide which treatment schedule should be used from the 
start. Summarizing it can be stated that more prospective randomized 
studies are needed to establish the optimal treatment regimen. 
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VIABILITY, DOSE AND APPROPRIATE STRAIN 
Comparative studies of different strains of BCG in a murine model 
revealed that the immunogenicity of a BCG-preparation was related 
directly to the viability of the vaccin (38). Shapiro, in a murine 
bladder tumor model observed variations in the viability and efficacy 
of different lots of BCG (60). 
The immunizing efficacy of a BCG vaccin depends on at least 2 factors: 
the number of bacilli and the ability of the organisms to multiply in 
vivo, that is the viability (13). Kelley et al. investigated the 
effect of BCG viability on treatment results in human superficial 
bladder cancer (27). They noted differences in the number of 
colony-forming units between different lots of BCG of the same strain 
and among different strains. In the Pasteur strain (Institute Armand 
Frappier, Quebec, Canada) the number of colony-forming units differed 
from 6x10^ till 1x10^2 per ampule and in the Tice strain (Institution 
Tuberculosis Research, Chicago, U.S.A.) from ЗхІО? till 4.6x10^ per 
ampule. In general one or two ampules are used for intravesical 
instillation. Treatment failures occurred more frequently among 
patients who received a preparation with low viability. Patients 
treated with 6x10^ c.p. per ampule had recurrent tumors in 71 per 
cent, while those patients treated with 3x1011
 c >
p . p
e r
 ampule showed 
recurrences in 25 per cent. 
The dose of BCG in the two BCG strains mostly used for intravesical 
instillation (Pasteur, Quebec and Tice, Chicago) is 120 mg per 
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instillation. The BCG preparations are lyophilized and dissolved in 50 
ml of saline. The amount of culturable particles per vial seems to be 
more important than the dry weight or biomass in the preparation. It 
was demonstrated in an experimental model that the antitumor activity 
increased with the dose, but after an optimal dose has been reached, 
further augmentation results in decreasing antitumor effect (36). 
A dose of 5x100 till 5x10' c.p. is considered to be the optimal dose, 
but again no conclusive evidence has been reached so far on this 
subject. 
Sofar the results of 6 strains used for immunotherapy in superficial 
bladder cancer have been published. These preparations are Pasteur 
(Quebec, Canada), Tice (Chicago, U.S.A.), Connaught (Toronto, Canada), 
Pasteur (Paris, France), Glaxo (Greenford, England) and Moreau 
(Sao Paulo, Brasil). 
Originally, most of these preparations were derived from the Pasteur 
strain in Paris. The Pasteur- (Quebec) and the Tice strain have been 
investigated most thoroughly in bladder cancer. Few reports have been 
published on results obtained by the preparations of Glaxo and 
Moreau. The Moreau strain was administered in fresh form orally in few 
patients and the Glaxo strain turned out to be of weak immunogenicity, 
probably due to a moderate biomass and viability in the vials used 
initially (46, 49). It seems that the efficacy of Pasteur (Quebec), 
Tice and Connaught BCG is comparable, but no prospective randomized 
clinical trials have been conducted sofar to determine which strain is 
the most appropriate one. 
- 32 -
From 19Θ5 onwards, a Dutch BCG-preparation produced at the 
Rijksinstituut voor Volksgezondheid en Milieuhygiene (RIVM), the 
National Institute of Public Health and Environmental Hygiene has been 
used for the treatment of superficial bladder cancer in the 
Netherlands. This strain has been derived from a seed lot of the 
French Pasteur strain in 1964. 
In culturing BCG-bacilli the mycobacteria usually are grown as a 
pellicle on the surface of a liquid medium. At harvesting the pellicle 
is ground in a ball mill to a paste. This results in a preparation not 
containing live BCG bacilli only, but also dead micro organisms and 
abundant subcellular debris. However, another method of culture, used 
at the RIVM, the Netherlands, is to grow the BCG-bacteria in a 
homogeneously stirred deep culture system. Higher viability per mg dry 
weight can be obtained if a detergent is added to the culture medium. 
This culture method ensures a relatively high ratio of viable 
organisms and a small quantity of subcellular debris and dead 
bacilli. After both methods of culture, the vaccines are harvested and 
can be lyophilized. Although differences in immunostimulating activity 
and antitumor activity have been observed, BCG-preparations cultured 
by these different methods show similar antitumor activity (58). The 
antitumor potency of BCG-RIVM conclusively was established in 
different animal tumor systems e.g. murine fibrosarcoma (58), line 10 
hepatocellular carcinoma in the guinea pig (25), bovine ocular 
squamous cell carcinoma (29) and equine sarcoid (30). 
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TOXICITY 
Local and systemic toxicity may occur after BCG immunotherapy. 
Important factors for these side effects are the route of 
administration, the dose of BCG and the number of repeated 
administrations. In superficial bladder cancer BCG has been 
administered orally, percutaneously and intravesically, of which the 
latter has proved to be the most important route. Only few patients 
have been treated orally (36, 49). No complications or side effects 
were reported, if the oral route was used. 
The local side effects of percutaneous BCG application are well known 
from the extensive experience with BCG vaccination for the prevention 
of tuberculosis (61). More than 500 million vaccinations have been 
performed all over the world (57). The post-vaccination reaction 
normally consists of erythema, in most cases followed by the formation 
of a crusted nodule, which may show ulceration. Moderate swelling of 
the regional lymph nodes is regarded as a normal reaction. As local 
complications of intradermal application are considered persistent 
ulceration, localized abcess, granuloma formation and regional 
lymphadenitis (61). 
Systemic complications after intradermal application caused by 
generalized BCG infection have rarely been observed (61) and if they 
are present, patients often suffered from immunodeficiency syndroms. 
Hypersensitivity reactions, arthritis, granulomatous hepatitis and 
pneumonitis have been reported (26). 
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The toxicity of intravesical instillation of BCG is of major 
importance in the treatment of superficial bladder cancer. The 
complications of intravesical BCG in 1278 patients were reviewed by 
Lamm (33). This author compiled the data of 195 patients treated by 
himself and from 1083 patients reported by 13 different investigators 
in the U.S.A. and Europe. These patients were treated with 5 different 
strains of BCG. No difference in the incidence or severity of side 
effects were observed in patients treated with Pasteur (Armand 
Frappier), Tice and Connaught preparations. Local side effects, 
restricted to the bladder were seen frequently. More than 90 per cent 
of the patients suffered from cystitis with frequency and dysuria. 
Hematuria was seen in 43 per cent, sometimes in severe form (0.5%) 
requiring catherization. The histological substrate of the cystitis 
consists, on biopsy, of acute and chronic inflammation with granuloma 
formation in the stroma of the bladder wall. Patients generally have 
symptoms of cystitis for a short period and find relief with 
non-steroidal anti-inflammatory agents. The bladder irritability 
usually begins after 2 or 3 instillations and may persist for about 2 
days. The vesical symptoms however increase with the frequency and 
duration of BCG administration. 
During maintenance therapy (monthly BCG) it is sometimes necessary to 
reduce dose and to treat patients with anti-tuberculosis drugs for 
these severe local side effects. 
Moderate systemic side effects were observed as well consisting of 
fever till 390C (28 per cent), malaise (24 per cent) and nausea (B per 
cent) (33). These side effects generally will subside spontaneously. 
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Severe local and systemic side effects, regarded as complications, 
were encountered in about 5% of all patients (see table 2). 
Table 2; Complications of intravesical BCG-instillation in 127Θ 
patients with superficial bladder cancer (33). 
Fever more than 39°C 
Granulomatous prostatitis 
BCG pneumonitis/hepatitis 
Arthritis/arthralgia 
Skin rash 
Ureteral obstruction 
Epididymo-orchitis 
Hypotension 
Cytopenia 
Contracted bladder 
3.9% 
1.3Й 
0.9Ä 
0.5% 
0.4% 
0.3Ä 
0.2S 
0.1Й 
O.U 
0.25Í 
If local or systemic complications, as described before, are 
encountered patients must be treated with antituberculous drugs. 
In case of severe or prolonged irritative vesical symptoms, fever, 
chills, or malaise it is recommended to lower the dose of BCG till 
half the normal dose and to treat the patients with isoniazide 
(I.N.H.) 300 mg per day starting one day before instillation and 
continuing for 3 days or until symptoms resolve. If severe systemic 
complications are present BCG administration must be withholded and a 
combination antituberculous therapy is started. This therapy consists 
of isoniazide 300 mg per day and rifampicin 600 mg per day for 3 
months. Fatal reactions to BCG in general can occur. In vaccination 
programs for tuberculosis one death per 50 million patients was 
observed (37). A higher mortality rate (1 death per 12,500 patients) 
occurred when BCG was administered as an immunotherapy for cancer. 
Almost all patients, however, had pre-existing defects in cellular 
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immunity. In the literature, until now, no fatalities have been 
reported in patients with bladder tumors treated with intravesical 
BCG. However, Lamm has reported recently one death after intravesical 
BCG administration (36). If a life threatening BCG infection or 
anaphylaxis should occur patients must be treated with 500 mg 
cycloserine twice daily for 3 days in addition to the combination 
anti-tuberculous therapy because rapid action of this drug may be life 
saving. 
In summary, it can be concluded that intravesical BCG administration 
for superficial bladder cancer generally is well tolerated and has 
produced no serious complications in more than 95 per cent of the 
patients treated. However, significant morbidity can occur and 
therefore urologists should be familiar with antituberculous therapy. 
EFFECTOR MECHANISM(S) OF BCG IN CANCER 
Of all issues concerning BCG-immunotherapy the most intruiging problem 
remains the unclarified mechanism(s) by which BCG exerts its anti­
tumor activity. Although second and third generation of immuno-
therapeutics (recombinant DNA products) are available nowadays, BCG 
probably remains the most important Biologic Response Modifier for 
bladder cancer. It has the potential to act as a non-specific immuno-
potentiator most likely, not by a single mechanism, but by a variety 
of actions involving a range of cells of the immune system including Τ 
and В lymphocytes, macrophages, К (killer)-, and NK (natural killer) 
cells. Three different effector mechanisms have been proposed (42). 
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1) Live BCG provokes immediately an inflammatory response in which 
macrophages, being the effector cells, may be activated directly by 
BCG without the participation of T-cells. 
2) A delayed type hypersensitivity reaction in which macrophages 
ingest BCG and additionally stimulate BCG-sensitized T-cells to 
produce lymphokines, which results in a further cascade of 
activation of parts of the immune system. 
3) The induction of tumor-specific immunity in which BCG stimulated 
proliferating T-cells may interact with macrophages that have 
ingested both BCG and cellular debris of tumor cells. 
An overview of the different possibilities of BCG to interact with the 
immune system is presented in fig. 1 (according to De Jong (26). 
What the eventual result of BCG administration will be, stimulation or 
suppression of the immune system, depends on multiple factors such as 
the genetic background, strain of BCG, administered dose and the route 
of administration. However, all interactions of BCG with the immune 
system depicted in fig. 1, may occur. 
The enhancing effect of BCG on antibody synthesis was frequently 
demonstrated. It can be the result of a direct effect on B-cells or 
indirectly via helper T-cells (Θ). When BCG is administered 
intravenously or subcutaneously the concentration ("trapping") of 
lymphocytes in lymph nodes is increased (63). This trapping phenomenon 
is T-cell dependent. 
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Fig. 1: Possible interactions of BCG with the immune system (from De 
Jong (26)). 
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Cell mediated immunity to thymus dependent antigens is enhanced by BCG 
(15) and furthermore BCG appears to be mitogenic for T-cells (44). BCG 
may induce enhancement of the immune system, but also suppression can 
occur. Part of the suppression may be the effect of induction of 
T-suppressor cells (12). It was demonstrated that BCG increases 
metabolic activity, release of extracellular enzymes, migration and 
pinocytosis of macrophages (54). 
BCG-activated macrophages can attack tumor cells directly or by 
mediating cytotoxic T-cell precursors (1, 43). Spleen macrophages, 
activated by BCG, produce enhanced lymphocyte activating factor 
(L.A.F.) so called interleukin 1. 
Besides macrophages, BCG enhances the activity of non Τ, non В 
lymphoid cells which show non specific cytotoxic activity against 
tumor cells, the so called natural killer cells (NK-cells) (24, 62). 
Finally, antibody dependend cellular cytotoxicity (A.D.C.C.) was 
enhanced, after injection of BCG, in two kinds of spleen cell 
populations, probably macrophages and K-cells (53). 
The mentioned activities and interactions by which BCG may exert its 
antitumor effect, are extremely complicated and not fully understood 
yet. 
In experimental and spontaneously arising animal tumors, BCG has 
conclusively proved to have the potency to inhibit tumor growth and 
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even to eradicate tumors completely. The local presence of BCG and the 
induction of a granulomatous reaction, together with activation of the 
mononuclear phagocytic system is regarded to be important. 
The conditions considered necessary for optimal BCG immunotherapy as 
advocated by Zbar and Rapp (64)are present in superficial bladder 
tumors (see chapter I). 
At this moment, the clinical use of BCG for non-specific immunotherapy 
appears to be indicated only in superficial bladder cancer. In other 
tumors, like carcinoma of the head and neck region (3) and melanoma 
(47) promising preliminary results were obtained, but the efficacy of 
BCG-therapy was not conclusively determined. 
However, recent data show that treatment of colon carcinoma with a 
mixture of BCG and autologous tumor cells may be successful (22, 23). 
For superficial bladder cancer the next decade has to give an answer 
how to use BCG successfully. More controlled clinical trials are 
needed to obtain knowledge about optimal treatment of superficial 
bladder tumors with Bacillus Calmette-Guérin. 
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SIMMRY 
Intravesical BCG is used as an adjuvant therapy after transurethral 
resection for superficial bladder cancer in man. The mechanism(s) of 
its antitumor activity are not known. The aim of this study was to 
characterize the histomorphological changes in various organs of 
guinea pigs after intravesical BCG administration. The BCG-preparation 
used was BCG-RIVM, a Dutch BCG preparation. Instillations were 
performed in previously undamaged bladders weekly for 6 consecutive 
weeks and lasted 30 minutes or 1 hour. Different doses were used 
ranging from 10' culturable particles (c.p.) to 5x10^ c.p. of BCG. 
After б weeks, animals were killed and postmortem examination was 
performed. The bladder wall, retroperitoneal lymph nodes, spleen, 
liver, lungs and distant lymph nodes were examined histologically. The 
BCG therapy, with a dose of 106 culturable particles and higher, 
induced an inflammatory reaction consisting of mononuclear infiltrates 
in the subepithelial tissue of the bladder wall. In approximately 50% 
of the animals investigated, the infiltrates were accompanied by 
non-caseating granulomatous lesions indicated by the presence of 
epithelioid cells. In general, the epithelial layer of the bladder 
showed no visible alterations. Similarly, a granulomatous inflammatory 
reaction was observed in the first draining retroperitoneal (iliac) 
lymph nodes of the bladder. Granulomatous lesions were occasionally 
present in liver and lung. In 3 of the 29 animals investigated, 
lesions were present both in liver and lungs, and in 2 of these 3 
animals a granulomatous reaction was observed in spleen and distant 
lymph nodes indicating a generalized inflammatory response induced by 
BCG. 
- 53 -
No micro-organisms were detected by Ziehl-Neelsen (ZN) staining or 
culture in Löwenstein-Jensen medium in the first draining (iliac) 
lymph nodes of the bladder or in the spleen. 
In this study we found that BCG could induce inflammatory reactions in 
the bladder wall after its introduction into the previously undamaged 
bladder. Ulceration of the epithelium covering the mononuclear 
infiltrates was not observed. Occasionally a generalized inflammatory 
response to BCG was present in the animals investigated. 
INTRODUCTION 
Bacillus Calmette-Guérin (BCG) has received much attention for its 
important role in the prophylaxis and treatment of superficial bladder 
carcinoma and primary carcinoma in situ of the urinary bladder in 
man. After the initial study of Morales et al. in 1976, several 
investigators published favorable results obtained with BCG (Lamm et 
al. 1980, Brosmann 19Θ2, Herr et al. 1983, Haaff et al. 1985, 
Badalament et al. 1987). The exact mechanisms by which BCG exerts its 
antitumor activity have not yet been revealed. However, the viability 
of BCG seems to be important for its efficacy (Kelley et al. 1985). 
Relatively few descriptions of the morphological changes induced by 
BCG in the bladder are reported. Granulomatous inflammatory reactions 
and mononuclear cell infiltration in the subepithelial layer of the 
bladder have been described in man (Lage et al. 1986). These 
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inflammatory reactions were frequently accompanied by epithelial 
ulceration. In dogs, minor inflammatory reaction resembling early 
granulomas, were present after combined intravesical and intradermal 
BCG administration (Van der Meijden et al. 1986). Intravesical 
instillation only, induced minimal changes into the dog bladder, 
whereas extensive inflammation was present after injection of BCG into 
the bladder wall (Bloomberg et al. 1975). In a study in rats, part of 
mononuclear infiltrate present after repeated BCG instillations, could 
be identified as Τ cells (Guiñan et al. 19B6). The granulomatous 
reactions were non-caseating. 
We used guinea pigs as a model to study the histopathological changes 
induced in the bladder, the regional iliac lymph nodes, the spleen, 
liver and lungs after intravesical administration of different doses 
of BCG. The guinea pig was chosen because this animal is known to be 
very susceptible to mycobacteria (Rosenthal 19Θ0). Therefore, the 
guinea pig is widely used for the diagnosis of tuberculosis in man, 
and in control tests for the absence of virulent mycobacteria in BCG 
vaccins (WHO 1979). Furthermore, the guinea pig also shows delayed 
type hypersensitivity reactions inside the bladder wall after a second 
intravesical antigen challenge (Сое and Feldman 1966). It is not known 
whether BCG-bacilli are capable of penetrating the intact bladder wall 
and of dissemination. Therefore, in addition we investigated whether 
BCG-bacilli or parts of it were present in the bladder wall, in the 
regional retroperitoneal (iliac) lymph nodes and spleen after a course 
of six weekly bladder instillations. 
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MATERIAL AND ÍCTHOOS 
Апіяаіз 
Random bred female albino and inbred female Sewall-Wright strain 2 
guinea pigs, age 4-6 months, weighing 400-600 g were used for the 
experiments. The animals were obtained from the laboratoy animal 
facility (Dr. B.C. Kruijt) of the Rijksinstituut voor Volksgezondheid 
en Milieuhygiëne (RIVM, National Institute of Public Health and 
Environmental Protection, Bilthoven, the Netherlands). Animals were 
fed guinea pig ration and water ad libitum. During the experiments, 
animals were housed separately. Cages were covered with plastic foil 
to prevent contamination with faeces or urine from neighbouring guinea 
pigs. 
Bacillus Calaette-Guérin (BCG) 
The BCG used for intravesical administration was produced at the RIVM 
(Laboratory for Vaccine Production, Dr. R.H. Tiesjema) for cancer 
immunotherapy (Ruitenberg et al 1981, De Jong et al. 19 4). BCG-RIVM 
has shown antitumor activity both in laboratory animal tumor systems 
(De Jong et al. 1984) and in spontaneously occurring bovine ocular 
squamous cell carcinoma (Klein et al. 1982, Misdorp et al. 1985) and 
equine sarcoid tumor of the skin (Klein et al. 1986). BCG-RIVM, 
originally obtained as a seed lot from the Institute Pasteur (Paris, 
France) is cultured in a homogeneous deep culture suspension under 
continuous stirring, and is freeze dried after harvesting. In this 
study BCG-RIVM batch no. 602, containing 6x10? culturable particles 
(c.p.) in 0.54 mg per vial was used. 
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Experiaental design 
In four separate experiments, the histopathological aspects of 
intravesical BCG administration were studied in random bred guinea 
pigs. In three additional experiments, in which the immune reactivity 
of inbred guinea pigs was studied after intravesical BCG 
administration (data reported elsewhere), the bladder, liver and lungs 
were removed for histologic examination. Animals were anaesthesized by 
intramuscular injection of 0.2 ml per 100 g body weight of a mixture 
of 20 mg/ml Ketalar® , 2.5 mg/ml Rompun® and 0.05 mg/ml atropine. The 
bladders were catheterised with teflon sheaths of Abbocath-T 20 gauge 
infusion needles (Abbott Ireland Ltd., Sligo, Ireland). The freeze 
dried BCG was dissolved in 1 ml of buffered saline 0.9% and diluted to 
the desired concentration, directly before use. After an initial 
dose-response study with doses of BCG ranging from 105 to 5x10^ с р . , 
additional experiments were performed with a dose of 5x10? c.p. of 
BCG. The BCG was administered intravesically in a volume of 1.0 ml in 
an empty bladder, and kept in the bladder for 0.5 or 1 hour by leaving 
the closed sheath in the bladder. In pilot experiments the normal 
bladder capacity was found to be 3 to 5 ml. Thereafter, the bladders 
were emptied by gentle compression at the suprapubic region. The 
procedure was repeated weekly for six consecutive weeks. After the 
instillation procedure, no signs of tissue damage, such as blood 
present on the catheter, were observed. In each experiment groups of 
4-5 animals were treated. Control animals were instilled 
intravesically with a placebo preparation. At week 7 animals were 
killed by exposure to a mixture of 75% CO2 and 25% O2. 
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Histological aethods 
Postmortem examination was performed immediately after death of the 
animals. The bladder was filled transurethrally with 3 ml fixative, 
consisting of 4й (w/v) formaldehyde in 0.067 M-Sörensen buffer, 
pH 6.9, and thereafter the urethra was ligated. This method provided 
intensive and direct fixation of the bladder lining. Retroperitoneal 
(iliac) and axillary lymph nodes were identified and resected. In the 
pelvic region and along the abdominal aorta, all visible lymph nodes 
were removed. In one experiment, half of the draining (iliac) lymph 
nodes, and half of the spleen were fixed in the b% formaldehyde 
fixative, and the other half of the lymph nodes and of the spleen were 
examined for the presence of viable mycobacteria. For culturing the 
mycobacteria, part of the lymph nodes were blended and centrifuged at 
150 G. The supernatant of this low centrifugation step was centrifuged 
at 4000 G. The sediment obtained was treated with 1 N sulfuric acid 
and washed with physiological saline. Subsequently the sediment was 
inoculated on Löwenstein-Jensen medium and incubated for at least θ 
weeks at 36°C. 
For histological examination, formaldehyde-fixed tissue from the 
bladder, retroperitoneal and axillary lymph nodes, spleen, liver and 
lungs was embedded in paraplast. Sections (4 μιη thick) were prepared 
and stained with hematoxylin and eosin (HE), and by the Ziehl-Neelsen 
(ZN) method for the detection of acid fast bacteria. When a dose of 
1θ5 BCG or less had been used, only the bladder was examined histo­
logically. Bladder sections were prepared at three different levels 
(cranial, medial and caudal part) of the organ. Histomorphological 
findings were evaluated in a semiquantitative way. 
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Fig. Is Micro-
scopical anotamy 
of guinea pig 
bladder showing 
transitional 
epithelial cells 
lamina propria and 
muscular wall. 
HE staining x80. 
Fig. 2: Mild 
inflammatory 
reaction in the 
bladder after 
intravesical BCG 
(5x107 c.p.) 
administration 
(once a week for 
six consecutive 
weeks). 
HE Staining x320. 
See also Table 1. 
Fig. 3: Severe 
inflammatory 
reaction in the 
lamina propria of 
the bladder after 
intravesical BCG 
(1x107 c.p.) 
administration 
(once a week for 
six consecutive 
weeks). 
Note cluster of 
epithelioid cells 
indicating a 
granulomatous type 
of reaction. 
HE staining x200. 
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RESULTS 
Detection of Mycobacteria 
After twelve weeks of incubation at 36°C, no bacterial colonies were 
detected in Löwenstein-Jensen cultures from the (iliac) lymph nodes 
draining the bladder and from the spleen. In tissue sections stained 
by the Ziehl-Neelsen method, no BCG bacilli, recognisable as slightly 
curved acid fast rods, were found at the surface or in the epithelial 
or muscle layer of the bladder, nor in the iliac lymph nodes. 
Histopathology after intravesical BCG actainistration 
Bladder 
The microscopical anatomy of the guinea pig bladder is shown in 
Fig. 1. The mucosal covering consists of 4 to 5 layers of transitional 
epithelial cells and so-called 'umbrella' cells are present. The 
basement membrane is well established and intact. Underlying the 
epithelium is the submucosa or lamina propria, containing blood 
vessels. Underlying the submucosa is the muscular wall consisting of 
smooth muscle tissue arranged in criss-cross bundels, the outside of 
the bladder is covered by a serosal layer. Perivesical fatty tissue is 
present locally in the subserosal area. 
Intravesical instillation of BCG-RIVM induced an inflammatory reaction 
in the bladder wall of the guinea pig. This imflammatory response 
consisted of a mononuclear infiltrate varying from small accumulation 
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of lymphoid cells to larger, more distinct areas (Fig. 2) composed of 
mononuclear cells with both lymphoid and histiocytic characteristics. 
Occasionally lymphoid follicles were observed in the larger 
inflammatory lesions. In approximately 50% of the animals, epithelioid 
cells, forming non-caseating granulomas, were present (Table 1, Fig. 
3). Occasionally, multinucleated giant cells were observed in the 
larger granulomatous reactions. Generally, the mucosal layer covering 
the inflammatory reactions, remained intact. In one case, the 
mononuclear inflammation extended into the covering epithelium, and it 
was accompanied by slight focal erosion, intra-epithelial haemorrhage 
and accumulation of neutrophilic granulocytes. 
There seemed to be a correlation between the dose of BCG administered 
intravesically, and the composition and extent of the inflammatory 
reactions. In the bladder wall of animals treated with 10^ c.p. of BCG 
or less, no pathological lesions were observed. When 106 c.p. BCG were 
administered, mild reactions in the submucosal connective tissue were 
present, consisting of small accumulations of lymphocytes, whithout 
epithelioid cells. When the intravesical dose of BCG was increased to 
IO? ср., the same morphological changes were present in the lamina 
propria, but were more frequent. Moreover, after treatment with 1x10' 
or 5x10? c.p. BCG, epithelioid cell clusters and well-developed 
non-caseating granulomas were observed. In bladders from animals 
treated with the highest dose (5x10? c.p.) the most severe 
inflammatory reactions were present. However, in 3 of these 30 
animals, no histopathological reactions were observed (Table 1). In 
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one animal the granulomatous reaction infiltrated through the muscle 
bundels into the perivesical fatty tissue. 
Table 1: Semiquantitative evaluation of inflammatory reaction in the 
bladder after intravesical ВС G administration. 
Treatmenta No reactionb Inflammatory Infammatory reaction with 
reactionb,c epithelioid cellsb.c.d 
mild moderate severe mild moderate severe 
Placebo 30/34 4/34e 0/34 0/34 0/34 0/34 0/34 
BCG 3/30 13/30 9/30 5/30 3/30 7/30 4/30 
8
 BCG (5x107 сp.) and placebo were administered once weekly for six 
consecutive weeks and remained in the bladder for 1 hour. 
b Number of animals with/whitout reaction and the total number of 
animals examined. 
c
 The lesions were scored semiquantatively: - mild: occasionally 
lymphocytes, or occasionally epithelioid cells in larger infiltrates 
- moderate: small accumulations of lymphocytes, or epithelioid cells 
were regularly present; - severe: large areas with cellular 
infiltrate, or large granulomas. Each animal was scored once i.e. 
under the most severe category of the observed lesions. 
d When lesions were accompanied by epithilioid cells animals were 
doubly scored. In total 14 of 30 animals investigated showed an 
inflammatory reaction in the bladder wall accompanied by epithelioid 
cells indicating a granulomatous reaction. 
e
 One animal showed a mild inflammatory reaction consisting only of 
neutrophilic granulocytes. 
In addition, we investigated whether the inflammatory reaction 
resolved after completing the six weeks treatment with BCG. Both at 
one month and at three months after completing the BCG (dose 5x10' 
c.p.) therapy, in 2 out of 4 animals investigated lesions were 
observed (data not shown), consisting of mild to moderate mononuclear 
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infiltrates, which in one animal were accompanied by epithelioid 
cells. 
Regional (iliac) lymph nodes 
In animals receiving intravesically 10^ c.p. BCG or more, the primary 
iliac lymph nodes draining the bladder were enlarged to at least twice 
the normal size. No enlargement was noticed in the iliac lymph nodes 
of animals which were treated with IO? c.p. BCG intradermally and in 
animals treated with 0.9% saline intravesically. Histologically, the 
iliac lymph nodes in animals treated with 10^ BCG showed besides 
regions of normal lymph node architecture, clusters of epithelioid 
cells and small granulomas located predominantly in the paracortex 
(Table 2). Lymph nodes from the axillary and para-aortal region showed 
no histological changes. 
Using higher doses of BCG (ІхЮ? and 5x10^ с р . ) , epithelioid cells 
were clearly present varying from small clusters to large typical 
granulomatous lesions (Fig. 4). These granulomatous reactions showed 
the same histological pattern as those present in the bladder wall. 
The histiocytes in a granuloma contained a pale nucleus and an large 
amount of cytoplasm. Langhans-type giant cells were sometimes present 
within the lesions. Occasionally, in the larger granulomas central 
necrosis (caseation) was noticed (Fig. 4a). Neutrophilic leukocytes 
were not encountered. Table 2 shows a semiquantitative evaluation of 
the granulomatous reactions in the primary draining (iliac) lymph node 
after intravesical BCG administration. 
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Table 2: Semiquantative evaluation of BCG-induced lesions in iliac 
lymph nodes after intradermal and intravesical BCG-RIVM 
administrationa. 
Dose Nb No Mild Moderate Severe 
reaction0 reaction^ reaction6 reaction^ 
IO7 BCG intradermal 4 
Saline intravesical 4 
106 BCG intravesical 4 
10 7 BCG intravesical 4 
5x107 BCG intravesical 3 
a
 Bladder instillations were performed once weekly for six consecutive 
weeks. 
Ь N = number of animals 
c
 Microscopically no histological alterations present. 
° Mild reaction, few small epithelioid cell clusters, no granulomas. 
e
 Moderate Reaction, epithelioid cell clusters and granulomas. 
f Severe reaction, large granulomas with central necrosis. 
Я Number of animals with/without reaction and total of animals examined. 
h - = number of animals in this category. 
Other organs 
At autopsy no gross pathologic changes were observed. In addition to 
the bladder and regional lymph nodes, liver, lung and spleen were 
examined histologically. In the liver of 12 of the 30 placebo treated 
animals and 18 of the 30 BCG (5x107) treated animals, scanty or 
moderate lymphoid infiltrates were observed (Table 3). These 
ц/цд _h 
4/4 
2/4 2/4 
1/4 2/4 1/4 
3/3 
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infiltrates were present both in the portal area and in parenchymal 
tissue. Occasionally, subacute focal parenchymal necrosis and focal 
calcification was found. In 5 of the 18 BCG treated animals showing 
infiltrates, these infiltrates contained epithelioid cells indicating 
a granulomatous type of reaction (Table 3, Fig. 5). 
Table 3: Histopathology of liver after intravesical BCG 
administration. 
Treatment3 No lesions Inflammatory Infammatory reaction with 
presentb reactionb,c epithelioid cells*3.cTd 
mild moderate severe mild moderate severe 
Placebo IB/30 11/30 1/30 0/30 0/30 0/30 0/30 
BCG 12/30 10/30 6/30 2/30 1/30 3/30 1/30 
a
 BCG (5x10? c.p.) and placebo were administered intravesically once 
weekly for six consecutive weeks. 
Ь Number of animals with/whitout reaction and total number of animals 
examined. Aminals were scored once, in case of the presence of 
epithelioid cells animals were doubly scored. 
c
 Semiquantitative evaluation of the inflammatory reaction, which 
mainly consisted of small mononuclear cells: - mild: occasionally 
small infiltrates present; - moderate: regularly small infiltrates 
present; - severe: densely disseminated infiltrates present. 
" 5 out of 30 animals investigated showed a granulomatous hepatitis 
(see also Tig. 5). 
In the lings of β of the 29 placebo treated animals and 3 of the 29 
BCG (5x107 c.p.) treated animals inflammatory lesions were present 
(Table 4). In these lungs, a multifocal interstitial pneumonia was 
noted. This pneumonia was localized perivascularly with or without 
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irregular infiltration in the surrounding interstitium. These 
inflammations were composed predominantly of mononuclear cells 
(lymphocytes and histocytes). Variable numbers of eosinophil 
leucocytes and local fibrinous exsudative changes were also observed. 
In 3 of the 29 BCG (5x107 c.p.) -treated animals, granulomatous 
lesions were observed, as indicated by the presence of epithelioid and 
occasional giant cells (Table 4). The BCG lesions showed more or less 
rounded configurations which were composed of epithelioid cells with a 
large pale nucleus and abundant cytoplasm, accompanied by lymphocytes. 
Table 4: Histopathology of lung after intravesical BCG administration 
Treatment3 
Placebo 
BCG 
No lesions 
presentb 
21/29 
21/29 
Inflammatory 
reactionb,c 
Θ/29 
5/29 
Infammatory reaction with 
epithelioid cellsb,cfd 
0/29 
3/29e 
a
 BCG (5x10? c.p.) and placebo were administered once weekly for six 
consecutive weeks. 
b Number of animals with/whitout reaction and total number of animals 
examined. Aminals were scored once. 
c
 Non specific multifocal interstitial pneumonia (see Results). 
" Presence of granulomatous inflammation as indicated by presence of 
epithelioid cells. 
e
 In two of these three animals also the sleen and distant lymph nodes 
(axillary lymph node) showed granulomatous lesions. In the third 
animal these organs were not examined. 
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Fig. 4: Granulo­
matous reaction in 
the primary 
draining iliac 
lymph node of the 
bladder after 
intravesical BCG 
(1x107 c.p.) 
administration 
(once a week for 
six consecutive 
weeks). 
A: 
Note the presence 
of granulomas 
varying in size 
from small epithe­
lioid cell clus­
ters to large 
granuloma with 
central necrosis. 
B: 
Detail of epithe­
lioid cell cluster 
HE Staining A x32, 
В x320. 
Fig. 5: Granulo­
matous hepatitis 
after intravesical 
BCG {5x107 c.p.) 
administration 
(once a week for 
six consecutive 
weeks). Notethe 
presence of 
epithelioid cells 
surrounded by 
lymphoid infil­
trate, and the 
rounded configu­
ration of the 
lesion. 
HE staining x320. 
In 16 placebo- and 16 BCG (5x10?) -treated animals, the spleen was 
examined histologically (data not shown). In two of the BCG treated 
animals the spleens showed a granulomatous reaction, with epithelioid 
cells and Langhans multlnuclear giant cells. These BCG granulomas were 
found mainly in the red pulp and occasionally in the white pulp of the 
spleen. These two animals also showed granulomatous lesions in liver 
and lungs. Furthermore, in the same animals granulomas were found in 
distant (axillary) lymph nodes. 
In conclusion, in 5 of the 30 BCG (5x10? c.p.) -treated animals, 
granulomatous lesions were found in the liver. In 3 of these 5 animals 
granulomatous lesions were also present in the lungs. Of these three 
animals with characteristic BCG lesions in both lung and liver, two 
animals were investigated further. In these two animals, granulomas 
were found both in the spleen and in a distant (axillary) lymph node. 
It appeared that three animals were suffering from a generalized 
inflammatory reaction to BCG. 
DISCUSSION 
During the last decade, intravesical BCG administration has attained 
an important role as a non specific adjuvant immunotherapy for the 
treatment of recurrent superficial bladder cancer (Shapiro et al. 
19Θ2, Morales 1984, Haaff et al. 1985, Morales and Nickel 1986). 
Although it is generally thought that BCG exerts its antitumor 
activity by stimulation of the inmune system, the precise mechanism is 
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still unknown. The mode of action of BCG is very complicated as BCG 
may, depending on dose, route of administration and timing, have a 
stimulating or a suppressive activity (Mitchell and Murahata 1979, De 
Jong et al. 19B7). Generally, the toxicity of BCG is limited to the 
site of administration and the primary draining lymph nodes. 
Disseminated infection is extremely uncommon (Sparks 1976, Pitlik et 
al. 1984). 
When BCG is administered intravesically, a relatively large mucosal 
surface is exposed. However, most of the inflammatory foci observed in 
our study, were scattered throughout the submucosa underlying the 
epithelium. In our series of animals investigated (N= 30), in only one 
case a slight focal erosion of the covering epithelium was observed. 
Even when a severe lymphocytic inflammation was present in a large 
submucosal area, no disruption of the epithelium was present. Our 
observations in guinea pigs are similar to observations in dogs, in 
which BCG instillation also provoked a submucosal reaction (Bloomberg 
et al. 1975, Van der Meijden et al. 19B6). With regard to the 
intensity of the inflammation in the bladder, the guinea pigs showed a 
more extensive reaction compared with the dogs. In patients with 
superficial bladder cancer treated with intravesical BCG, 
subepithelial granulomas, accompanied by erosion of the covering 
epithelial layer, were observed (Lage et al. 19Θ6). Several factors 
may enhance BCG attachment and thereby increase the local BCG effect 
inside the bladder wall. In particular, endoscopic resection of 
bladder tumors probably results in enhanced adherence of BCG to the 
bladder wall. It has been demonstrated that BCG adheres minimally to 
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undamaged murine bladders, but the adherence is increased more than 
100-fold in bladders damaged by electrocautery (Ratliff et al. 19Θ7). 
In particular the extracellular matrix protein fibronectin was found 
to mediate BCG adherence. Fribronectin is a major constituent of 
healing wounds (Grinnel et al. 1980). Intravesical wounds, causing 
fibrin-clot formation, are induced by transurethral resection and 
electrocautery of bladder tumors. 
It was suggested by Ratliff et al. 19Θ7, that fibronectin acts as an 
attachment matrix to mediate BCG retention, thus allowing induction of 
the inmune response. Although in our studies, it cannot be excluded 
completely that the instillation procedure caused epithelial lesions 
in the bladder mucosa, in none of the animals investigated (both BCG 
and placebo treated) were there, indications for epithelial damage on 
histological examination at three different levels. Thus, our 
observations strongly suggest that a local and regional immune 
reaction can occur through an intact bladder epithelium. This is 
indicated by the induction of a lymphocytic inflammation in the 
submucosa underlying an intact epithelium and by the granulomatous 
reaction in the primary draining lymph nodes. In addition, guinea pigs 
treated intravesically with BCG (once a week for six consecutive 
weeks) developed a delayed type hypersensitivity (DTH) skin reaction 
to purified protein derivative (PPD) of Mycobacterium tuberculosis 
(Van der Meijden et al, submitted for publication). This DTH reaction 
is the result of antigen-specific priming of Τ cells, which occurs 
only after a proper immunization procedure. Thus, the contact of BCG 
with an (apparently) intact bladder wall results in a systemic 
- 70 -
immunological reaction. Secondly, the beneficial effects of prolonged 
(maintenance) BCG therapy in patients with superficial bladder tumors, 
where it is likely that the bladder wall has healed completely, 
suggests that BCG may act through an undamaged bladder wall (Brosman 
1982). In this case,primary BCG sensitization was probably enhanced by 
the defects in the bladder wall, present after the first tumor 
resection. We conclude that a damaged bladder wall is not required in 
order to provoke a BCG mediated immune reaction to BCG itself. Whether 
a damaged bladder is needed for the expression of the antitumor 
activity of BCG remains to be established. 
Besides a local granulomatous reaction in the primary draining lymph 
nodes, occasionally granulomatous lesions were also observed in the 
liver and the lungs. In three animals a generalized reaction to BCG 
occured. The reactions in the bladder and lymph nodes can be 
considered beneficial, as these indicate continuing immune reaction to 
the mycobacteria. However, the reactions in liver and lungs may be 
considered as unwanted side effects. In cancer patients, granulomatous 
hepatitis has been reported after intralesional and intradermal BCG 
administration. These reactions appeared to be allergic in nature 
since viable organisms could not be recovered from these lesions (Hunt 
et al. 1973, Bodurtha et al. 1974). It is likely that the development 
of hepatic granulomas represents a hypersensitivity reaction to the 
BCG antigens. In addition, another source of antigen exposure may be 
the BCG processing by phagocytizing mononuclear cells. We were not 
able to find viable mycobacteria in the draining (retroperitoneal) 
lymph nodes of the bladder or in the spleen and it is probably that 
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these reactions were also allergic in nature. In man, after 
intravesical BCG administration, serious side effects are encountered 
in approximately 2% of patients. Generally, the side effects are 
limited to the bladder, although BCG pneumonitis and hepatitis have 
been described occasionally (Lamm et al. 19B6). Serious side effects, 
however, can be treated effectively by antituberculous therapy. 
Although the intensity of the inflammatory reaction in the bladder 
wall was occasionally very severe, the presence of the specific 
mycobacterial granulomatous component in the inflammation was 
limited. In contrast the primary draining (iliac) lymph nodes showed a 
more consistent reaction. In all lymph nodes investigated, the 
presence of granulomas was observed. Mycobacteria invoke a 
granulomatous inflammation including epithelioid cells and T-cells 
(MGregor 1975). After intravesical BCG administration in the rat, the 
mononuclear cellular infiltrate contained particularly T-cells (Guiñan 
et al. 1986). This suggests a T-cell-mediated inmune response. The 
occurence of such an immune response was demonstrated by the 
development of a positive PPD skin reaction in the guinea pigs treated 
only intravesically with BCG. These results will be reported 
elsewhere. Whether this BCG-specific antigen response is accompanied 
by an antitumor response of antigen specific or nonspecific nature, is 
still unknown. However, data from clinical trails clearly show that 
BCG indeed is effective as an adjuvant therapy for the treatment of 
superficial bladder cancer and carcinoma in situ. Further studies are 
required to elucidate the mechanism by which BCG exerts its antitumor 
activity. 
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SUfWRY 
Intravesical and intradermal application of BCG (Bacillus Calmette 
Guérin) has proven to be effective in the prophylaxis of recurrence of 
superficial bladder carcinoma after transurethral resection and in the 
treatment of carcinoma in situ (CIS) in man. Different strains of BCG 
have been used for this purpose. In this article a new strain of BCG 
(BCG-RIVM) has been tested to assess its toxicity. The effects of 
intravesical and intradermal application of BCG-RIVM were studied on 
normal and on coagulated canine urothelium. In this study no general 
side effects of BCG-RIVM were seen. 
Only minor local changes occurred in the bladder wall. 
Small granulomas were found in the suburothelial tissue. 
No granulomas or signs of active inflammation were observed in the 
pelvic lymph nodes, spleen and liver. Because BCG-RIVM seemed to be a 
safe agent in the dog we have started to use it for prophylaxis in 
superficial bladder cancer in man. 
Key words: Bladder carcinoma, Intravesical BCG-RIVM toxicity-study. 
INTRODUCTION 
Since 1976 an increasing experience has been obtained with 
intravesical nonspecific immunotherapy for superficial bladder 
cancer. Morales et al. (1976) described the beneficial effects of 
intravesical BCG administration. Since then, several reports have 
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demonstrated that intravesical application together with intradermal 
administration of BCG reduces tumor recurrence rate of superficial 
bladder tumors 2, 3J 9. 
It has been shown that intravesical BCG therapy is effective in the 
treatment of carcinoma in situ (CIS) 2
>
 4 f 12 and of residual 
papillary tumors 12. 
In most studies Pasteur, Connaught or Tice BCG were used. These 
daughter strains seem to be equally effective in the management of 
superficial bladder cancer. A considerable variation in the content of 
viable bacilli in each vial occurs and may be responsible for 
differences in toxicity. High concentrations might account for 
increased toxicity observed after some instillations. Severe toxicity 
was seen after prolonged intravesical in3tillations2. In some clinical 
cases prolonged episodes of fever, chills and malaise were also 
observed. Nearly all investigators reported mild toxicity symptoms 
manifest by hematuria, nausea and frequency of micturation *, Ю , 15, 
Recently Morales showed that BCG instillations were safe"". 
The Dutch National Institute of Public Health and Environmental 
Protection (RIVM - Bilthoven, The Netherlands) produces a 
BCG-preparation with a stable content and a relatively high ratio 
viable/dead organisms. Most studies have been performed with BCG grown 
as a surface culture and homogenized in a ball mill. However, BCG-RIVM 
orginally obtained from a seed lot of the Institute Pasteur, Pans, 
France, is cultured and dispersed homogeneously. This culture method 
results in a high ratio of viable/dead organisms 5, 8 j 14. 
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The aim of the present study was to evaluate the toxicity of BCG-RIVM, 
used intravesically and intradeimally in the dog. 
MATERIALS AND hETHODS 
Twelve female beagle dogs (average weight 15-20 kg) were used in this 
study. First a skin test with 0,1 ml of PPD (purified proteine 
derivate of Mycobacterium tuberculosis) was performed and evaluated 
after 48 and 72 hours. Cystoscopy was performed under general 
anaesthesia and three biopsies were taken from the right bladder 
wall. On the left of the bladder wall a coagulation lesion (diameter 
of 2-3 cm) was made. Ten days after this procedure intravesical 
instillation was started. The dogs were randomly assigned into three 
groups. Four dogs received 50 ml. of 0,9% saline, four were instilled 
with 1 χ 10 9 BCG-RIVM in 50 ml 0,9% saline and four dogs received an 
intradermal injection together with the intravesical instillation of 
BCG. For the intradermal administration a multipuncture apparatus was 
used (fig. 1). Each instillation lasted for two hours and was repeated 
weekly for six consecutive weeks. All instillations were made under 
general anaesthesia by means of an θ French silastic catheter. Before 
and two days after each instillation a blood sample was obtained and 
analysed for haemoglobin, thrombocytes, leucocytes, GOT, GPT, 
gamma-GT, AF, creatinine and urea. Urine-analysis and bacterial 
culture were also performed. 
The body temperature was measured every day. Two days after the last 
- 83 -
instillation a cystoscopy was performed and biopsies from the right 
and left bladder wall were taken. 
PPD-skin tests were repeated at ten and at thirteen weeks. 
On three dogs, one out of each group, an autopsy was performed. The 
bladder, regional pelvic lymphnodes, liver and spleen were examined 
histologically. 
The tissues obtained by the biopsies before and after the 
instillations of BCG or saline and those removed at autopsy were fixed 
in 45· buffered formalin and embedded in paraffin. For microscopic 
examination sections stained with hematoxylin and eosine (Η A E) and 
Periodic Acid Schiff were studied. 
RESULTS 
Toxicity 
All dogs completed the study, except one from the control group. In 
this dog a bladder perforation was made by taking biopsies from the 
bladder wall. Prior to the instillation regimen all skin tests were 
negative. Afterwards they remained negative. After three months none 
of the dogs had a positive PPD-test. During the treatment there was no 
significant rise in body temperature (less than 0,2oC). 
Haematological and biochemical parameters remained within the normal 
range during the study in all animals. Only a slight leuococytosis was 
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noted for two or three days after instillation in each dog but there 
was no significant difference between the three groups. 
In none of the dogs was an urinary tract infection observed. 
Cystoscopy was done after completing the six instillations. A slightly 
reddish bladder mucosa was seen. All biopsy and coagulation lesions 
were macroscopically healed. 
Histology 
Histological examination of bladder biopsies of the 11 dogs taken 
before instillation of either saline solution or BCG showed no 
pathologic changes, except for some extravasation of erythrocytes and 
local intravascular accumulation of polymorphononuclear granulocytes, 
due to the biopsy procedure. In the multiple bladder biopsies taken at 
one week after 6 instillations of either saline or BCG the 
histological picture of the bladder mucosa in both groups was the 
same. Apart from minimal mechanical lesions the urothelium was intact 
and showed no abnormalities. In the suburothelial stroma there was 
some edema or hyperemia, and sporadically a small concentration of 
lymphocytes (fig. 2), but no signs of active inflammation. 
Granulomatous lesions could not be found. However, in the biopsies of 
the dogs that received BCG both intravesically and intradermally, 
sporadic small subepithelial accumulations of histocytes resembling 
early granulomas (fig. 3), were observed. These histiocytic epitheloid 
cells were not accompanied by lymphocytes and giant cells were absent 
in these lesions. 
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Fig. 1: Multipuncture apparatus 
for intradermal application of 
BCG. 
¿^••-^ % 
Fig. 2: Histological appearance 
of the bladder mucosa of a dog 
after six weeks of intravesical 
instillations of BCG. Apart 
from a sporadic follicular 
accunulation of lymphocytes in 
the suburothelial tissue no 
pathologic changes are found. 
H4E, 32x. 
л ·,• 
Fig. 3: A sporadic small 
granulomatous lesion can be 
seen in the suburothelial 
bladder tissue of a dog treated 
with intravesical instillations 
and intradermal injection of 
BCG. Otherwise the bladder 
shows no pathology. H4E, 32x. 
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At autopsy, the 3 dogs that were sacrificed, showed no gross 
pathology. The bladders had a normal appearance but regional pelvic 
lymph nodes were slightly enlarged. Liver and spleen were of normal 
weight with no pathologic changes. Microscopically the bladder mucosa 
of the 3 dogs showed the same features as those in the biopsies. 
There were no signs of epithelium reaction or active inflammation. In 
the bladders of the 2 dogs that received BCG instillation few small 
concentrations of lymphocytes could be found in the suburothelial 
tissue and also sporadic granulomatous accumulations of histiocytes 
resembling small granulomas, in one place accompanied with deposition 
of hemosiderin pigment. The bladder of the dog that received 
instillation of saline solution showed no granulomas. The muscle 
tissue of the bladders and the perivesical tissues were normal. The 
pelvic lymph nodes of all 3 dogs showed a slight follicular 
hyperplasia with perisinusoidal plasmocytosis. 
DISCUSSION 
Immunostimulation and antitumor activity of BCG-RIVM were tested in 
laboratory animals with chemically induced tumors 5
 anc| in naturally 
occuring tumors in the cow and the horse 6,7. In man the BCG-RIVM is 
used as an adjuvant therapy in melanoma (EORTC-trial no. 18781). 
Recently this partcular BCG was investigated in a bladder carcinoma 
phase I study. Thirty patients were treated by the intravesical and 
intradermal administration. In this study no side effects of any 
- 87 -
significance were seen. In 1975 Bloomberg et al.1 investigated the 
side effects of BCG (Tice strain) on the dog bladder. In this study 
some of the dogs were sensitized for PPD. The histological changes of 
the bladder in sensitized (PPD) and non sensitized dogs were 
compared. When BCG was injected directly into the submucosa through an 
open cystostomy a marked inflammatory reaction was seen in all of the 
sensitized and some of the non sensitized dogs. This reaction was 
characterized by an extensive histiocytic infiltration with 
polymorphonuclear leucocytes, lymphocytes and plasmacells in varying 
proportions. There were no granulomas or signs of acute cystitis when 
BCG was applied as an intravesical instillation regardless of prior 
sensitization only a mild vascular congestion and dilatation of the 
lamina propria was observed. 
From the present study, despite the small number of animals, we 
conclude that intravesical instillation together with intradermal 
application of BCG-RIVM is safe and without significant toxicity in 
dogs. Intradermal administration of BCG seems to enhance the formation 
of small granulomatous lesions in the suburothelial tissue, but does 
not sensitize any dog to BCG as was indicated by the negative PPD-skin 
tests at three months after the start of the BCG-treatment. 
We think our results might indicate that BCG-RIVM is a safe agent in 
the treatment of superficial bladder cancer after transurethral 
resection. Therefore a prospective randomised study comparing BCG-RIVM 
versus Mitomycin-C in Tis, Ta en Τ·) primary and recurrent carcinoma of 
the bladder has been started. 
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ABSTRACT 
In thirty patients toxic side effects of Bacillus Calmette-Guérin 
(BCG) were evaluated after intradermal and intravesical 
administration. The BCG preparation (BCG-RIVM) was produced in a 
homogeneously dispersed culture yielding a relatively high number of 
culturable particles per milligram dry weight BCG. All patients had a 
history of recurrent multiple non-invasive superficial transitional 
cell carcinoma of the bladder, and were previously unsuccessfully 
treated with intravesical chemotherapy (epodyl and/or) adriamycin). 
BCG-RIVM dxlO' culturable particles) was instilled in the bladder, in 
combination with intradermal BCG-RIVM ( хІО? culturable particles) 
administration once a week for six consecutive weeks. BCG was 
applied intradermally by a multiple-puncture technique. During and 
after therapy, subjective and objective side effects and toxicity were 
registered. Hematology and blood chemistry, including hepatic and 
renal function, was monitored. Only minor toxicity and/or side effects 
were observed during therapy and for a period of 6 months after 
treatment. After a period of 7 days no significant amount of 
BCG-bacteria could be detected in the urine of 24 investigated 
patients. 
Key words: Bacillus Calmette-Guérin, Bladder instillation, toxicity 
and clearance. 
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INTRODUCTION 
Since 1976 an increasing experience has been obtained with 
intravesical immunotherapy for superficial bladder cancer (37). 
Morales et al. (30) first described in 1976 the beneficial effect of 
intravesical Bacillus Calmette-Guérin (BCG). Since then, further 
reports have demonstrated that intravesical treatment of recurrent 
superficial bladder tumors with BCG reduces tumor recurrence rate and 
lengthens the tumor free interval (1, 3, 5, 8, 15, 25, 27, 33). In 
addition it has been shown that BCG-therapy is also effective in the 
treatment of carcinoma in situ and residual papillary tumors (4, 11, 
31). 
The exact mechanism by which BCG exerts its antitumor activity is 
still unknown (6, 13, 29). However, close contact of BCG with tumor 
cells was found to be of major importance. By local administration, 
BCG may act immunologically as adjuvant for the initiation of an 
antitumor reaction. In several laboratory animal tumor systems, BCG 
administration resulted in the induction of tumor immunity (10, 14, 
20, 36). So, hypothetical!y local BCG immunotherapy may result in 
tumor immunity thus controlling residual disease and preventing 
recurrent tumor. 
For the treatment of bladder cancer the role of the additional 
intradermal administration of BCG remains questionable and unclear. 
Most of the patients show a positive PPD skin test after prolonged 
intravesical application of BCG (4). As long as it remains uncertain 
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whether or not intradermal BCG application is necessary for the 
immunological antitumor effect in the bladder, we decided to test the 
toxicity of BCG administered intravesically as well as intradermally. 
For bladder instillation, in most studies BCG Pasteur (27, 29, 33), 
Connaught (1), "Parking" (22), Tice (3, 4) or Glaxo (35) was used. 
Some preparations seem to differ in their efficacy for the management 
of superficial bladder cancer, also differences have been observed in 
guinea pigs and mice (24). A variation in the content of viable bacil-
li in each vial and between batches and/or preparations may be present 
and can be responsible for differences in activity and toxicity. 
Instillations with the dosage given in the scheme used by Morales (120 
mg in 50 ml saline, once a week for six consecutive weeks) induced 
transiently minor toxicity symptoms (3, 5, 11, 22, 32). Lamm et al. 
(26) reviewed a large series of more than 1000 patients in which 
severe toxicity, including BCG pneumonitis and hepatitis, occurred in 
less than 2% of the treated patients. In more than 95% of the patients 
intravesical BCG administration was well tolerated. 
Moat of the BCG preparations contain a high number of dead bacteria 
and subcellular debris. The National Institute of Public Health and 
Environmental Protection (RIVM, Bilthoven, The Netherlands) produces a 
BCG preparation with a relatively high number of viable mycobacteria 
per milligram dry weight. This high viability is obtained by growing 
the bacilli in a homogeneously dispersed culture under continuous 
stirring. In this way no surface pellicle of mycobacteriae is formed, 
and the disruption of the pellicle by a ball mill procedure is 
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avoided, a treatment in which, besides live BCG, a relative high 
amount of dead bacilli and subcellular debris is harvested. 
Immunostimulation and antitumor activity by the BCG-RIVM was observed 
both in experimental (14, 19, 21, 34) and spontaneous animal tumors 
(17, IB). In man, this BCG preparation was studied as adjuvant 
immunotherapy in melanoma patients (7) and adjuvant therapy in 
bronchus carcinoma (12). The toxicity of the combined intradermal and 
intravesical application of BCG-RIVM was investigated on normal and 
coagulated urothelium in the dog bladder (28). In this animal system 
no general side effects were observed. Only minor local changes 
'occurred in the bladder wall consisting of small granulomas. The aim 
of the present study is to evaluate the toxicity of BCG-RIVM in man. 
MATERIAL AM) ICTHODS 
Patients characteristics 
Thirty patients, 2 females and 2Θ males with a mean age of 64 + 11 
years, were included in this study. All patients had histologically 
proven recurrent superficial bladder tumors for many years. Patients 
tumor characteristics are shown in Table I. All patients were treated 
previously with intravesical chemotherapy with epodyl and adriamycin 
or both, however, in all patients bladder tumors recurred. 
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Table I; Histological diagnosis in 30 patients with superficial 
bladder cancer treated with intravesical and intradermal 
BCG-RIVM. 
Histological 
classification0 
pTaGI 
pTaGII 
pTaGIII 
pTIGII 
pTIGIII 
Total 
PATIENTS n. 
18 
7 
3 
1 
1 
30 
8
 According to TNM classification of the International Union Against 
Cancer. 
Bacillus Caleette-Guérin 
BCG-RIVM lot 901 for intravesical treatment and lot 601 used for 
intradermal application, were derived from the same seed lot and 
consecutively cultured in a homogeneous deep culture. BCG-RIVM was 
originally derived from seed lot 1173 P2 obtained from the Pasteur 
Institute, Paris, France. Seed lot P3 was prepared by the National 
Institute of Public Health and Environmental Hygiene, and stored in a 
lyophilized form at -70oC. A secondary seed lot was used for a 
homogeneously dispersed culture in modified Ungar medium at 360C with 
continuous monitoring of temperature, pH and oxygen concentration. 
After continuous stirring the culture was harvested at about the end 
of logarithmic growth, when the concentration of dissolved oxygen had 
reached a minimum value. After centrifugation the bacteria were 
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resuspended in a solution containing .ЗЙ w/v Haemaccel 5S w/v 
D-glucose and 0.005% w/v Tween 80 and were lyophilized. The number of 
culturable particles (c.p.) was determined by culturing serial 
dilutions, made in liquid Sauton medium diluted 1:4 with distilled 
water solid Löwenstein-Jensen medium. Colonies were counted after 4 
weeks incubation at 360C. BCG-RIVM lot 901 consisted of 108 c.p./mg 
dry weight and BCG-RIVM lot 601 consisted of 1.7x108/mg dry weight. 
Treatnent 
Instillation was started 10 days after transurethral resection of all 
visible tumors, once a week for 6 consecutive weeks. 10^ c.p. in 
10.5 mg dry weight BCG-RIVM was diluted in 50 ml 0.9% saline and 
administered by a 12 French catheter in an empty bladder. The BCG 
solution was retained in the bladder for 2 h. Together with the 
instillation an intradermal BCG-RIVM application, O.BxIO8 c.p. in 
0.48 mg, was performed with a multiple-puncture apparatus Mark 5 
(Bignell Surgical Instruments Ltd., Littlehampton, W. Sussex, UK) on 
the innerside of the upper leg. Each time four punctures, depth 
2.0 mil, were given. This was repeated weekly for six weeks on 
alternating thighs. 
Assessnent of toxicity 
Local toxicity after intradermal BCG-RIVM administration was assessed 
by observation of the skin lesions 1 week after each application of 
BCG and also 1, 3 and 6 months after completing the treatment regimen. 
Severity of the local skin reaction was semiquantitatively scored by 
0-4, indicating 0= no reaction; 1= small papules; 2= papulopustules 
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and moderate erythema; 3 as 2 but strong erythema and swelling and 4 
as 3 with ulceration. Regional inguinal lymph nodes were palpated at 
the same time. 
Systemic toxicity was measured by hematologic parameters (erythrocyte 
sedimentation rate, hemoglobin, hematocrit, leucocytes, trombocytes 
and differential leucocyte count) and biochemical parameters (serum 
glutamic oxaloacetic transaminase (SCOT), serum glutamic pyruvic 
transaminase (SGPT), alkaline phosphatase (AF), glutamyltransferase 
(gamma-GT), lactate dehydrogenase (LDH) and creatinine). 
Subjective side effects were noted after extensive anamnesis before 
each treatment. Objective side effects (enlargement of liver, increase 
of body temperature, decrease in body weight) were scored 1, 3 and 6 
months after therapy. Bladder symptoms (frequency, hematuria) were 
noted on a score scale. Every three months X-rays of the chest were 
made. PPD (purified protein derivative of Mycobacterium tuberculosis) 
skin reactivity was tested before starting therapy and 1, 4, 13 and 26 
weeks after the instillation regimen. Cystoscopy was done 4, 13 and 26 
weeks after therapy. 
The number of mycobacteria in urine was estimated 7 days after each 
instillation and 1, 4, 13 and 26 weeks after treatment. In 11 patients 
the excretion of mycobacteria was measured during 7 days. Urine (15-50 
ml) of patients was centrifuged at 3000 g for 5 min. and the sediment 
was suspended in 0.2 ml 0.955 NaCl and stained according the 
Ziehl-Neelsen method. 
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RESULTS 
Thirty patients completed the instillation treatments. Five patients 
did not complete the treatment regimen, 1 patient died due to a cause 
not related to the BCG treatment, and 4 patients developed common 
bacterial infections of the urinary tract. As antibiotics 
(co-trimoxazole, pipimidine acid and ammoxycillin) were found to have 
growth-inhibitory effects on mycobacteria in vitro (unpubl. 
observations), patients treated with antibiotics due to urinary tract 
infections were excluded for the evaluation of the BCG-RIVM toxicity. 
Systeaic toxicity 
Out of 30 patients there were 7 who suffered from malaise during 
treatment. No objective signs of systemic toxicity were observed. The 
mean body temperature did not increase for more than 0.3°C, also the 
mean body weight did not change (data not shown). In 2 patients lymph 
node enlargement in the inguinal region was present prior to 
treatment. During treatment 1 patient developed lymph node 
enlargement. At 3 months after therapy no enlargement of the regional 
lymph nodes was observed. In none of the patients was liver enlargement 
noted. A compilation of results is presented in Table II. 
Prior to treatment ,14 out of 30 patients showed an increase of the 
erythrocyte sedimentation rate, after therapy in 14 patients a 
transient elevation of the pretreatment value was observed. Two out of 
30 patients showed an increase in the number of leucocytes. During the 
6 months observation period a transient increase was observed for 
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eosinophilic granulocytes in 12, for basophilic granulocytes in 4, for 
neutrophilic granulocytes in 4, for lymphocytes in 5, for atypical 
lymphocytes in 1, and for monocytes in 12 patients respectively (data 
not shown). Blood chemistry revealed that in 1 patient the SGPT level 
was increased. In 2 patients the alkaline phosphatase and in 1 patient 
the serum creatinine was slightly elevated. 
Table II; Compilation of toxic effects of BCG-RIVM after intravesical 
and intradermal administration for 6 consecutive weeks. 
Number of 
patients 
investigated 
Inguinal lymph 
node swelling 
Enlargement of 
spleen 
Enlargement of 
liver 
Malaise 
Prior to 
therapya 
30 
2b 
0 
0 
N.D. 
During therapy3, 
weeks 
1 2 3 4 5 
30 30 30 30 30 
3 2 2 2 2 
0 0 0 0 0 
0 0 0 0 0 
2 1 2 2 1 
After therapy, 
weeks 
1 4 13 26 
30 30 24 15 
2 1 0 0 
0 0 0 0 
0 0 0 0 
2 1 0 0 
a
 BCG was administered 6 times; week 0, 1, 2, 3, 4 and 5 
Ь Number of patients with reaction as indicated 
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Table H I ; Skin reactivity after intradermal and intravesical 
application of BCG-RIVM by multipuncture technique3. 
No. of patients 
investigated 
Skin reaction 
None 
Small papules 
Papulopustules 
with moderate 
erythema 
As 2 but with 
strong erythema 
and swelling 
As 3 with 
ulceration 
Skin reactivityc 
mean ± SD 
score 
0 
1 
2 
3 
4 
Dur 
1 
30 
6b 
14 
7 
1 
2 
1.3 
+1.1 
ing therapy (weeks) 
2 3 4 5 
30 30 30 30 
1 0 0 0 
15 11 7 5 
9 11 12 14 
0 3 5 5 
5 5 6 6 
1.8 2.1 2.3 2.4 
+1.1 +1.1 +1.1 +1.0 
After 
1 
30 
0 
7 
14 
6 
3 
2.2 
+0.9 
therapy (weeks) 
4 13 26 
30 24 15 
0 5 5 
11 6 8 
13 10 2 
6 3 0 
0 0 0 
1.Θ 1.5 0.8 
+0.7 +1.0 +0.7 
a
 Intracutaneous multiple puncture injection, 4 times with 20 needles, 
depth of injection 2.0 mm. 
b Number of patients 
c
 Expressed as score 0-4 
Local toxicity 
Skin reactions after intradermal multiple-puncture application of 
BCG-RIVM were distinct but well tolerated. In all patients small 
papulae or papulopustulae with moderate erythema were observed (Table 
III). In 6 patients ulcerative lesions were present which disappeared 
within 1-3 weeks. Erythema, small papules and desquamation were seen in 
10 out of 15 évaluable patients at 6 months after treatment. 
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Table IV: Presence of BCG in urine after intravesical administration of 1x109 culturable 
particles of BCG-RIVMa. 
Number of 
patients 
investigated 
Urine with 
BCG 
Number of 
bacteria per 
ml urine 
During 
1 
24 
lb 
e 
2x102 
therapy, 
2 
24 
2 
с 
2x102 
3x102 
weeks 
3 
24 
2 
5x103 
1x102 
4 
24 
2 
С 
1x102 
4x102 
5 
24 
0 
After therapy, 
1 4 
24 20 
1 0 
weeks 
13 
17 
0 
26 
13 
0 
52 
7 
0 
1x102 
a
 Weeks 1-6, 7 days after instillation, thereafter at 1, 3, 6 and 12 months after the last 
(sixth) BCG instillation 
ь
 Number of patients 
c
 The same patient 
Table V; BCG secretion in urine during 7 consecutive days after intravesical administration 
of 1x10' culturable particles of BCG-RIVM. 
Time a f t e r BCG i n s t i l l a t i o n I 
Number p o s i t i v e 
t o t a l numbers 
Range of BCG 
b a c t e r i a / ml 
urine 
1-2 h 
11/11 
5 χ 1 0 Μ χ 1 0 7 
1 2 3 4 
6/10 5/11 5/11 6/10 
102-7x10* 2χ1θ2-7χ1θ3 2x102-10* 20-7χ1θ2 
5 
2/11 
2x102 
6 
4/10 
20-5x102 
7 days 
1/10 
3χ1θ2 
8
 Urine of patients positive for mycobacteria versus number of patients investigated 
Prior to treatment, irritation of the bladder, as indicated by a 
reddish appearance of the urothelium, was observed in 7 (23S) out of 
30 patients. At cystoscopy, 1 month after the last BCG instillation, 
irritated bladder mucosa was seen in 16 (59Й) out of 27 patients. The 
clearance of BCG bacilli from the urine was completed in almost all 
patients, within 7 days after instillation (Table IV). At a total of 
180 instillations, mycobacteria were found only θ times 7 days after 
instillation. These mycobacteria were detected in 6 different 
patients, and in 1 patient mycobacteria were repeatedly (3x) 
observed. The highest concentration of bacilli in the urine, found in 
the sediment 7 days after instillation was 5x10^. Table V shows that 
in the first 2 h most of the mycobacteria were excreted with the 
urine. At 7 days, mycobacteria were still detected in 1 out of 10 
patients. 
Table VI; Skin reaction to tuberculin PPD after intravesical and 
intradermal BCG immunotherapy. 
Number positive/ 
total number8 
Prior to treatment 
0 
12/30 
After BCG treatment 
1 4 13 26 
28/29 24/28 22/26 15/16 
a
 Number of patients with positive delayed type hypersensitivity 
(PPD) reaction versus number of patients investigated 
The PPD skin reactivity test was positive in 12 out of 30 patients 
prior to therapy (Table VI). PPD conversion was observed 1 week after 
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treatment in 17 out of the 18 patients, which showed a negative 
reactions before BCG treatment. Six months after therapy, 15 out of 
the 16 patients investigated, showed a positive Mantoux reaction. 
DISCUSSION 
In this study we investigated the toxicity of BCG-RIVM after 
intravesical and intradermal administration. Our results indicate that 
the intravesical and intradermal administration of BCG-RIVM once a 
week for 6 consecutive weeks was reasonably well tolerated. No serious 
local or severe systemic side effects were observed. Seven patients 
(23%) showed symptoms of malaise. In 1 out of 30 patients a local 
(inguinal region) lymph node enlargement was noted. In general, 
hematological and blood chemistry parameters remained within normal 
ranges after the BCG-treatment. 
For intravesical and intradermal administration, most investigators 
have used Pasteur or Tice strain. Morales (30, 32) used 120 mg (1.2x 
10' colony-forming units) intravesically and 5 mg (5x10? colony 
forming units) intradermally on alternating thighs weekly for 6 
weeks. With this scheme, complications were tolerable. Mild hematuria 
and bladder irritability were common and occurred after each treatment 
but were usually of short duration. Low grade fever and malaise 
lasting less than 48 h also were common, especially following the last 
2 or 3 treatments. More severe complications were rare and included 
partial ureter obstruction or a migratory polyarthritis (26). Most of 
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the complications were self-limiting. The incidence of severe 
complications was less than 2%. In case of systemic reaction to BCG, a 
10-day course of isoniazide is necessary. Lamm et al. (23, 26) used 
the same strain (Pasteur) as Morales (30, 32). Irritative bladder 
symptoms were common. Dysurie (91 percent), and freqency (83 percent) 
occurred within one day and lasted for 24-28 h. These symptoms 
generally increased with successive instillations but responded to 
symptomatic medication. Patients had mild hematuria (37S), temperature 
elevation (22Sí), or nausea (22%). Malaise, weight loss or allergic 
reaction were not seen and decreased bladder capacity was not 
observed. 
The Tice-strain of BCG was used by Brosman (3, 4). He used 600 mg 
(6x10° culturable particles) in 50 ml saline, 6 weekly administrations 
intravesically, then every 2 weeks during a period of 3 months, and 
thereafter monthly for a total treatment period of 24 months. No 
intradermal administration was used. With this high dose, all patients 
had irritative bladder symptoms. Some patients developed serious side 
effects. Fever, chills, anorexia, severe bladder-irritation, hepatic 
function disturbances or pulmonary infections were observed. In those 
cases isoniazide, ethambutol and rifampicin treatment was required. De 
Kernion et al. (15) used the Tice-strain intravesically and 
intradermally for 6 weeks and continued with monthly administration 
intravesically. Most patients showed side effects. Almost all patients 
(88%) had irritative bladder symptoms, which subsided within several 
days without therapy. However, twenty percent of the patients had 
severe cystitis. Fever occurred in 15 percent of the patients, of 
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which in 2 cases hospitalization was necessary. Malaise, loss of 
appetite and mild myalgia was observed in 15% of the patients. These 
symptoms resolved within 3 days in most cases (15). 
Haaff et al. (9) suggested that BCG viability is related to 
therapeutic success. They found that the number of colony-forming 
particles in vials of the same producer or between different producers 
varied considerably. When the results of treatment with lots with low 
and high viability were compared, a 33 and 70Й PPD conversion rate was 
found, and 75 and 355» tumor recurrence rate, respectively. Also for 
adjuvant BCG therapy in lung cancer patients, therapeutic results 
varied with the viability of the BCG vaccine, a higher viability being 
more effective (2). The viability of mycobacteria seems therefore to 
be a crucial factor for the antitumor response induced by a BCG 
preparation. It is probably better to express the treatment dose of 
BCG in culturable particles (colony forming units) rather than in 
milligrams dry weight. For this reason an optimal preparation has to 
be designed which consists of at least a constant number of viable 
mycobacteria. In this regard BCG-RIVM seems to be a good preparation. 
Due to its production method, it contains 10 times less nonviable 
material compared to most other BCG preparations. A study in dogs has 
already revealed that BCG-RIVM induces no significant toxicity (2B). 
Biopsies of the bladder of the dogs showed the presence of submucosal 
granulomas. This reaction was enhanced by combining the intravesical 
immunotherapy with intradermal BCG application. Kelly et al. (16) have 
indicated that there is a correlation between the development of 
noncaseated submucosal granulomas and a favorable response to BCG. 
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In conclusion, in our series of 30 patients no significant toxicity 
was seen after intravesical and intradermal administration of BCG-RIVM 
once a week for 6 consecutive weeks. 
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SIMWRY 
The only form of immunotherapy useful for the treatment of cancer in 
man, seems at this moment the intravesical administration of BCG for 
the treatment of superficial bladder tumors. In this study BCG was 
administered intravesically (once a week for six consecutive weeks) in 
guinea pigs in order to investigate the immune responses after BCG 
treatment. Both specific immune responses against BCG itself and 
non-specific immune responses such as leukocyte subset distribution, 
mitogenic (Con A, PHA, LPS) lymphocyte stimulation and spontaneous 
cytotoxic (NK- and LAK-cell) activity, were determined in the regional 
draining (iliac) lymph nodes and in the spleen. 
The PPD skin test became positive after the fourth intravesical 
instillation of BCG, when 1x105 culturable particles or higher dosages 
of BCG were administered. The low dose of 1x103 c.p. of BCG was also 
able to induce a positive PPD skin reaction in 2 of 4 animals after 
six BCG instillations. After six BCG instillations, BCG-immune 
lymphocytes were present locally in the iliac lymph nodes and 
systemically in the spleen. No differences in mitogenic responses to 
Con A, PHA and LPS were observed in iliac lymph nodes or the spleen 
between placebo or BCG treated animals. In the regional iliac lymph 
nodes a significantly increased number of leukocytes was present. 
These lymph node cells showed a significant increase in the expression 
of MHC class II (la) immune response antigen on their surface. In the 
spleen no differences were observed after BCG administration regarding 
the number of cells present and the la antigen expression of the 
leukocytes. 
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The spontaneous cytotoxic (NK) cell activity was not increased after 
the BCG administration. Both in the iliac lymph node cells and in 
spleen cells lymphokine activated killer (LAK) cell activity could be 
induced by human recombinant interleukin 2. At day 1 after the sixth 
intravesical BCG administration, the BCG treated animals showed in the 
iliac lymph nodes a significantly higher induction of LAK-cell 
activity compared to placebo treated animals. Such a difference was 
not present in the spleen. Our data indicate that, with the exception 
of the BCG antigen specific reaction, the immunological responses 
after intravesical BCG administration in the guinea pig are mainly 
limited to the regional draining (iliac) lymph nodes. 
INTRODUCTION 
The immunostimulation and antitumor activity of Bacillus Calmette-
Guérin (BCG) has been intensively studied (reviewed in 10, 26) BCG is 
known to stimulate various parts of the immune system both at the 
humoral and cellular level. Especially the stimulation of the cell 
mediated immunity seems to be important for the activity of BCG as 
immunotherapeutic agent against cancer. BCG was reported to induce 
and/or enhance the activity of cytotoxic T-lymphocytes, various 
activities of macrophages including macrophage cytotoxicity, and the 
activity of natural killer (NK) cells. The antitumor activity of BCG 
has been clearly demonstrated in laboratory animal tumor systems and 
in spontaneously occurring tumors in farm animals like bovine ocular 
squamous cell carcinoma and equine sarcoid tumors of the skin (10, 
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26). Although the exact mechanism by which BCG exerts its antitumor 
activity is not known, it is generally thought that BCG operates by 
activation of the immune system. Whether this is merely a kind of 
adjuvant activity of BCG, or whether intermediate mediators are of 
importance, remains to be established. 
Clinically the use of BCG seems at this moment indicated only for 
superficial bladder cancer. BCG has been used succesfully for 
prevention of recurrences of superficial bladder tumors after 
transurethral resection, for residual disease (after incomplete 
resection) and for carcinoma in situ (4, 6, 13, 15, 16, 23, 28, 39). 
BCG is administered by intravesical instillation, once a week for 
several consecutive weeks or months. It remains in the bladder for 1-2 
hours, thus providing a close contact between BCG , tumor cells and 
the epithelial layer of the bladder. 
Especially a local administration was important in various animal 
tumor models for the antitumor activity of BCG (3). In some animal 
tumor systems the local BCG treatment resulted in the induction of 
tumor immunity (10). 
Limited knowledge exists about the reactions inside the bladder, after 
intravesical BCG administration. In man, bladder irritability as a 
result of cystitis was observed frequently (21). Histologically, 
mononuclear infiltrates were present, sometimes accompanied by 
epithelioid cells (indicating a granulomatous inflammatory reaction) 
(12, 20, 42). This infiltration may also reflect an ongoing immune 
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reaction against the BCG. This is supported by the fact that after 
repeated intravesical BCG instillation interleukin 2 (IL2) was found 
in the urine of BCG treated patients (32). Whether this reflects or is 
related to the antitumor activity of BCG, is unknown. 
In order to determine what occurs immunologically after intravesical 
BCG administration, we investigated both the local and systemic immune 
reactions after repeated instillations of BCG. Both the specific 
immune reaction to BCG itself and non-specific immune parameters like 
mitogenic stimulation and natural killer (NK) cell-activity were 
investigated. As guinea pigs seem to be most comparable to man with 
regard to their sensitivity for mycobacteria, (37) these studies were 
performed in female guinea pigs. 
MATERIAL AM) METHODS 
Алімаів 
Random bred female albino and inbred female Sewall-Wright strain 2 
guinea pigs, 4- to 6- months of age and weighing about 400 g, were 
used in the various experiments. The animals were obtained from the 
laboratory animal facility of the RIVM, Bilthoven, The Netherlands. 
The animals were fed guinea pig ration and water ad libitum. During 
the experiments animals were housed individually. Cages were covered 
with plastic foil to prevent contamination with faeces or urine from 
neighbouring guinea pigs. 
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Bacillus Caleette-Guérin (BCG) 
The BCG preparation was produced by the National Institute of Public 
Health and Environmental Protection (RIVM, Bilthoven, The 
Netherlands). BCG-RIVM lot 602 containing бхІО? culturable particles 
(c.p.) in 0.54 mg dry weight, was used. The BCG-RIVM is produced in a 
homogeneously dispersed culture, which is harvested at the end of 
logarithmic growth. The original seedlot for BCG-RIVM was obtained 
from the Institute Pasteur, Paris, France. BCG-RIVM was found to 
activate several immune parameters including natural killer (NK) cell 
activity (9). The antitumor activity of BCG-RIVM was demonstrated both 
in laboratory animal tumor systems (9) and in spontaneously occuring 
bovine ocular squamous cell carcinoma and in equine sarcoid tumors of 
the skin (17, 1 , 25). 
Experiaental desicpi 
BCG was administered intravesically in female guinea pigs at doses as 
indicated in the tables and figures. After desinfection of the vulva 
the BCG was instilled in an empty bladder in anaesthesized animals 
using teflon sheats (Abbocath-T, 24 gauge, 1202) as a transurethral 
catheter, and remained in the bladder for 0.5 or 1 hour. The animals 
were anaesthesized by intramuscular injection of 0.8 ml of a mixture 
of 20 mg/ml Ketalar* , 2.5 mg/ml Rompun® and 0.05 mg/ml atropine. The 
BCG was instilled once weekly, for six consecutive weeks, a treatment 
schedule which was used in the first clinical studies reported (22, 
27, 39). Control animals were treated similarly with a placebo 
preparation. 
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PPD skin reactivity 
In vivo antigen specific immune response to BCG was determined by 
injecting 20 pg PPD (purified protein derivate of Mycobacterium 
tuberculosis, produced at the RIVM, Bilthoven, The Netherlands) 
intradermally in 0.1 ml. At 24 and 48 hours after the PPD injection 
the diameter of the skin reaction, as indicated by redness and 
swelling, was measured. 
Isolation of leukocytes 
Leukocytes were obtained generally one week after the last BCG 
instillation. Animals were killed and the primary draining lymph nodes 
of the bladder (the iliac lymph nodes) and the spleen were removed 
aseptically. Spleen cells were isolated by gently pressing organ 
fragments through a 60 mesh stainless steel wire screen in Isocove's 
modified Dulbecco's medium (IMDM, Gilbo Loboratories, Grand Island, 
NY, USA) supplemented with 10% heat inactivated foetal calf serum 
(FCS, Boehringer, FRG) penicillin (100 lU/ml), streptomycin 
(100 yg/ml) and 5x10~5 M 2-mercaptoethanol, further referred to as 
complete IMDM. After centrifugation, erythrocytes were lysed by a 
buffer containing 8.3 g/1 MN4CI, 1.0 g/1 KHCO3 and 37.2 mg/l EDTA. The 
spleen cells were washed twice and for in vitro studies resuspended in 
complete IMDM. Lymph node cells were isolated by gently pressing the 
lymph nodes between two glass slides. After centrifugation and waahing 
the lymph node cells were resuspended in complete IMDM. Viable 
nucleated cells were counted by trypan blue (0,5%) exclusion. 
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In vitro antigen an aitgen stimulation 
Leukocytes were cultured (37eC, 5Й CO2) in triplicate in 200 μΐ 
complete IMDM in polystyrene 96 well tissue clusters with flat bottom 
wells (Coster, Cambridge, Mass., USA). PPD (5, 10 and 20 pg/ml) and 
mitogens, Con A (Concanavalin A, 1.25, 2.5, 5.0 jjg/ml, Miles-Yeda 
Ltd., Rehovot, Israel), PHA (phytohaemagglutinin, 2Θ, 56 and 
112 pg/ml, Wellcome Research Laboratories, Beckenham, UK) and LPS 
(0.25, 0.5 and 1.0 mg/ml, lipopolysaccharide W of E. coli, 055:B5 
Difco Laboratories, Detroit USA) were added. The highest value 
obtained with one of the added concentrations, is presented in the 
tables and figures. After 2- to 4 days the cell cultures were pulse 
labeled by the addition of 5 pCi methyl-^H-thymidine (specific 
activity 5 Ci/mmol, Radiochemical Centre, Amersham, Buckinghamshire 
UK) per ml culture for four hours. Cellular DNA was harvested on glass 
fiber filters using a multiple cell culture harvester (Titertek). 
Tritium thymidine incorporation was measured in an ISO cap/300 liquid 
scintillations counter (Nuclear Inc., Des Plaines, ILL, USA) and 
expressed as counts per minute (cpm). 
In vitro cytotoxicity assay 
The spontaneous cytotoxic activity, (natural killer cell activity) and 
the interleukin 2 induced cytotoxic activity (lymphokine activated 
killer (LAK) cell activity) from spleen and iliac lymph node 
leukocytes was determined in a 1B h chromium release assay (2). In the 
chromium-release assay, К 562 a hunan erythroid leukemia cell line 
sentive for both NK- and LAK-cell activity of guinea pigs, was used as 
target cell. К 562 target cells were labeled with ^Сг by incubating 
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50 μ Ci per 1x106 cells in 0.1 ml for 1 hour in a rocking waterbath. 
After washing (5 times) viable cells were counted by trypan blue 
exclusion. Target cells (1x10* per well) were incubated with effector 
cells in duplo at E:T cell ratios of 25, 50 and 100. After 
centrifugation (5 min, 200 g) the microtiter trays (Removawell System, 
Dynatech Companies, Zug, Switzerland) were incubated for 18 hours at 
37°, 55Í C02 in a humified atmosphere (11). 
After incubations and a second centrifugation step half of the 
supernatant was collected. The percentage ^ІСг-геІеазе was determined 
by measuring the radioactivity in half of the supernatant and half of 
the supernatant plus sediment. The radioactivity was determined in a 
gamma counter and expressed as counts per minute (cpm). The percentage 
release was calculated according to the formula: 
2x cpm (0.5 supernatant) 
% release = -
cpm (sediment +0.5 supernatant) + cmp (0.5 supernatant) 
The cytolytic activity was expressed as specific release i.e. 
percentage experimental release minus percentage spontaneous release. 
The spontaneous release was determined by incubating 51Cr labeled 
target cells with medium alone (200 μΐ) without effector cell 
addition. 
For estimation of lymphokine activated killer cell activity the same 
assay was used. However, the chromium release assay was performed in 
the presence of recombinant interleukin 2 (70 U/ml, kindly provided by 
Biogen, Geneva, Switzerland). 
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Апаіувів of lyaphoid cell populations 
Phenotype characteristics of leukocytes in the draining (iliac) lymph 
nodes and spleen were determined by flow cytofluorometric analysis in 
a Fluorescence Activated Cell Sorter (FACS-Analyser, Becton-Dickinson 
Immunocytometry Systems, Mountain View, Ca, USA). Analysis of the data 
was performed with Consort 30 software (Becton-Dickinson) on a 
Hewlett-Packard 9920 S computer. For detection of various leukocyte 
markers the following monoclonal antibodies (MoAb) were used: CT5 a 
MoAb for guinea pig T-cells (41), T167 a MoAb for guinea pig T-cells 
and thymocytes (Burger, personal communication), 31D2 a MoAb detecting 
guinea pig B-cells (Burger, personal communication), 305 a MoAb 
detecting guinea pig macrophages (24) and 25E3, a MoAb detecting la 
antigens on guinea pig cells (5). CT5 was kindly provided by 
Dr. R.J.Scheper (Free University, Amsterdam, The Netherlands), T167, 
3102 and 305 were kindly provided by Dr. R. Burger (Heidelberg, FRG) 
and 25E3 was kindly provided by Dr. E. Shevach (New York, USA). 
Spleen and iliac lymph node cells were obtained as mentioned above, 
CT5, T167, 31D2 and 305 were diluted 1:200, and 25E3 was diluted 
1:500. After washing the antibody coated cells were incubated for 
45 min at 4 ^ with rabbit anti-mouse-FITC diluted 1:40 in PBS, 
10 pg/106 cells (RAM-FITC, Cappel, Cooper Biomedical Inc., Malvern, 
PA, USA). 
After removing the surplus of RAM-FITC, for the analysis 750 μΐ PBS 
(phosphate buffered saline) was added to the cells. From each sample 
1θ4 cells were analysed in the FACS. For control on non-specific 
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binding a commercially available control ascites was used (Cappel). 
The data obtained with the FACS measurements were corrected for the 
non-antigen specific binding of the control ascites by subtracting the 
percentage of positive cells binding the control ascites from the 
percentage of cells reacting with the various specific monoclonal 
antibodies. The non-specific binding of the control ascites was in the 
range of 20 to 30 per cent. For control on the specific activity of 
the monoclonal antibodies an la positive guinea pig B-cell leukemia 
(EN-L2C), thymocytes and peritoneal exsudate cells (PEC) were used. 
Statistical analysis 
For differences between BCG and placebo treated animals two sided 
significances were determined with Students t-test. In case of 
insufficient homogeneity of variances, the Welch correction with 
respect to the degrees of freedom was applied. 
RESULTS 
Antigen specific reactions to BCG 
Initially several dose response studies were performed in which BCG, 
in doses ranging from 1x10^ to IxlO? c.p. was administered once a week 
for six consecutive weeks. During these studies PPD skin reactions 
were monitored. At week 3, after 2 BCG instillations, no positive PPD 
skin reactions could be detected (Table 1). However, with the 
exception of the doses IxlO3 ср., after four BCG instillations all 
the other doses, 1x105 and higher, resulted in positive PPD skin 
reactions. 
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Table 1: Induction of delayed type hypersensitivity (DTH) skin 
reaction after intravesical administration of BCGa. 
Dosage 
c.p. 
Number of instillations 
I x l O 3 
1x105 
5x10 6 
1x107 
5x10 7 
Placebo 
0 * 0 
0 ± 0 
0 ± 0 
1.0 ± 3.8 
0 * 0 
0 * 0 
( 0 A ) b 
(0A) 
(0/4) 
(1/14) 
(0/9) 
(0/20) 
0 * 0 
13.2 * 9.5 
13.1 * 2.6 
14.1 * 5.1 
13.4 * 5.5 
0.5 * 2.2 
(0/4) 
(3/4) 
(4/4) 
(13/14) 
(8/9) 
(1/20) 
7.θ * 2.9 (2/4) 
11.1 * 3.0 (3/4) 
12.5 * 2.0 (4/4) 
14.6 * 1.7 (11/11) 
15.0 * 2.2 (9/9) 
2.9 * 5.8 (3/17) 
8
 BCG was administered once weekly for six consecutive weeks. 
The DTH reactions waa measured at 24 h. after intradermal injection 
of 20 pg PPD, one week after the previous BCG instillation. 
ь
 Diameter of redness, mean * s.d., within parentheses, number of 
animals with positive reactions (diameter Ζ '\0 mm) versus number of 
animals tested. Combined results of four experiments are presented. 
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One animal in different doses groups did not show a positive skin 
reaction (diameter ^10 mm) after four BCG instillations. After six 
intravesical BCG instillations, at 7 days after the last instillation 
all dosages induced a positive PPD skin reaction, although in the 
lower dosages investigated, a smaller reaction size was noted together 
with the presence of non-reacting animals (Table 1). In figure 1 
results are presented in which the DTH reaction, measured at 24 hours 
after PPD injection, was followed for a period of 12 weeks. 
Fig. 1 
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All BCG treated (5x107 c.p. intravesically) animals became positive at 
4 weeks after start of the treatment (after four BCG instillations) 
and remained positive during the observations period of 12 weeks. 
BCG-immune lymphocytes were present both in the regional draining 
(iliac) lymph nodes and in the spleen at one week after the last BCG 
instillation (Figures 2 and 3). The presence of the BCG inmune 
lymphocytes was demonstrated in the in vitro antigen stimulation assay 
using purified protein derivative (PPD) of Mycobacterium tuberculosis 
as recognition antigen. 
Non antigen specific reactions after BCG actainistration 
The non antigen specific responses of lymphocytes from the iliac lymph 
nodes and from the spleen were studied with a B-cell mitogen (LPS) and 
two T-cell mitogens (Con A and PHA). One representative from four 
experiments is presented in Figures 2 and 3. No differences in 
responses were observed between placebo and BCG treated animals. 
However, a significant increase (p<00.5 and ρ <0.01, Students t-test, 
two sided) was noted in the number of leukocytes, harvested from the 
regional draining (iliac) lymph nodes after the six weeks treatment 
with BCG (Figure 4). In contrast, this increase in cell number was not 
found in the spleen. Using various monoclonal antibodies (see material 
and methods) for the detection of guinea pig T-cells, B-cells and 
macrophages, we found that the subpopulations of the leukocytes in the 
iliac lymph nodes expressing the CT5 antigen was increased 
significantly (p < 0.05, Students t-test, two sided) (Table 2). In 
addition, there was a two sided significant (p<0.01) increase in the 
expression of la antigens on the leukocytes as detected by the 25E3 
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monoclonal antibody (Table 2). A very low amount of macrophages was 
detected by the 305 monoclonal antibody after the repeated BCG 
instillations. This is in contrast to our previous histological 
observations, in which epithelioid cells from the monocyte/macrophage 
types were present in the iliac lymph nodes after the six weeks 
treatment with BCG (42). In the spleen no differences were found 
between the leukocyte subpopulations and the expression of la antigen 
on the spleen cells. 
Fig. 4 
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Table 2: Phenotype of leukocyte populations in regional (iliac) lymph nodes and apleen of guinea 
pigs after intravesical administration (once a week for six consecutive weeks) of BCG. 
Organ 
Iliac 
lymph node 
Spleen 
Treatment 
Placebo (2)b 
BCG (3) 
Placebo (4) 
BCG (3) 
CT5 
34.0 * 5.7C 
52.7 * 6.7d 
50.2 ± 5.7 
55.5 ± 5.9 
Monoclonal antibodies3 
T167 
64.5 ± 6.6 
68.В ± 7.6 
56.1 ± 7.6 
60.0 ± 12.9 
31D2 
15.1 ± 2.3 
19.4 ± 5.3 
19.4 ± 1.3 
16.5 ± 19.5 
305 
2.5 ± 1.3 
0.6 ± 6.7 
16.0 ± 12.3 
24.5 ± 30.4 
25E3 
22.3 ± 1.5 
35.8 * 2.0e 
36.3 ± 3.5 
37.В ± 4.4 
a Monoclonal antibodies used as markers for guinea pig leukocytes: CT5: T_cells, T167: T-cells and 
thymocytes, 31D2: B-cells, 305: macrophages, 25E3: la antigens. 
Ь Within parentheses number of samples evaluated; for placebo treated animals lymph nodes of four 
animals were pooled; for BCG treated animals lymph nodes of individual animals were evaluated. 
c
 Percentage of cells reacting with monoclonal antibodies, determined by FACS analysis (see materials 
and methods). 
ρ <0.05 e p< 0,01 respect ively, Students t - t e s t , two sided. 
Tabel 3: natural killer (NK) cell activity in regional draining 
(iliac) lymph nodes and spleen of guinea pigs after 
intravesical BCG administration^. 
Iliac lymph 
Placebo 
BCGd 
Spleen 
Placebo 
BCG 
nodes day 1b 
3.3 * 1.5 (7)c 
4.1 ± 2.5 (8) 
day 1 
41.8 ± 12.5 (7) 
45.4 ± 7.4 (8) 
day 4 
2.1 * 1.9 (7) 
2.6 ± 2.3 (8) 
day 4 
28.7 ± 14.0 (8) 
28.8 ± 12.1 (8) 
day 7 
2.8 * 1.6 (6) 
1.7 * 1.0 (7) 
day 7 
37.7 ± 10.5 (8) 
47.6 ± 12.1 (8) 
№<-cell activity was measured in a 18 h chromium-51 release assay 
using K562 target cells. 
Indicated are the days after the last BCG instillation. 
c
 Percentage specific chromium-51 release, mean * s.d. (number of 
animals) at effector to target cell ratio 100:1. 
d BCG, 5x10? ср., was administered once weekly for six consecutive 
weeks. 
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Table 4: Lymphokine activated killer (LAK) cell activity in regional 
draining (iliac) lymph nodes and spleen of guinea pigs after 
intravesical BCG administration3. 
Iliac lymph 
Placebo 
BCGd 
Spleen 
Placebo 
BCG 
nodes day lb 
16.7 * 3.9 (7)c 
25.2 * 9.2 (8)" 
day 1 
69.1 ± 7.0 (7) 
68.7 * 2.8 (8) 
day 4 
13.0 * 6.0 (8) 
12.3 ± 8.2 (8) 
day 4 
53.4 ± 11.6 (8) 
56.8 ± 6.4 (8) 
day 7 
14.2 ± 9.8 (8) 
9.2 * 4.6 (7) 
day 7 
58.4 ± 6.2 (8) 
62.6 ± 5.4 (8) 
8
 LAK-cell activity was determined in a 18 h chromium-Si release assay 
with the addition of recombinant interleukin 2 (70 units/ml) using 
K562 target cells. The IL-2 presence induced for all cell 
populations at all days investigated a significantly (at least 
ρ < 0.02, Students t-Test, two sided) increased cytotoxic activity 
(Compare results of table 4 with table 3). 
Ь Indicated are the days after the last BCG instillation. 
c
 Percentage specific chromium-51 release, mean ± s.d. (number of 
animals) at effector to target cell ratio 100:1. 
d BCG, 5x10? c.p., was administered once weekly for six consecutive 
weeks. 
e
 At day 1 significantly (p<0.05, Students t-test, two sided) 
increased induction of activity compared to placebo treated animals. 
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The non antigen specific spontaneous cytotoxicity (NK-cell activity) 
was measured in a 18h 51cr-release assay with К 562 target cells. In 
the iliac lymph nodes, both after placebo and BCG treatment, a low NK-
cell activity was observed at various days (day 1, 4 and 7) after the 
sixth BCG instillation (Table 3). In the spleen no differences in NK 
cell activity were present after intravesical BCG treatment compared 
to placebo treated animals (Table 3). Both in the iliac lymph nodes 
and in the spleen lymphokine activated killer (LAK) cell activity 
could be induced by adding recombinant interleukine 2 to the NK-cell 
test system. In both organs at all days tested, a significantly 
increased NK-cell activity was measured (p < 0.01, and in two cases 
ρ< 0.02, Students t-test, two sided) (compare the results presented in 
tables 3 and 4). At day 1, after the last BCG instillation, the BCG 
treated animals showed a significantly higher response in the iliac 
lynph nodes to co-culture with interleukin 2 compared to placebo 
treated animals (p<0.05, Students t-test, two sided). 
DISCUSSION 
In our studies on the induction of enhanced immune responses after 
intravesical BCG administration, most non-antigen specific immune 
reactions, such as lymphocyte mitogen responses and natural killer 
cell activity, were not increased when compared to placebo treated 
animals. The major difference between BCG and placebo treated animals 
was the induction of BCG antigen specific immune reactions in the 
formerly. This was expressed by the positive PPD skin tests, and by 
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the lymphocyte response of both locally the draining (iliac) lymph 
nodes and systemically of the spleen, when the in vitro antigen 
stimulation assay with purified protein derivative of Mycobacterium 
tuberculosis was used. 
The BCG specific reactivity was obtained after the intravesical 
administration of BCG in an intact bladder, as no intracavitary 
pretreatment damage was induced. Ratliff et al. (33) demonstrated in a 
murine model that attachment of BCG to the bladder wall was related to 
damage of the epithelial layer. When the bladder epithelium was 
coagulated locally, the attachment of BCG was increased 
significantly. Histopathologically we were not able to find damage of 
the epithelial layer covering the bladder wall (42). Although in these 
studies bladder damage could not definitively be excluded, we think 
that it is unlikely that our treatment schedule induced bladder 
damage. In this respect our data confirm the high sensitivity of the 
guinea pig for infections with mycobacteria (37). Even in the lowest 
dosis used (1x10' c.p. BCG), a systemic immune reaction to BCG could 
be obtained, as indicated by the positive PPD skin reaction. For the 
induction of a positive PPD skin reaction, however, repeated BCG 
instillations are needed. After two BCG instillations almost all 
aminala were negative, whereas after four BCG instillations all, exept 
two in the lowest dose administered (1x10^ с р . ) , animals became 
positive. Although we did not follow the positive PPD skin reactions 
for a long time, two months after the six week course of BCG, the 
animals still showed a positive skin reaction to PPD. 
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The capability of the BCG vaccine, used for intravesical 
administration, to induce a delayed type hypersensitivity skin 
reaction seems to be very important. In a murine bladder tumor system 
it was found that the antitumor effect of BCG was correlated with the 
viability and growth rate of BCG. Immunologically, e correlation was 
observed also with positive footpad reactions to PPD and augmentation 
of NK-cell activity. Low viable BCG-preparations did not induce both 
kind of activities (40). Also in bladder cancer patients a correlation 
was found between the PPD skin reaction and therapeutic results (16, 
23, A3). A similar correlation was observed after intralesional BCG 
immunotherapy in spontaneously occurring bovine ocular squamous cell 
carcinoma (19). Considering the relation between therapeutic effect 
and viability of the BCG both in the murine bladder tumor system (40) 
and in bladder cancer patients (16), not only the viability of the 
vaccine but also the total dose of BCG administered might be 
responsible for the data reported. In the murine system low and high 
viability BCG only were investigated at equal doses in microgram, and 
not in doses of culturable particles administered (40). Although 
differences between BCG preparations may be present, the differences 
observed by Shapiro et al. (40) may reflect the dependency of the 
assay system to a dose expressed in culturable particles instead of 
microgram of BCG. Such a dependency on dosage in culturable particles 
was previously demonstrated by us on the activation of splenic 
macrophages (38). 
Our results predominantly indicate local activation of the draining 
iliac lymph nodes. Systemically (measured by the iimiunologic activity 
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of spleen cells) besides the induction of BCG immune lymphocytes, no 
increased activity was observed after the six week course of 
intravesical BCG administration. Due to an influx or proliferation of 
leukocytes, an increased number of cells was present in the iliac 
lymph nodes. On these leukocytes and increased expression of the MHC 
class II (la) inmune response antigen was present. Using monoclonal 
antibodies detecting guinea pig T-lymphocytes with T167 an increased 
number of T-cells was detected in placebo treated animals. When CT5 
was used, the number of T-cells was not increased. After BCG 
administration an increase of T-cells was noted when CT5 was used, but 
not if T167 was employed. Both monoclonal antibodies were reported to 
act as pan T-markers for guinea pig T-cells (41, Burger, personal 
communication). In the spleen cell population our data for CT5 and 
T167 are more in accordance. At this moment we have no explanation for 
the difference observed. However, it might be that the T167 mono-
cloncal antibody shows cross reaction with guinea pig B-cells Burger, 
personal communication). With MoAb 305, detecting guinea pig macro-
phages, probably the presence of monocytes/macrophages was under-
estimated. Histologically the increase in size of the iliac lymph node 
is partly due to the BCG induced granulomas of monocyte/macrophage 
origin (30, 42). MoAb 305 was produced in mice immunized with adherent 
peritoneal cells, and reacts with mature, elicited, and activated 
macrophages (24). Part of the lymph node macrophages in our study were 
probably mature monocytes/macrophages further differentiated to 
epithelioid cells forming granulomas (1). It is possible that these 
epithelioid cells might not be recognised by the 305 MoAb. However, 
this does not explain the low number of macrophages detected in 
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placebo treated animals. Our data and also those of others (Scheper, 
personal communication), indicate that MoAb 305 is less suited as 
marker for lymph node macrophages in FACS analysis. 
In contrast to studies in mice (40) we did not find an increased 
natural killer (NK) cell activity in the guinea pig after intravesical 
BCG administration, probably due to the differences in methods used 
(damaged versus non-damaged bladder). Our data on NK-cell activity are 
in the same range as previously reported (2). At day 1 after the last 
BCG instillation we found an increased susceptibility for the 
induction of enhanced NK-cell activity (LAKlcells) by interleukin 2 in 
the iliac lymph node cells. In contrast to data reported by Zwilling 
et al. (44), our results clearly demonstrate that guinea pig lymph 
node cells can be significantly activated for cytotoxicity by 
interleukin 2. 
Although initially correlations were found between the antitumor 
activity in a murine bladder tumor system, and the NK-cell activity 
(40), additional studies indicated that NK-cells are not a major 
contribution to the antitumor activity after intravesical BCG 
administration (34). Of major importance seems to be the thymus 
dependent immune response to BCG (31). This thymus dependent immune 
response to BCG, also was reported to be essential for the antitumor 
activity of BCG, after local BCG administration in murine and guinea 
pig tumor systems (7, 14, 35). In the bladder wall repeated antigen 
contact may lead to a delayed type hypersensitivity reaction (Θ). 
Probably the mononuclear infiltrates present in the bladder wall after 
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repeated BCG administration (6, 12, 20, 42) can be interpreted as an 
expression of a delayed type hypersensitivity reaction. One of the 
lymphokines involved in the delayed type hypersensitivity reaction is 
interleukin 2. In bladder cancer patients interleukin 2 could be 
detected in the urine during the six week BCG course (unpublished 
observations, 32). Besides T-cell proliferation by interleukin 2, this 
lympokine produces lymphokine activated killler (LAK) cells which are 
able to lyse a broad range of tumor target cells (reviewed by 
Rosenberg, 36). For the in vivo antitumor activity both NK-derived and 
T-cell derived LAK-cells were found to be responsible, depending on 
the immunogenicity of the tumor used (29). 
For the effect of BCG in the treatment of superficial bladder cancer 
in different systems, various indications were found for the activity 
of BCG. However, although several suggestions were reported both in 
experimental aminal tumor systems and in man, more knowledge is needed 
on the mechanism of the antitumor activity of BCG in superficial 
bladder cancer. 
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SUMMARY 
The inmune reactivity of selected patients with strongly recurrent 
superficial bladder cancer was followed after combined intravesical 
and intradermal BCG (Bacillus Calmette-Guérin) immunotherapy. All 
patients in this study had been treated previously without succes with 
intravesical chemotherapy. The BCG treatment regimen consisted of 
weekly administrations of BCG-RIVM for six consecutive weeks, both 
intravesically and intradermally. In this study, sera and PBLs 
(peripheral blood leukocytes) of patients were tested serially. 
Besides BCG antigen specific reactions e.g. skin reactivity to 
tuberculin PPD (purified protein derivative of Mycobacterien 
tuberculosis), antibody formation and antigen stimulation of PBLs in 
vitro, also non-antigen specific immune reactivities were measured 
e.g. mitogen response and spontaneous cytotoxic activity of PBLs. In 
addition, the antibody response to bladder carcinoma antigens and the 
cytotoxic activity of PBLs to the bladder carcinoma cell line Τ 24 and 
the NK sensitive К 562 cell line were investigated. The results 
obtained from the various assays were evaluated for their prognostic 
value in relation to the length of the tumor-free interval after the 
BCG treatment. Because sera and PBLs were only obtained during the 
first 6 months after the BCG treatment, the immune reactivity was 
compared to the clinical results at the same time point. At 6 months 
after therapy 12 of the 40 BCG treated patients were tumor free 
whereas 28 of the 40 had a recurrence. Skin reactivity to tuberculin 
PPD was measured in 40 patients during a period of 3 to 6 months after 
therapy. Of the patients, who showed a period of 3 to 6 months after 
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therapy. Of the patients, who showed a recurrence of the tumor within 
6 months, 4Θ% had a transient response or showed no response at all to 
PPD. In the group of patients with a longer tumor free periode (N= 
10), only one patient lost his responsiveness to tuberculin PPD. 
Although the PBLs of a limited number of patients were tested, we 
observed that the cytotoxicity to the bladder carcinoma cell line 
Τ 24, and to the NK sensitive К 562 cell line increased in a number of 
patients (7 of the 14,-and 9 of the 14, respectively). Reactivity of 
PBLs to mitogens and the subset distribution (ratio T-helper: T-
suppressor/cytotoxic) were not influenced by the BCG treatment. 
Antibody response to mycobacterial antigen was detected in 9 of the 23 
investigated patients. Eight of these 9 patients belonged to the group 
with a recurrence of the tumor within 6 months (N= 17). There was no 
correlation between the skin reactivity and the antibody response to 
tuberculin PPD. Furthermore, only 1 of the 25 patients showed an 
antibody response to bladder carcinoma antigens. Sera of bladder 
carcinoma patients (N= 19) reduced the mitogen induced proliferation 
of lymphocytes. This indicates the presence of circulating suppressor 
factor(s). Our results show that the absence of PPD conversion or the 
presence of a transient reaction to tuberculin PPD were related (9155) 
to a relapse of the disease. On the other hand, the cytotoxic activity 
of PBLs to Τ 24 and К 562 cell lines, or their reactivity to 
tuberculin PPD or mitogens, provided no predictive information about 
the clinical results (tumor-free interval) of the BCG therapy. 
Finally, there may be an inverse relationship between the antibody 
response to BCG and its antitumor activity. 
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INTRODUCTION 
In many studies intravesical immunotherapy with Bacillus 
Calmette-Guérin (BCG) has shown beneficial results in the prevention 
of recurrent superficial bladder cancer after transurethral resection 
(reviewed in 14). Presently, BCG immunotherapy for superficial bladder 
cancer is besides the Interferon treatment of Hairy cell leukemia 
(42), an immunotherapeutic treatment modality which has shown 
indisputable success in man. To elucidate the mechanism of this kind 
of therapy, basic studies need to be performed in patients during 
treatment. However, there are many doubts whether the assessment of 
immune functions gives any information about the host-tumor 
relationship (reviewed in 7). In most cases, immune functions were 
studied after treating the tumor by surgical excision, by irradiation 
or after BCG immunotherapy in non-bladder related tumors. As these 
tumors were not reacting to the BCG therapy, the linkage of inmune 
responses to favorable therapeutic results was not possible. In 
contrast with this, treatment of patients with superficial bladder 
tumors actually offers a situation suitable for the examination of 
euch a relationship, as a high percentage of patients respond 
favorably to BCG immunotherapy (14). 
Is is still unknown which of the processes that may be activated by 
BCG are responsible for the prevention of superficial bladder tumors. 
Zbar et al. (55) have shown that BCG induces regression of the primary 
tumor, eliminates metastases, prevents recurrent tumors and induces 
specific immunity to the line 10 hepatocellular carcinoma, in the 
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strain-2 guinea pig. Whether or not a specific immune response is 
responsible for the antitumor effect of BCG in superficial bladder 
cancer, is unknown. However, there is evidence that immunological 
reactions may occur. It has been reported that lymphocyte reactivity 
to bladder tumor cell lines is present in PBLs of patients with 
superficial tumors of the bladder (10, 19, 27, 37, 38, 51). Humoral 
response to the tumor has also been reported (10, 17, 48, 51). In 
addition, the presence of tumor antigens at tumors of the bladder has 
been demonstrated by using monoclonal antibodies (MoAb) (13, 24, 30, 
31, 52, 54). Probably, an immune response might be evoked against 
these bladder tumor related antigens. BCG can exert various activities 
on the immune system (reviewed in 20). T-cells may be activated, 
resulting in increased activity of cytotoxic T-cells but also in 
increased activity of T-suppressor cells. Moreover, various macrophage 
activities may be enhanced, like phagocytosis and killing of bacterial 
and tumor cells. 
In this study we investigated which immune parameters might be 
predictive for the prevention of recurrent superficial bladder tumors 
after BCG immunotherapy. Serum and peripheral blood leukocytes of 
selected patients with a history of strongly recurrent superficial 
bladder carcinoma were collected. These patients were treated with 
both intravesical and intradermal administration of BCG-RIVM. We 
investigated the local and systemic toxicity during and after 
treatment (46). A range of parameters was studied in order to select 
useful tools for immunological monitoring. We serially investigated 
the reactivity to PPD in vivo and in vitro. The reactivity of PBLs to 
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mitogens, to a bladder tumor cell line and a to NK sensitive target 
cell was determined. The humoral response was assessed by measuring 
the antibody response to mycobacteria and to bladder carcinoma 
antigens. 
MATERIAL AND METHODS 
Patient characteristics and treatment 
Patients in this study had histologically proven strongly recurrent 
superficial bladder tumors (pTa or pTI) Tor several years (at least 3 
recurrences within the last 5 years). All patients had been treated 
previously with adjuvant intravesical chemotherapy using epodyl and 
adriamycin or both after repeated transurethral resection of the 
tumors. However, in all patients bladder tumors recurred, despite 
chemotherapy. Patients were treated according to the regimen Morales 
initially had used (33). Ten days after transurethral resection of all 
visible tumors instillations were started for once a week for 6 
consecutive weeks. About Ю ? culturable particles (c.p.) in 10.5 mg 
dry weight BCG-RIVM (lot 901) were diluted in 50 ml 0.9Й saline and 
administered by a transurethral catheter in an empty bladder. The BCG 
solution was retained in the bladder for 2 h., if possible. 
Together with the intravesical instillation, О. хЮв c.p. in 0.48 mg 
of BCG-RIVM (lot 601) were administered intradermally using a 
multi-puncture apparatus Mark 5 (Bignell Surgical Instruments Ltd., 
Little Hampton, W. Sussex, UK) on the innerside of the upper leg. This 
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administration was repeated weekly for 6 consecutive weeks at 
alternating thighs. 
PPD (purified protein derivative of Mycobacterium tuberculosis) skin 
reactivity was tested before starting therapy and at 1, 4, 13 and 26 
weeks after completion of the instillation regimen. Skin reaction was 
considered to be positive when an induration was measured with a 
diameter of Ì 10 mm. Cystoscopy was performed at 4, 13 and 26 weeks 
after completion of the BCG therapy. 
Isolation and storage of PBLs 
Non heparized (20 ID/ml) venous blood was collected prior to 
treatment and at 1, 4, 13 and 26 weeks after BCG treatment, or until 
recurrence of the tumor. PBLs were isolated from heparized blood by 
Ficoll-Isopaque (density of 1.077, Pharmacia Inc., Uppsala, Sweden), 
during 40 min., Θ00 g, at room temperature. Cells were resuspended in 
cold RPMI-1640 containing 2 mM L-glutamine and 25 mM Hepes buffer 
(Gibco, Grand Island, New York, USA) and supplemented with 20% 
heat-inactivated (45 min., 560C) fetal calf serum (FCS, Gibco Europe 
Palsly, Scottland). Dimethylsulfoxide (DMS0, Fluka Ag, Chem Fabr. 
Bucks, Switzerland) was added dropwise until a concentration of 10% 
DMSO was reached. The PBLs were divided into aliquota over 4 ampules 
at a concentration of * 5x10^ cells per ml, deep frozen and stored in 
liquid nitrogen. Before assaying the cells, samples were rapidly 
thawed and washed twice to remove DMSO. Only the activity of PBLs with 
a viability of 60Й or more were investigated. All PBLs or sera of each 
time interval from one patient were tested at the same day to avoid 
variation in the immunological assays. 
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T-cell subset distribution PBLs 
T-cell subpopulations of the PBLs were determined at the day of 
isolation by the use of monoclonal antibodies (MoAb). The MoAbs used 
for this study were obtained from the national Institute of Public 
Health and Environmental Protection (RIVM, Bilthoven, The Netherlands) 
and used in the following dilutions: anti-T3 (RIV 3) defining all 
mature T-Lymphocytes (anti-Pan T) in human PBL (1:100); anti-T4 
(RIV 6) defining T-lymphocytea with a helper function (1:300) and 
anti-T8 (RIV 2) defining T-lymphocytes with suppressor/cytotoxic 
function (1:300). 
The PBLs isolated from the plasma-Ficoll Isopaque interface were 
washed twice using cold PBS supplemented with 1% bovine serum albunin 
(BSA) and O.IJS NaN3 and diluted to a concentration of 4x10^/ml. One 
hundred μΐ of the suspension containing 4x10^ cells were incubated 
(30 min., on melting ice) with 100 μΐ antibody dilution in 3 ml 
plastic tubes. After washing (twice, 5 min. 900 g) with supplemented 
PBS, the cell pellet was incubated (30 min. on melting ice) with goat 
anti-mouse serum conjugated with fluorescein isothiocyanate (dilution 
1:20, FITC, Nordic Immunological Laboratories, Tilburg, The 
Netherlands). After washing (twice, 5 min. 900 g) with supplemented 
PBS, one drop of glycerol (87Й) was added to each pellet. Of each 
suspension 200 lymphocytes were counted using fluorescence 
microscopy. The ratio T-helper versus T-suppressor cytotoxic cell was 
calculated. Of only patients with a score of more than 50 percent of 
cells positive for pan Τ (anti-T3, RIV 3), the T-cell subset ratio was 
determined. 
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In vitro lymphocyte transformation assay 
Stimulation assays were performed in 96-well round-bottom microtiter 
plates (Costar, Cambridge, Mass., USA). PBLs were diluted in RPMI-1640 
containing 2 mM glutamide and 25 mM Hepes buffer, supplemented by 
100 ID/ml penicillin and 100 ng/ml streptomycin, and incubated with 
25 μΐ heat inactivated pooled human serum AB RN- and 50 μΐ mitogen or 
antigen. The final cell concentration used for the mitogen response 
was 1.2x106 viable cells/ml and for the antigen response to purified 
protein derivate (PPD) of Mycobacterium tuberculosis 4x1 Об viable 
cells/ml. The optimal concentration for concanavalin A (Con A, 
Miles-Yeda Ltd., Rehovot, Israel) was 10 pg/ml, for phytohaemag-
glutinin (PHA, Wellcome Research Laboratories, Beckenham, UK) 5 μΐ/ml 
and for pokeweed mitogen (PWM, Gibco, Grand Island, New York, USA) 
10μg/ml. The final concentration of PPD was 3 pg/ml. The final culture 
volume was 0.1 ml/well. Cells were cultured in vitro for 6 days at 
37"C in a humidified atmosphere of 5% CO2 in air. Sixteen hours before 
harvesting, 0.5 pCi methyl-3h-thymidine ('HTdR specific activity of 
1.0 Сi/mmol; Radiochemical Centre, Amersham, Buckinghamshire, UK) was 
added per well. Cellular DNA was harvested on glass fiber filters 
using a multiple cell culture harvester (Skatron Lierbyen, Norway). 
The filter samples were dissolved in 20 ml toluene, containing 15 g 
2,5-diphenyloxazole (PP0) and 1.0 g 1.4-bi3-2-(5-phenyloxazolyl)-
benzene (P0P0P) per 2,500 ml toluene. 3HRdR incorporation was measured 
in an ISO cap/300 liquid scintillation counter (Nuclear Chicago Corp., 
Des Plaines, ILL, USA). Results were expressed as counts per minute 
(CPM) using the median of triplicate values corrected by subtracting 
the isotope uptake in control cultures. 
- 15B -
The presence of suppressive factors in sera of patients with recurrent 
superficial bladder cancer was determined by exposing these sera to 
the blastogenic response of PBLs from a healthy donor. PBLs of the 
healthy donor (with a positive tuberculin reaction) were cultured 
immediately after isolation in the presence of heat inactivated 
(45 min. 560C) and sterilized (0.22 um millipore filters) sera of 19 
patients with superficial bladder cancer at a concentration of 25% of 
the culture volume. The sera of these patients were collected before 
the BCG treatment. The lymphocyte stimulation in the presence of serum 
from 19 bladder carcinoma patients was compared to the stimulation of 
these lymphocytes in the presence of serum from 13 healthy donors. For 
statistical analysis of the inhibition experiments the Students t-test 
was used to calculate two-sided significance of differences. 
Cytotoxic assays 
Target cells: To measure the NK activity of PBLs from patients, the NK 
sensitive human cell line К 562 was used (5). The К 562 cell line has 
been derived from a patient with chronic erythroid leukemia in blast 
crisis. In oder to determine reactivity to carcinoma cells of the 
bladder, the Τ 24 cell line (10, 11) was used. This tumor cell line 
was kindly provided by Dr. F. Ramaekers, Department of Pathology, 
University Hospital Nijmegen, The Netherlands). The К 562 cells, were 
cultured in RPMP-1640, containing 2 mM glutamide and 25 mM Hepes 
buffer supplemented with 100 ID/ml penicillin, 100 jjg/ml streptomycin 
and 10S heat inactivated FCS (referred to as complemented RPMI-1640). 
The tumor bladder cell lines were cultured in Eagles Minimal Essential 
Medium (MEM), containing 10 mM Hepes buffer and 10 mM МаНСОз 
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supplemented by non-essential amino acids (MA Bioproducts, 
Walkersville, USA), 100 IU/μΙ penicillin, 100 iiq/μΐ streptomycin and 
IOS FCS, further referred to as supplemented MEM. Prior to the use in 
the 51Cr-release assay, these cells were harvested and dispersed into 
a single cell suspension, using a mixture of 0.25л trypsin (Difco, 
Detroit, USA) and 0.02% ethylene diamine tetra-acetic acid (EDTA, 
Sigma) in PBS рНд. 
ЯСг-геІеазе assay: Target cells (2x106 cells in 0.2 ml RPMI-1640 or 
MEM) were labelled with 150 μϋϊ radioactive sodium Chromate (Na2 
5 1Cr04, specific activity 5 mCi, 1B5 M Bq 40 pgCr/ml, Radiochemical 
Centre, Amersham, UK) for 2 h. at 37eC. After labelling, the cells 
were washed 3 times (10 min., 300 g) in 45 ml supplemented medium and 
the number of viable cells was determined by the trypan blue (0.5%) 
exclusion method. 
5x10' viable 51cr-labelled target cells in 100 μΐ cultured media were 
added to the wells of a microtiter plate (Removawell System, Dynatech 
Companies, Zug, Switzerland). To reach an effector to target (E:T) 
cell ratio of 80 and 40, 4x105 or 2x105 viable effector cells in 
100 μΐ complete RPMI-1640 were added respectively. Tests were 
performed in triplicate. After centrifugation at 200 g for 5 min., the 
plates were incubated for 4 h. or IB h. at 370C in a humified 
atmosphere of 5% CO2 in air. After incubation, the plates were 
centrifuged again and half of the supernatant (100 μΐ) was collected. 
The radioactivity was determined by a gamma counter LKB, Wallac 12B0 
Ultra gamma, LKB-Produkter AB Bromma, Sweden) and expressed in counts 
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per min. (CMP). The spontaneous release of 51ς
Γ
 labelled target cells 
was determined by incubating the labeled cells in medium alone (5x10' 
target cells in 200 μΐ). The release was calculated as follows: 
2xs 
% release = x 100Ä, where s equals the cpm in half of the 
sed+s 
supernatant and sed equals the cmp in sediment and the other half of 
the supernatant. 
Cytotoxic activity was expressed in the percentage of specific 
release, i.e. percentage release minus percentage spontaneous release, 
using the median of triplicate values. The spontaneous release varied 
in the different assays: for К 562 after 4 h. incubation from 3 to 9% 
51Cr release; for Τ 24, after IB h. incubation from 20 to ЗОЙ, 5 1Cr 
release. 
Antibodies to BCG 
Antibodies to BCG were measured by the enzyme-linked immunosorbent 
assay ELISA (23). In short: flat-bottom microliter plates (Titertek 
Type II, Flow Laboratories, Irvine, Ayrshire, Scottland) were coated 
with 100 μΐ carbonate buffer containing 10 μς/ηΐ purified protein 
derivative (PPD) of Mycobacterium tuberculosis. Dilutions of the sera 
and a range of dilutions from a known standard were prepared using a 
mixture of 0.5% BSA and 0.01Й Tween 20 and subsequently 100 μΐ was 
incubated with the antigen for 2 h. at 37"C. After washing, the 
blocked antibody was determined by adding 100 μΐ anti-human gamma­
globulin, conjugated with horse radish peroxidase (diluted 1:200, 
RIVM, Bilthoven, The Netherlands), and incubated for 2 h. at 370C. 
After washing, the total complex was visualized by adding 100 μΐ, 5 
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amino salicylic acid (5 AS) and H2O2 per well. After incubation for 10 
min. at room temperature the enzyme reaction was blocked by adding 
0.33N NaOH and the brown colored reaction product was measured in a 
multichannel spectrophotometer at 455 nm (Titertek Multiscan, Flow 
Laboratories, Irvine, Ayrshire, Scottland). The extinction values of 
the samples were compared to standard dilutions, and the concentration 
was expressed in a percentage of a standard positive reference serum. 
A patient was considered to have an anti-BCG response when the 
difference in antibody-level between post- and pre-BCG treatment 
samples exceeded the sum of 2x sd of both samples. 
Antibodies to bladder carcinoma antigens 
Antibodies to bladder carcinoma antigens were measured in an ELISA 
(24) using fixed target cells (T 24 and В 12 cells) or a soluble 
antigen derived from a transitional cell carcinoma (TCC sup, 40). The 
В 12 cell line was derived and cultured at the RIVM from a patient 
with recurrent superficial bladder tumor (stage pTa). TCC sup. was 
kindly provided by Dr. S. Paulie, (Department of Immunology, 
University of Stockholm, Sweden). In the ELISA a monoclonal antibody 
(MoAB), kindly provided by Dr. S. Paulie (40), was used as a positive 
reference. In short: flat-bottom microtiter plates were coated with 
BO fig/ml TCC sup (0.02S № N 3 in PBS) for 1 h. at 370C. For the 
cell-ELISA, 2-3χ104 Τ 24 or В 12 cells were cultured for 2 to 3 days 
in a flat-bottom microtiter plate to obtain monolayers which were 
fixed with 0.05JÓ glutaraldehyde in PBS for 5 min. Wells were incubated 
for 1 h. with 15» BSA in PBS and stored at 4,,C in PBS containing IS BSA 
and 0.02% NaN3. Prior to use, antigen or cell coated microtiter plates 
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were incubated with gelatin 0.1% in PBS with 0.02% № N 3 for 20 min. at 
room temperature. 
After washing with PBS (0.05Й Tween 20 and 0.02% № N 3 ) , 100 μΐ serum 
from patients or from healthy donors was added in a twofold dilution 
to the wells and incubated for 1 h. After washing, sheep anti-human 
gammaglobulin conjugated with horse radish peroxidase (RIVM) was added 
in a dilution of 1:10,000 and incubated overnight at room temperature. 
After washing, the antigen-antibody complex was visualized by 5 AS and 
measured in a multichannel spectrophotometer at 450 nm. An extinction 
value of over 0.20 was considered to be positive. 
RESULTS 
Cellular and huaoral responses to Mycobacteria 
Delayed type hypersensitivity reactions to tuberculin PPD: A skin test 
was performed in a total of 40 patients, at 1, 4, and 13 weeks after 
the final (6tb) intradermal administration and intravesical 
instillation of BCG. Of these patients 9 (23%) were PPD positive prior 
to treatment (table 1). After BCG treatment, 6 of these 9 
pretreatment-positive patients showed an increased reactivity. The PPD 
reaction was considered to be increased when the induration of the 
skin was enlarged more than 25% compared to the pretreatment value. Of 
the 31 patients who had PPD negative skin tests prior to treatment, 26 
patients (84%) showed a PPD conversion from negative to positive after 
the treatment. However, in a number of these patients the reaction to 
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PPD started to decrease during the follow-up period. Of the 26 
patients with a PPD conversion 20 (7755) showed a positive response 
(induration size è 10 mm) during at least 13 weeks. Skin reactivity to 
tuberculin PPD was not evaluated at 26 weeks as several patients with 
a recurrence of the tumor within 13 weeks were not consequently 
followed. 
Table 1: Skin reaction (DTH) to tuberculin PPD in patients with 
superficial bladder carcinomas prior to and after BCG 
treatment. 
Pretreatment 
Posttreatment 
Skin reaction 
at 13 weeksd 
PPD 
negative8 
31/40 (77K)c 
skin reaction8 
positive8 
9/40 (23Й) 
26/31 (84%) 
20/26 (77«) 
increaseb 
6/9 (67Й) 
8
 Skin reaction: PPD negative induration < 10 mm; PPD positive à 10 mm 
" Increase in diameter 2 25% compared to pretreatment value only for 
PPD positive pretreatment patients 
c
 Number of patients with/without a reaction to tuberculin PPD versus 
number of patients investigated, within parentheses percentage of 
patients 
" Patients who were PPD positive at week 1, 4 and 13 after BCG 
treatment 
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Table 2: Diameter of the skin reaction after BCG treatment in bladder 
cancer patients with a PPD positives or PPD negativeb 
pretreatment reaction. 
Patient 
Group 
Positive 
Negative 
Pretreatment 
reaction mm 
18.4 ± 12.7 (9)c 
2.1 * 3.0 (20) 
weeks 
1 
22.0 ± 16.2 (7) 
16.2 * 7.0 (18) 
after BCG treatment 
4 
18.9 ± 6.7 (9) 
16.5 ± 8.2 (18) 
13 
18.9 * 4.9 (β) 
19.1 ± 6.3 (20) 
a
 Patients with a PPD reaction with diameter i 10 mm 
Ь Patients with a PPD reaction with diameter < 10 mm 
c
 Mean * sd of diameter in mm, within parentheses number of patients 
tested 
The size of induration, evoked by the DTH reaction to tuberculin PPD, 
was compared among patienta with PPD positive (N= 9) and PPD negative 
(N= 20) pretreatment values. No significant difference in induration 
size was found between the two groups (table 2). 
We investigated whether or not there was a correlation between the 
reaction to tuberculin PPD and the clinical result (tumor-free 
interval) after BCG treatment. Therefore, the patients (N= 40) were 
divided into two groups: 
1. patients with a recurrence of the tumor within 6 months (N= 28) and 
2. patients who were free of tumor at 6 months (N= 12). As the 
immunological follow-up was limited to 6 months, this time point was 
arbitrarily chosen for evaluation. Of the 12 patients, who were tumor 
free at 6 months, 6 developed a recurrence between 6 and 12 months and 
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6 remained tumor free for more than 12 months after BCG treatment. 
Seven of the 9 patients (78%), who already had PPD positive skin tests 
prior to BCG treatment (N= 9), had a recurrence of the tumor within 6 
months (table 3). Considering the 31 patients with PPD negative 
pretreatment values, we found that 21 patients (68%) showed a 
recurrence of the tumor within 6 months. 
Table 3: Pretreatment value of the skin reaction to tuberculin PPD 
and the clinical result after BCG treatment. 
Pretreatment Number Clinical results at 6 months 
responses to of Tumor recurrence Tumor free 
PPD skin test patients N= 28 N=12 
Positive8 9 7 (78S)c 2 (22Й) 
Negative0 31 21 (68й) 10 (32S) 
a
 Patients with a PPD reaction with diameter S 10 mm 
b
 Patients with a PPD reaction with diameter < 10 mm 
c
 Prediction (in percentages) of which a response is correlated with 
the clinical result after BCG treatment 
With regard to the PPD reaction the patients can be subdivided in 
non-responders, transient responders and reaponders at 13 weeks. Most 
of the patients with a negative or transient reaction to tuberculin 
PPD had a recurrence of the tumor within 6 months, whereas only one 
patient with a transient reaction was tumor free. Associating the DTK 
response with the length of the tumor-free interval (table 4), we 
found that, of the 20 patients with a positive response to tuberculin 
PPD at 13 weeks, 9 (45S) were tumor free. This is in contrast to the 
patients who had a negative PPD response at 13 weeks and of whom only 
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1 of 11 (9%) was without tumor. Both the absence of the PPD conversion 
and the presence of a transient reaction to tuberculin PPD were 
indicative for recurrence of the bladder tumor as this was observed in 
91» of the patients (10 of 11). 
Table 4: Correlation between the reaction to Mycobacteria specific 
antigens (tuberculin PPD) and the clinical result after BCG 
treatment. 
Clinical results at 6 months 
Number of a Tumor recurrence Tumor free 
patients 
Skin reaction to PPD: 
- positive at week 13b 20 
- negative/transient^ 11 
events 
In vitro reactivity 
of PBLs to PPD: 
- increased^ 17 
- unchanged/decreased 16 
patients 
Antibody production: 
- presentf 9 θ (89S) 1 (11«) 
- absent 14 9 (64Й) 5 (36«) 
a
 Events: number of samples obtained after 1, 4, 13 and 26 weeks 
b Positive at week 1, 4, and 13 (induration i 10mm) 
c
 Prediction value of parameter expressed as chance (percentage) to 
belong to the group of patients which showed a tumor recurrence or 
were tumor free 
d Negative (induration < 10 mm); transient: PPD conversion (induration 
2 10 mm) was lost within 13 weeks after BCG treatment (induration 
<10 mm) 
e
 Reactivity of the PBLs to tuberculin PPD was positive when 5H-TdR 
incorporations were at least 20% increased compared to the 
pretreatment values 
f A patient was considered to have an anti-BCG respons, when the 
response difference in antibody-level between post and pretreatment 
samples was more than the sum of 2x sd of each sample 
11 (55S)c 9 (45«) 
10 (91«) 1 (9«) 
12 (71«) 5 (29«) 
9 (56«) 7 (44«) 
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In vitro PPD lymphocyte stimulation; The lymphocyte response to PPD in 
11 patients is shown in Figure 1. During the 26 weeks, in 9 of the 11 
patients at least once an increase of Зн-TdR incorporation was 
measured, exceeding the pretreatment value. Two patients, who showed 
no increased reactivity to PPD, had high pretreatment values. 
Figure 1: 
Response to PPD of PBL 
from patiente with euper-
ГІСІ8І bladder carcinona 
after treatment with BCG. 
* Recurrence at 26 weeks 
• Timor free at 26 weeks 
+ Moan value 
26 
lent 
These two patients were PPD positive prior to treatment. Of these 
patients with a positive lymphocyte response to PPD (N= 9), 6 patients 
showed tumor recurrence within 6 months and 3 patients did not. The 
reactivity of the PBLs to PPD was not always present at each time 
point of investigation. Therefore all separate time points (week 1, 4, 
13 and 26) were used to analyse whether or not the measurement of this 
immunological parameter at a specific time point could be used to 
predict the clinical results. All results at different measuring 
points were subdivided into increased or unchanged/decreased réponse 
to tuberculin PPD. Table 4 shows that patients with an increased 
°25h 
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с 
о 
15 
Q. 
с 
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weeks otter BCG treahr 
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reaction to tuberculin PPD and patients with an unchanged/decreased 
reaction have almost similar tumor responses after 26 weeks. This 
indicates that the PPD responsiveness of PBLs as an immunological 
parameter has no predictive value for the clinical response to BCG 
treatment. 
Antibody response to Mycobacteria; Sera of 23 patients were tested for 
the presence of antibodies to mycobacteria. In 9 of the 23 patients 
(39%), an antibody response to mycobacteria was measured after BCG 
treatment. Eight of these 9 patients showed a recurrence of the tumor 
within 6 months. We investigated whether or not the presence of 
antibodies could be used as a prognostic parameter with regard to the 
tumor-free interval. Table 4 shows that the production of antibodies 
to tuberculin PPD may correlate with an unfavorable clinical response 
to BCG treatment. 
While considering both anti-BCG reactions, i.e. a positive PPD skin 
test and antibody production, these reactions showed no correlation 
with each other. All 23 patients, that were tested for the presence of 
antibodies to BCG, had a positive PPD skin reaction, either before or 
after the BCG treatment. 
Cellular and hunral response to bladder сагсігкжа antigens 
Cellular responses: The 4 h. 51c
r
_
r e
i
e a s e
 assay with cell line Τ 24 
revealed no cytotoxicity of the PBLs, isolated at different time 
points after completion of the BCG treatment. However, cytotoxicity 
could be detected in the 18 h. 51с
г
_
Г
е1еаэе assay. The results of this 
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assay using Τ 24 cells at a target effector ratio of 1:80 are 
presented in figure 2. BCG treatment resulted in an increased 
cytotoxicity of PBLs in 7 of the 14 (505i) patients. The activity was 
considered to be increased, when the specific release exceeded twice 
the pretreatment value, at least once during the observation period. 
Of these 7 patients, 4 showed a recurrent tumor within 6 months and 3 
patients were free of tumor at 6 months. 
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Figure 2: 
Cytotoxic activity of P8L from 
patients with superficial 
bladder carcinoma against Τ 24 
cells. 
* Recurrence at 26 weeks 
• Tumor free at 26 неекв 
+ Mean value 
Cytotoxicity was determined i n 
a 18 h 5 1Cr-releeee asssy at a 
target to effector c e l l rat io 
of 1:80. 
1 U 13 26 
weeks after BCG treatment 
The c e l l u l a r response to Τ 24 c e l l l i n e was evaluated as a possible 
prognostic parameter for the tumor-free i n t e r v a l . For t h i s evaluation 
44 post-BCG-treatment samples were analysed. Table 5 shows that 4 of 
the 14 (19%) pat ients with an increase i n cytotoxic a c t i v i t y to Τ 24 
bladder carcinoma c e l l l i n e were f r e e of tumor at week 26, whereas 10 
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of the 30 (ЗЗй) of the patients with unchanged/decreased activity were 
tumor-free. Our data indicate that cellular response to Τ 24 cells is 
not predictive for the clinical course of the disease. 
Table 5: Correlation between the cytotoxicity of PBLs for the Τ 24 
cells and the clinical result after BCG treatment. 
Cytotoxicity Number of Clinical results at 6 months 
to Τ 24 cells eventsa Tumor recurrence Tumor free 
Increasedb 14 10 (7U)c 4 {23%) 
Unchanged/ 30 20 (67») 10 (ЗЗЙ) 
Decreased 
a
 Events: number of measuring points obtained after 1, 4, 13 and 26 
weeks 
b Increase was determined when the specific release exceeded twice the 
pretreatment value 
c
 Prediction (in percentages) of which a response is correlated with 
the clinical result after BCG treatment 
Antibody response 
Sera from 25 patients were tested for the presence of antibodies 
against bladder carcinoma antigens, using the Τ 24 and В 12 cell lines 
and the soluble antigen extract (TCC sup). In none of these patients 
the presence of antibodies was measured. 
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Non antigen specific imune reactions 
T-cell subset distribution of PBLs: Table 6 presents the T-cell subset 
distribution of PBLs T-helper and T-suppressor/cytotoxic cells. In a 
total of 17 investigated patients, no significant change in ratio was 
observed after the BCG treatment. 
Table 6: Ratio T-helper and T-suppressor/cytotoxic cellsa of peripheral 
blood lymphocytes of patients with superficial bladder 
carcinoma after treatment with BCG. 
Clinical results 
at 6 months 
Prior to " 
treatment 1 
Ratio Th/Ta 
weeks after BCG treatment 
4 13 26 
Tumor recurrence 2.0 ± 1.4 2.4 ± 1.7 2.4 ± 1.7 2.0 * 1.2 2.3 * 1.0 
(11)b (11) (10) (11) (B) 
Tumor free 2.0 * 0.8 2.4 * 0.7 2.2 ± 0.7 1.9 ± 0.7 1.7 * 1.0 
(6) (5) (6) (6) (5) 
a
 T-helper and T-suppressor cells were determined by anti-T^ and anti-Tfl 
Moab respectively 
b
 Mean * ad of ratio within parentheses number of patienta 
Considering the response of the individual patient, we observed that in 
the tumor free patients, 3 of the 6 {50%) showed at least once an 
increase in Th/Ts ratio. In patients with a recurrent tumor an increase 
was observed in 8 of the 11 (72Ä) patients. Evaluating the 63 post-
treatment samples, we found that the T-cell subset distribution of PBLs 
has no prognostic value for the anti-tumor response after BCG 
treatment (table 7). 
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Table 7: Correlation between the non-specific immune reactions of 
PBLs and the clinical results after BCG treatment. 
Number of Clinical result at 6 months 
eventsa Tumor recurrence Tumor free 
Ratio T-helper and 
T-suppressor/cyto-
toxic cells of PBLs: 
- increasedb 23 1Θ (56й)с 5 (443) 
- unchanged/decreased 40 23 (5B%) 17 (425S) 
Mitogen1^ response: 
- increasedb 
- unchanged/decreased 
NK activity: 
- increased6 
- unchanged/decreased 
27 
56 
21 
21 
21 (78Й) 
42 (63S) 
15 (71Й) 
13 (13«) 
6 (22») 
14 (37») 
6 (29») 
θ (38») 
a
 Events: number of measuring points obtained after 1, 4, 13 and 26 
weeks 
b A patient was considered to have an increased Τ^/Τ9 ratio or mitogen 
response when an increase of Ь 20» was found compared to the 
pretreatment value 
c
 Prediction (in percentages) of which a response is correlated with 
the clinical result after BCG treatment 
d Mitogen response to Con A, PHA and PWM mitogen 
e
 Increase was determined when the specific release exceeded twice the 
pretreatment value 
Mitogen stimulation of PBLs: Figures ЗА, В and С present the results 
of the mitogen stimulation assay. During the observation period, 5 of 
the 11 investigated patients showed at least once an increased 
activity ( > 20» compared to the pretreatment values) to Con A, PHA or 
PWM. Four patients with an increased reactivity to Con A, PHA and PWM 
belonged to the group of patients (N= 8) with a relapse of the disease 
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within 6 months. One patient with an increased response to PWM 
belonged to the group of patients (N= 3) with a relapse of the tumor 
after 6 months. After evaluation of 93 post-treatment samples, we 
concluded that the mitogen response of PBLs has no prognostic value 
for the clinical results after BCG treatment (table 7 ) . 
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Figure 3: 
Mitogenic response of PBL from 
patients with superficial 
bladder carcinoma after 
treatment with BCG. 
* Recurrence at 26 weeks 
Τ Timor free at 26 weeks 
+ Mean value 
NK-activity of PBLs; Figure 4 presents the results of the PBL a c t i v i t y 
of 14 patients to the К 562 c e l l l i n e , at a target/effector r a t i o of 
1:80. PBLs from 9 of the 14 patients (64Ä) showed an increased 
response after the BCG treatment. A patient was considered to have an 
increased NK-response, when the NK-activity measured, exceeded twice 
the pretreatment value at least once during the observation period. 
- 174 -
Five patients (50%) who had a recurrent tumor at 6 months showed 
increased NK-activity, as opposed to 4 patients (100Ä) who were tumor 
free at 6 montha. However, the initial cytotoxicity of the PBLs of 
tumor free patients was at a low level (figure 4 ) . This immunological 
parameter also showed no prognostic value for the clinical response 
after BCG treatment (table 7). 
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Figure 4 : 
NK-act iv i ty o f PBL froe 
pat ients w i t h s u p e r f i c i a l 
bladder carcinoma a f t e r 
treatment w i t h BCG. 
NK-act iv i ty was determined i n 
a 4 h . 5 1Сг-ге1еаэе aaaay at 
a t a r g e t to e f f e c t o r c e l l 
r a t i o o f 1:80. 
• Recurrence at 26 weeks 
Τ Tumor free at 26 weeks 
+ Mean value 
Suppressive factor i n serum; To measure the presence of suppressive 
a c t i v i t y i n serum, we compared 19 sera of patients with s u p e r f i c i a l 
bladder tumors versus 13 sera of healthy donors in a lymphocyte 
st imulat ion assay of PBLs obtained from a healthy donor. Figure 5 
shows t h a t , compared to the sera of healthy donors, the sera obtained 
from patients with s u p e r f i c i a l bladder tumors s i g n i f i c a n t l y suppressed 
the mitogenic response to Con A, PHA and PWM and the antigenic 
response to PPD. 
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DISCUSSION 
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(ve control aera) 
The recurrence rate of superficial bladder tumors after transurethral 
resection is considerable: 50-708. Adjuvant treatment using BCG 
reduces the recurrence rate significantly. The complete response after 
BCG therapy is approximately 70 procent (14). The response rate in our 
study is less favorable. This is probably due to the fact that we 
investigated selected patients, who showed strongly recurrent bladder 
tumors, resistant to several intravesical chemotherapeutic agents. In 
addition, the treatment schedule used for these patients, consisting 
of intravesical and intradermal administration of BCG during 6 
consecutive weeks, might suboptimal. Prolonged treatment (maintenance 
therapy) for one or two years is probably a more suitable treatment 
schedule for this group of patients (4, 8). Our own data (not 
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published), using maintenance therapy, indicate that this kind of 
therapy provides more favorable results in this group of patients. 
In several studies, in which patients with superficial recurrent 
bladder tumors were treated intravesically with BCG, the immune 
reactivity of the patient to BCG was subsequently measured by skin 
tests using PPD. Kelley et al. (21), Haaff et al. (14), Lamm (25) and 
Brosman (8) have shown a correlation between the development of a 
delayed type hypersensitivity response to tuberculin PPD antigen and 
the length of the tumor-free interval. Kelley reported that prolonged 
treatment resulted in the conversion of PPD skin tests from negative 
to positive, and was followed by a more favorable tumor response 
(21). However, Badalament et al. (4) were not able to detect a 
positive correlation between PPD conversion and antitumor response. 
Only a positive PPD reaction before and after BCG instillation was 
associated with delayed tumor recurrence. Several reports indicate 
that PPD conversion does not depend on the combined (intradermal and 
intravesical) BCG regimen, but that it can be achieved by intravesical 
treatment alone (4, B, 41). In our previous studies (22, 23), using 
intralesional BCG therapy for the treatment of ocular squamous cell 
carcinoma in cows, we were able to induce complete regression in 
60-70% of the carcinomas. In these studies we observed that 
longlasting PPD conversion was correlated with a longer tumor free 
period. In superficial bladder cancer our data may indicate that a 
prolonged PPD reaction correlates with a longer tumor-free interval. 
Furthermore, we observed that the major part of the patients, already 
PPD positive prior to treatment, did not show increased reactions to 
tuberculin PPD after BCG treatment (see table 2). 
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It might be expected that the in vitro lymphocyte stimulation to PPD 
correlates with the delayed hypersensitivity reaction in the skin to 
PPD. However, our results (figure 3, table 4) do not show that this in 
vitro assay has a predictive value for the course of disease. Winters 
and Lamm (53) suggested that the measurement of the antibody response 
to BCG during immunotherapy is as useful as PPD skin tests. However, 
our results are in contrast with this suggestion. Only 9 of the 23 
patients produced antibodies to mycobacteria and В of these 9 patients 
had a recurrence of the tumor within 6 months (table A). Moreover, 14 
patients who did not produce antibodies, showed a positive skin 
reaction, either before or after BCG treatment. We suggest that the 
differences in results are due to the BCG preparation itself. In a 
randomized study the therapeutic effect of BCG-Pasteur and BCG-RIVM 
was compared in patients with malignant melanoma (EORTC protocol 
18781). We found that the number of patients producing antibodies to 
mycobacteria was significantly reduced in the BCG-RIVM-treated 
patients compared to the BCG-Pasteur-treated patients (unpublished 
observations). BCG-Pasteur and BCG-Armand Frappier, used by Winters 
and Lamm, are produced in the same way. Both preparations are cultured 
as a surface pellicle, whereas BCG-RIVM is produced in a homogeneously 
dispersed culture (44). The major difference between both culture 
conditions is the harvesting procedure, as the surface grown pellicle 
needs to be disrupted in order to obtain small clumps of bacteria. 
Generally, a ball-mill is used for this procedure. However, this 
results in a higher rate of dead bacteria and subcellular debris and 
therefore in an increased amount of soluble antigens (43). It has been 
suggested that the presence of soluble antigens might interfere with 
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the response to BCG, but also with the adjuvant activity of the 
preparation (29, 43). Whether the skin reactivity to PPD can be 
replaced by measuring the antibody response to PPD, will probably 
depend on the intrinsic properties of the BCG preparation. 
It has been reported that PBLs of bladder cancer patients exhibit 
cytotoxic activity to bladder carcinoma target cells in vitro (10, 19, 
27, 37, 3B, 51). It was suggested that the PBls might be able to react 
with tumor associated/specific antigens of bladder tumor cell lines. 
Hakala et al. (16) demonstrated that the observed cytotoxicity was 
probably not related to tumor associated antigens alone. Moreover, 
Bolhuis et al. (5, 6) showed that PBLs activated in a mixed lymphocyte 
culture (MLC), lysed cells of the Τ 24 cell line, which indicates that 
recognition sites for lysis by NK-like cells, are present on Τ 24 
cells. We investigated NK-activity of the PBLs to the К 562 cell line 
and to the Τ 24 bladder carcinoma cell line. We found that the NK-
activity to the К 562 cell line could be demonstrated in the short 
4 h. assay. However, no cytotoxic activity could be measured at 4 h. 
using the Τ 24 bladder carcinoma cell line, which is in agreement with 
the observations of Bolhuis (6). In preliminary experiments we 
observed that after restimulation for 7 days with Τ 24, PBLs became 
prone to lyse Τ 24 at 4 h., whereas also the cytotoxic activity to 
К 562 increased. This activity was probably due to the lytic activity 
of activated NK-cells after allogenic stimulation with Τ 24 cells 
(6). Data on the cytotoxic activity of PBLs from BCG treated bladder 
carcinoma patients have been reported by Antonaca et al. (3) and Lamm 
et al. (26). Antonaca et al. showed that, after transurethral 
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resection, the cytotoxicity of PBLs to Τ 24 and HT 29 was decreased. 
After BCG treatment (intradermally and intravesically) the cytotoxic 
capacity was restored. Lamm et al. (26) investigated the reactivity of 
PBLs to Τ 24 antigens by measuring the inhibition of leukocyte 
migration. They observed that this lymphocyte reactivity was 
correlated with tumor recurrence. To our knowledge, no studies have 
been published on the NK-activity of PBLs in bladder carcinoma 
patients treated with BCG. Shapiro et al. (47) demonstrated that BCG 
instillations in mice resulted in a dose dependent increase in NK-
activity. However, when the NK-activity was abrogated in vivo by 
treatment with anti asialo GM antibodies, the antitumor activity of 
BCG was still present, suggesting that NK-cells are not a major 
contributor (43). In the present study the cytotoxicity of PBLs both 
to the Τ 24 and to the К 562 cell line increased in 50% and 64% of the 
investigated patients (N= 14), respectively. As most of the PBLs of 
patients reacting to the Τ 24 cell line also showed a reaction to the 
К 562 cell line, the cytotoxicity measured was probably evoked by 
activated killing activity (6). However, the observed increase of 
cytoxicity was not correlated with the clinical course of the disease 
(table 5). 
The presence of circulating antibodies against various human 
malignant tumors has been reported (1, 2B, 34, 35). Antibodies to 
membrane associated antigens have also been described in patients with 
superficial tumors of the urinary bladder (10, 15, 46, 48). In most of 
the reports, antibody formation was detected by the antibody dependent 
cell mediated cytoxocity test (ADCC). Studer et al. (4β) used a very 
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sensitive immuno-assay with molecules conjugated to avidin and 
biotine. We used the ELISA technique with tumor cells and soluble 
antigens. Although in these ELISA systems, mouse monoclonal antibodies 
against membrane associated antigens (24) showed reactivity, no 
increased antibody response was present in our patients after BCG 
treatment (table 8). 
To investigate the non-antigen specific (not BCG or tumor related) 
immune functions, we used monoclonal antibodies which distinguished 
leukocyte subsets as helper and suppressor/cytotoxic T-cells. BCG may 
activate T-cells resulting in T-suppressor or T-helper cell activity 
(20). We did not observe a significant increase or decrease in Th/Ts 
ratio. 
In several reports the T-cell mitogen response has been employed (7). 
Also this assay shows a broad biological variation. However, it has 
been reported that the responsiveness to Con A and PHA increases after 
therapy (including BCG therapy) and decreases after disease relapse 
(reviewed in 7). In our study, in comparison to the pretreatment 
values (figure 3, table 7), the response to Con A, PHA and PWM showed 
no marked differences after BCG therapy. 
Using the same mitogenic stimulation assay, we tested the presence of 
circulating suppressive molecules (figure 5). Humoral suppressive 
factors have been demonstrated in patients with malignant melanoma 
(16), leukemia (9), gastric cancer (49) and ovarian cancer (45). Our 
results indicate that an immunosuppressive factor also is present in 
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the serum of patients with superficial tumors of the urinary bladder. 
The relevance of this factor is unknown. We also detected an 
immunosuppressive factor in serum of cattle with ocular sguamous cell 
carcinoma. After surgical removal or complete regression of the tumor 
following intralesional therapy with BCG, this activity was still 
present after two years. These suppressive factors could be virion 
polypeptides (12, 32), alpha-glubulins (39), lymphotoxins (45), fatty 
acids (9) or circulating immune complexes. In cows with ocular 
squamous cell carcinoma, it was unlikely that these suppressive 
factors were produced by tumor cells (23). Further studies are needed 
to elucidate the impact of the presence of these factors in sera of 
patients with superficial bladder cancer. 
In conclusion, several comprehensive studies have been conducted in 
cancer patients in which the BCG therapy was accompanied by an 
examination of a number of immunological parameters (2, 36 and 
reviewed in 7). However, the results of the different studies vary 
considerably. In patients with superficial bladder tumors, we and 
other authors have shown that with regard to the clinical course of 
patients with superficial bladder tumors, the PPD conversion in PPD 
negative patients may be important. Although in a number of patients 
we measured an increase of cytotoxicty to Τ 24 and to К 562 target 
cells, this increase was not associated with the clinical results 
(tumor-free interval) after BCG therapy. All other immunological 
parameters investigated in the peripheral blood seem to be of minor 
relevance. 
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ABSTRACT 
This study presents the preliminary results of a randomized 
prospective two-arm study in which BCG RIVM, a Dutch BCG 
preparation, is compared with mitomycin С (MMC) in patients with 
primary or recurrent superficial bladder tumors, including carcinoma 
in situ (CIS). Therapeutic regimens were as follows: after complete 
transurethral resection of all visible tumors, BCG RIVM (IxlO9 
bacilli in 50 ml saline) was instilled once a week for six 
consecutive weeks, and mitomycin С (30 mg in 50 ml saline) was 
administered once a week for one month (weeks 1 to 4) and thereafter 
once a month for a total of six months. Reported are the incidence 
of side effects in 165 patients and the recurrence rate of tumors in 
308 patients after a follow-up period of twelve months. 
Drug-induced, or chemical, cystitis was observed in 13 (16.7%) of 7B 
BCG treated patients and in 12 (13.8%) of 87 MMC treated patients. 
In the seme groups bacterial cystitis occurred in 17 (21.8%) 
patients and in 16 (18.4%) patients, respectively. In the BCG 
treated group (N=148), 44 (29.8%) had recurrent tumors, while in the 
mitomycin group (N=160), 40 (25.0%) had a recurrence. The recurrence 
rate for BCG treated patients was 0.33; the recurrence rate for MMC 
treated patients was 0.29 (p=0.560, not significant). These 
preliminary data demonstrated no statistically significant 
difference between the two arms with regard to toxicity and 
recurrence of tumors. 
- 193 -
Prophylactic intravesical therapy following transurethral resection of 
superficial bladder cancer (Stages Ta, T1 and carcinoma in situ 
(CIS))significantly reduces the tumor recurrence rate and is 
beneficial in preventing tumor progression. 
Intravesical chemotherapy has been used for these purposes for almost 
two decades, and different agents have proven to be effective.^ 
Japanese studies, for example, have shown that superficial bladder 
cancer can be treated effectively by repeated intravesical 
instillations of mitomycin С (KMC).2 Clinical reports since then have 
demonstrated complete response rates between 4* percent and 77 
percent, following intravesical MMC.^-^ From these results it is 
concluded that MMC is one of the most potent agents for intravesical 
chemotherapy in the treatment of superficial bladder cancer. 
Since the first report in 1976 by Morales, Eidinger and Bruce? on the 
use of Bacillus Calmette-Guérin (BCG) intravesical immunotherapy, it 
has become evident that this form of adjuvant therapy is also 
effective. In fact, more recent reports have claimed that BCG is 
superior to other forms of intravesical chemotherapy and hence could 
be one of the most effective agents currently available, at least for 
the prophylactic treatment of superficial bladder cancer.β?' This 
suggestion, however, has not been fully supported by results of a 
sufficient number of prospective randomized clinial trials in which 
intravesical immunotherapy and chemoprophylaxis are compared. 
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Furthermore, several types of BCG vaccines — prepared from different 
BCG strains — have been used in different studies and it is not yet 
clear whether all of the strains are similarly effective. 
In this study, a Dutch BCG strain produced at the Rijksinstituut voor 
Volksgezondheid en Milieuhygiene (RIVM) (National Institute of Public 
Health and Environmental Protection) was investigated in the 
prophylactic management of superficial bladder cancer after 
transurethral resection. The BCG strain used for the RIVM vaccine was 
originally derived from a lot from the Pasteur Institute in Paris. 
Immunostimulation and antitumor activity by the BCG RIVM was observed 
both in experimental and spontaneous animal tumors.10-15 From these 
studies it became clear that an antitumor effect could be achieved in 
animals. 
Before attempting the use of BCG RIVM for intravesical 
immunoprophylaxia in superficial bladder cancer in humans, local and 
systemic toxicity studies were performed both in animals (dogs) and in 
man.'"',17 From those studies it was concluded that there was no 
systemic toxicity, and local toxicity was minimal. 
MATERIAL AND METHODS 
In January, 1985, a clinical trial was initiated to compare BCG RIVM 
with MMC. The study was a joint effort of the EORTC Genitourinary (GU) 
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Group and the Dutch Southeastern Urological Cooperative Group 
(protocol No. 30845). Comparison with MMC was chosen since at that 
time MMC was assumed to be the most potent, least toxic drug for 
intravesical chemotherapy.5,18 
The objective of the two-armed, prospectively controlled and 
randomized trial was to compare the prophylactic effect of 
intravesically administered BCG RIVM with that of MMC in patients with 
primary or recurrent superficial bladder tumors, including CIS. The 
parameters compared were recurrence rate, including evaluation of the 
number and size of recurrent tumors (the recurrence rate was defined 
as the number of cystoscopies at which recurrences were observed, 
divided by the number of months of patient follow-up); duration of 
disease-free interval; rate of progression to a higher stage (T 
category) of disease; and incidence and severity of side effects. 
Intradermal scarrification with BCG, initially thought to act 
synergistically with the intravesical administration to produce 
optimal prophylactic immunostimulation, was omitted in agreement with 
the observation by Brosman" and Herr et al.^, who suggested that 
percutaneous sensitization with BCG before the intravesical 
administration may not be necessary to achieve its effect. 
All patients with a primary or recurrent resectable Stage Ta or T1 
papillary transitional cell carcinoma (TCC) of the bladder, proved by 
histopathologic investigation, were admitted to the study. All visible 
lesions had to have been completely removed by differentiated 
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transurethral resection, and random biopsy specimen of the mucosa had 
to have been taken. Also eligible were patients with carcinoma in situ 
(CIS). Previous intravesical or systemic therapy with cytotoxic drugs 
excluded patients from entry, as did untreated urinary tract infection 
or recurrent severe bacterial cystitis. 
Patients were randomly allocated to BCG RIVM or MMC intravesical 
instillation, which started between seven and fifteen days after 
complete transurethral resection of all papillary superficial tumors. 
Study regimens were as follows: BCG (1 χ IO9 bacilli in 50 ml saline) 
was given once a week for six consecutive weeks, and MMC (30 mg in 
50 ml saline) was instilled once a week for one month (weeks 1 to 4) 
and thereafter once a month for a total of six months. Control 
cystoscopy was performed at three-month intervals for three years. If 
recurrence was observed at three months in the BCG group, the tumor 
was again completely resected and additional intravesical BCG therapy 
was restarted for six weekly instillations. If recurrence was observed 
in the MMC group, the tumor was totally resected and the MMC treatment 
was continued monthly. If, however, at 3 months an increase in Τ 
category to T2 or higher was observed, the patient was taken out of 
the study. Patients were removed from the study at their first 
recurrence after completion of intravesical treatment; i.e. at six 
months or thereafter. 
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RESULTS 
A total number of 337 patients took part in this study, which was 
closed October ist, 19Θ6. The toxicity data from 165 patients entered 
by the Dutch Southeastern Cooperative Group (enrolled by 14 
Institutions) were analyzed in January 1987. 
Stratification for CIS, and Stages Ta and TI, as well as for G 
category, number of tumors, primary and recurrent tumors was similar 
in both treatment arms (Tables I-IV). Local and systemic toxicity and 
comparison of the occurrence of bacterial and drug-induced, or 
chemical, cystitis by both number of patients and number of 
instillations are shown in Table V. Drug-induced cystitis was observed 
in 13 (16.7Й) of 7Θ BCG treated patients and in 12 (13.B%) of 87 MMC 
treated patients. In the same group, bacterial cystitis occurred in 17 
(21.85») patients and in 16 (18.4S) patients, respectively. No 
significant difference between the two treatment groups was observed. 
Severe systemic toxicity was absent in both treatment arms. The number 
of occurrences of allergic reactions is shown in Table V. Allergic 
reactions, requiring cessation of the therapy, was seen in 1 (1.3%) of 
78 BCG treated patients and in 6 (6.9%) of 87 patients of the MMC 
group. This analysis shows more frequent allergic reactions in the MMC 
arm. With regard to recurrence, the results are presented for 308 
patients after a follow-up period of twelve months (Table VI). In the 
BCG-treated group (N=148), 44 (29.8%) patients had recurrent tumors, 
while in the mitomycin group (N=160) 40 (25%) patients had a 
recurrence (Table VI). The recurrence rate for BCG-treated patients 
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was 0.33. For MMC-treated patients, the rate was 0.29 (P=0.560, not 
significant). 
These preliminary results demonstrate no statistically significant 
difference between the two therapeutic regimens. 
Table I. Protocol 30B45: pT category 
Therapy 
BCG RIVM 
MMC 
Totals 
No. 
pTis 
5 
5 
10 
of Pati 
рТа 
106 
107 
213 
enta 
pTI 
59 
55 
m 
Total No. 
Pts. (.%) 
170 (50.4) 
167 (49.6) 
337 (100) 
Table II. Protocol 30Θ45: G category 
Therapy 
BCG RIVM 
uur 
Totals 
GO 
3 
0 
3 
No. 
GI 
4B 
60 
108 
of Pat: 
GII 
90 
79 
169 
lents 
GUI 
27 
24 
51 
GX 
2 
4 
6 
Total No. 
Pts. (Ä) 
170 (50.4) 
167 (49.6) 
337 (100) 
Table III. Protocol 30B45: Number of tumors 
Therapy 
BCG RIVM 
MMC 
Totals 
0 
1 
1 
2 
No. 
1 
89 
89 
178 
of Pati 
2-3 
44 
41 
Θ5 
ents 
4-10 
36 
36 
72 
Total No. 
Pts. (») 
170 (50.4) 
167 (49.6) 
337 (100) 
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Table IV. Protocol 30Θ45: Primary/recurrent bladder cancer 
Therapy 
BCG RIVM 
MMC 
Totals 
No. of 
Primary (%) 
117 
118 
235 (69.7) 
Patients 
Recurrent (%) 
53 
49 
102 (30.3) 
Total No. 
Pts. (Й) 
170 (50.4) 
167 (49.6) 
337 (100) 
Table V. Protocol 30Θ45: Occurrences of chemical cystitis and 
bacterial cystitis and allergic reactions 
Chemical cystitis 
Total patients 
Occurrences 
Instillations 
Occurrences 
Bacterial cystitis 
Total patients 
Occurrences 
Instillations 
Occurrences 
Allergic reactions 
Total patients 
Occurrences 
Instillations 
Occurrences 
BCG 
No 
78 
13 
510 
32 
78 
17 
510 
29 
78 
1 
510 
2 
1. (*) 
(16.7») 
(6.ЗА) 
(21.8Й) 
(5.7S) 
(1.35ί) 
(0.4Ж) 
MMC 
No 
87 
12 
727 
28 
87 
16 
727 
23 
87 
6 
727 
14 
·. (S) 
(13.В») 
(3.9«) 
(18.H%) 
(3.2Й) 
(6.9%) 
(1.9S) 
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Table VI. Protocol 30845: Available follow-up until August, 1987 
BCG RIVM MMC 
Patients with follow-up 148 160 
Mean follow-up (months) 11.63 11.78 
Mean no. of cystoacopies 4 4 
Total number of recurrences 47 45 
Recurrence rate 0.33 0.29 
COMENT 
BCG immunoprophylaxis has become an important form of adjuvant 
treatment in superficial bladder tumors. Predictive factors of 
effective intravesical BCG prophylaxis include the ability of the host 
to react to mycobacterial antigens, small tumor load, and adequate 
numbers of living bacilli. Particularly important is the close contact 
between the bacilli and the tumor.20 
The clinically relevant mechanisms of action of immunotherapeutic 
agents are still unknown and their use remains largely empirical. The 
immunostimulating effect of intravesical BCG therapy is, however, 
clearly demonstrated by the local reaction in the bladder as well as 
by the conversion of the purified protein derivative (PPD) skin 
reaction, from negative to positive, which can be regarded as an 
expression of the systemic immune reaction to BCG. 
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Different vaccines prepared from BCG have been used for intravesical 
immunoprophylaxis. Apart from the BCG RIVM vaccine used in our study, 
several reports on other vaccines such as BCG Tice, BCG Armand 
Frappier, BCG Connaught, BCG Glaxo and BCG Pasteur have been 
published. All vaccines seem to have antitumor activity, with the 
exception of the Glaxo preparation, the negativity of which, according 
to Lamm, is probably due to a low number of viable organisms (personal 
communication, 1987). 
Kelley et al.21 investigated the efficacy of different strains and 
showed that there was a correlation between the development of a 
delayed hypersensitivity response to PPD antigen and treatment 
results. Thus, patients whose skin test converted from negative to 
positive remained significantly more free of tumor recurrence. 
It was also demonstrated that there was a relationship between 
treatment results and different lots of BCG. In fact, striking 
differences in the number of colony-forming units among BCG lots of 
the same preparation as well as among different preparations were 
revealed. Differences can range from 10^ to 1012 colonies per 
ampule.22 Furthermore, it is not only the number of bacilli present in 
the vaccine that is important but also the activity to multiply in 
vivo; i.e. the viability of the vaccine. 
It is not known whether the culture method of BCG might influence its 
efficacy in the prophylactic treatment of superficial bladder cancer. 
In general, two different culture methods are used: the first 
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(classic) way of preparing ВС G is to grow it as a surface culture. 
This surface pellicle is subsequently homogenized in a ball mill such 
that together with viable bacilli, subcellular debris and dead bacilli 
also are harvested. In the second method, BCG is grown in a 
homogeneously stirred deep culture medium. Bacteria are collected by 
centrifugation and resuspended. This culture method insures a 
relatively high ratio of viable organisms and a small quantity of 
subcellular debris and dead microorganisms; BCG RIVM is prepared 
according to the second method. 
Other preparations (Tice, Connaught, Armand Frappier) are cultured as 
a surface pellicle. It is possible that the difference in culture 
method is responsible for the significant difference in local side 
effects noted between BCG RIVM and other vaccines. In the present 
study, agent-induced cystitis was only seen in 16.7 per cent of the 
patients (comparable with the local toxicity of intravesical 
chemotherapy), whereas about 90 per cent of the patients complain of 
(transient) cystitis when the other strains are used.23 Qn the other 
hand, the question arises whether or not the efficacy of the 
preparation may be related to its local toxicity: the adherence of the 
bacilli to the bladder wall is probably an important factor by which 
BCG excerts its effect. It is therefore possible that subcellular 
debris or cell products are necessary to achieve attachment of BCG to 
the bladder wall.24 Ratliff et al.25 demonstrated that the protein 
fibronectin plays a role in the attachment of BCG. 
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The results pertaining to recurrence rate obtained so far in our 
study, although preliminary, do not indicate superiority of BCG RIVM 
over MMC. This is in contrast to other studies in which it has been 
demonstrated that BCG strains are superior to intravesical 
chemotherapy.8,26-28 However, additional prospective studies are 
indispensable to prove the superiority of one agent over another and 
of one regimen over another. For example, it is not yet clear whether 
six weekly instillations are suboptimal, as suggested by Haaff et 
al.29 it has also yet to be determined whether or not maintenance 
therapy is necessary. In general, treatment results have been more 
favorable with intensive regimens,8»'0 but the toxicity also has 
been substantially greater with intensive regimens. Recently 
Badalement et al.'l showed that BCG maintenance therapy does not 
improve the results, and Catalona et al.'2 showed that giving more 
than two courses of BCG therapy was not beneficial in patients who 
failed to respond after 2 six-week courses. 
These data indicate that several questions with regard to intravesical 
BCG therapy still remain. These questions can only be solved by 
conducting further prospective, randomized clinical trials to evaluate 
the prophylactic use of BCG in superficial bladder cancer. As far as 
the BCG RIVM vaccine is concerned, the most urgent question to be 
answered is whether or not this preparation, with its minimal 
toxicity, is as effective as other strains of BCG. A comparative 
protocol is therefore now being studied by the Dutch Southeastern 
Cooperative Group in which two different BCG preparations are compared 
with standard intravesical chemotherapy. The BCG Tice strain has 
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proven antitumor efficacy but its associated side effects cannot be 
ignored. The RIVM preparation has fewer associated side effects as 
well as proven antitumor activity. As in the first protocol, MMC has 
been chosen as standard intravesical chemotherapy. 
This and other studies will certainly contribute to further 
elucidation of the exact value of active non specific immunotherapy 
with BCG in the treatment of superficial bladder cancer. 
ACKNONLEDGQCNTS 
To all collaborating urologists, members of the EORTC-GU group 
(participating institutions were Ziekenhuis De Stadsmaten, Enschede; 
Ziekenhuis Ziekenzorg, Enschede; Juliana Ziekenhuis, Apeldoorn; Lukas 
Ziekenhuis, Apeldoorn; Malberg Ziekenhuis, Arnhem; Ziekenhuis 
Rivierenland, Tiel; St. Ignatius Ziekenhuis, Breda; St. Maartens 
Gasthuis, Venlo; De Wever Ziekenhuis, Heerlen; St. Radboudziekenhuis, 
Nijmegen; Willem Alexander Ziekenhuis, 's Hertogenbosch; St. 
Franciscua Ziekenhuis, Roosendaal; Ziekenhuis De Tjongerschans, 
Heerenveen; and Laurentius Ziekenhuis, Roermond), and their nursing 
staffs for their excellent contributions to this study; and thanks to 
Miss T. Moors and Mrs. D. Litjens-de Heus for assistance in preparing 
and typing the manuscript. 
- 205 -
1. Soloway M: Rationale for intensive intravesical chemotherapy for 
superficial bladder cancer. J Urol 123; 461-466 (1980). 
2. Mishina T, et al.; Mitomycin С bladder instillation therapy for 
bladder tumors. J Urol 114: 217 (1975). 
3. Bracken B, et al. : Role of intravesical mitomycin in management 
of superficial bladder tumors. Urology 16: 11-15 (19B0). 
4. Harrison GM5, et al.; A phase II study of intravesical mitomycin 
С in the treatment of superficial bladder cancer. Br J Urol 55: 
676 (19B3). 
5. Huland H and Otto U: Mitomycin instillation to prevent recurrence 
of superficial bladder carcinoma. Results of a controlled 
prospective study in 58 patients. Eur Urol 9: B4-86 (1983). 
6. Huland H, Otto U, Droese M, and Klöppel G: Long-term mitomycin С 
instillation after transurethral resection of superficial bladder 
carcinoma: influence on recurrence progression and survival. J^  
Urol 132: 27 (19B4). 
7. Morales A, Eidinger D, and Bruce AW: Intracavitary bacillus 
Calmette-Guérin in the treatment of superficial bladder cancer. 3_ 
Urol 116: 180-183 (1976). 
8. Brosman SA: Experience with bacillus Calmette-Guérin in patients 
with superficial bladder carcinoma. J Urol 128: 27-30 (19B2). 
9. Lamm DL, Thor DE, Stogdill VD, and Radwin HM: Bladder cancer 
immunotherapy. J Urol 128: 931-935 (1982). 
0. De Jong WH, et al. : Effects of bacillus Calmette-Guérin on 
natural killer cell activity in random bred rats, in Crispen RG 
(Ed.): Cancer Etiology and Prevention. Elsevier Science 
Publishing Co, Ine, Amsterdam, 1983, ρ 123. 
- 206 -
De Jong WH, et al.; Experimental screening of BCG preparation 
produced for cancer immunotherapy: safety and immunostimulating 
and antitumor activity of four consecutively produced batches. 
Cancer Immunol Immunother 17; 18-27 (1984). 
Klein WR, et al.; Immunotherapy by intralesional injection of BCG 
cell walla or live BCG in bovine ocular squamous cell carcinoma: 
a preliminary report. J Nat Cancer Inst 69; 1095-1103 (1982). 
Kreeftenberg JG, et al. ; Experimental screening of two BCG 
preparations produced according to different principles. 
Immunostimulating properties, safety and antitumor activity. 
Cancer Immunol Immunother 12: 21-29 (1981). 
Lagrange PH and Gheorghiu M: Antitumor activity of two BCG 
vaccine preparations against the lewis lung carcinoma in mice. 
Cancer Immunol Immunother 12: 217-224 (1981). 
Ruitenberg EJ, et al.; BCG preparations, cultured homogeneously 
dispersed or as surface pellicle, elicit different 
immunopotentiating effects but have similar antitumor activity in 
a murine fibrosarcoma. Cancer Immunol Immunother 11: 45-51 
(1981). 
Meijden van der АРМ, et al. : The effects of intravesical and 
intradermal application of a new BCG on the dog bladder. Urol Res 
14: 207-210 (19B6). 
Schreinemachers LMH, et al.; BCG intravesical and intradermal 
application. A phase I study to the toxicity of a Dutch BCG 
preparation in patients with superficial bladder cancer. Eur Urol 
14: 15-21 (1988). 
Soloway M: Rationale for intensive intravesical chemotherapy for 
superficial bladder cancer, in Kurth KH, et al. (Eds): Progress 
and Controversies in Oncological Urology. New York, Alan R Liss, 
1984, ρ 608. 
- 207 -
Herr HW, et al.; Long-term effect of intravesical bacillus 
Calmette-Guérin on flat carcinoma in situ of the bladder. J Urol 
135: 265-267 (1986). 
Zbar В and Rapp HJ: Immunotherapy of guinea pig cancer with BCG. 
Cancer 34; 1532-1536 (1974). 
Kelley DR, et al.; Prognostic value of purified protein derivate 
skin test and granuloma formation in patients treated with 
intravesical bacillus Calmette-Guérin. J Urol 135: 268-271 
(1986). 
Kelley DR, et al.; Intravesical bacillus Calmette-Guérin therapy 
for superficial bladder cancer: effect of bacillus 
Calmette-Guérin viability on treatment results. 3 Urol 134: 48-53 
(1985). 
Lamm DL, Stogdill VD, Stogdill BJ, and Crispen RG: Complications 
of bacillus Calmette-Guérin immunotherapy in 1278 patients with 
bladder cancer. J Urol 135: 272-274 (1986). 
Nickel JC, Morales A, Heaton JPW, and Costerton JW: 
Ultrastructural study of the interaction of BCG with bladder 
mucosa after intravesical treatment of bladder cancer. J Urol 
133: 268A (19B5). 
Ratliff TL, Palmer JO, McGarr JA, and Brown EJ: Intravesical 
bacillus Calmette-Guérin therapy for murine bladder tumors: 
Initiation of the response by fibronectin-mediated attachment of 
BCG. Cancer Res 47: 1762-1766 (1987). 
Lamm DL, et al.: BCG versus Adriamycin in the treatment of 
transitional cell carcinoma in situ: a South-west Oncology Group 
Study. J Urol 133: 1β4Α (1987). 
Netto MR and Lemos GC: A comparison of treatment methods for the 
prophylaxis of recurrent superficial bladder tumors. J Urol 129: 
33-34 (1983). 
- 20Θ -
2B. Shapiro A, Ratliff TL, Oakley DM, and Catalona WJ: Comparison of 
the efficacy of intravesical Calmette-Guérin with thiotepa, 
mitomycin-C, poly I: C/Poly L-Lysin and cisplatinum in murine 
bladder cancer. J Urol 131; 139-ПЗ (19B4). 
29. Haaff £0, Dresner SM, Ratliff TL, and Catalona WJ: Two courses of 
intravesical bacillus Calmette-Guérin for transitional cell 
carcinoma of the bladder. J Urol 136: 820-824 (1986). 
30. Brosman SA: The use of bacillus Calmette-Guérin in the therapy of 
bladder carcinoma in situ. J Urol 134: 36-39 (19Θ5). 
31. Badalement RA, et al. : A prospective randomized trial of 
maintenance versus nonmaintenance intravesical bacillus 
Calmette-Guérin therapy of superficial bladder cancer. 
J Clinic Oncol 5: 441-449 (19B7). 
32. Catalona WJ, et al. : Risks and benefits of repeated courses of 
intravesical bacillus Calmette-Guérin therapy for superficial 
bladder cancer. J Urol 137: 220-224 (1987). 
- 209 -

CHAPTER IX 
SUtWARY AND PROSPECTS 

This thesis presents data on the histological, immunological and 
therapeutic aspects of BCG-RIVM, used as a form of non specific 
immunotherapy in superficial bladder cancer. This Dutch 
BCG-preparation is produced by the Rijksinstituut voor Volksgezondheid 
en Milieuhygiëne (National Institute of Public Health and 
Environmental Protection, RIVM), Bilthoven, The Netherlands. 
In chapter I the characteristics and management of superficial bladder 
cancer are presented. After surgical ablation of tumors, adjuvant 
treatment is advocated, to prevent recurrent superficial tumors and/or 
progression to muscle invasive disease. Until now predominantly 
intravesical instilled chemotherapeutic agents were chosen to reach 
that goal, but since 1976, also BC G has been used as an adjuvant 
anti-tumor therapy. Conditions, warranted for successful anti-tumor 
therapy in animals, as were described by Zbar and Rapp (9), also are 
present in patients bearing superficial bladder tumors. This could be 
the reason why BCG is effective against this disease while it has no 
efficacy against most other human neoplasms. 
Chapter II presents an overview of BCG immunotherapy in superficial 
bladder cancer. The over-all complete response rate after BCG therapy, 
reported in literature is approximately 70 per cent. Although BCG has 
been used now for more than 10 years, no concensus has been reached on 
the treatment schedule, the optimal dose and the appropriate strain. 
The exact mechanism, how BCG exerts its anti-tumor activity has not 
been revealed yet. This indicates that a number of problems still have 
to be solved. 
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The histomorphological effects of intravesical BCG-RIVM administration 
in the intact bladder of the guinea pig, are reported in chapter III. 
The results indicate that BCG is able to act through the apparently 
intact epithelial layer of the bladder wall, inducing inflammatory 
infiltrates in the subepithelial layer of the bladder wall. These 
infiltrates consist of mononuclear infiltrates, in approximately 50% 
of the animals accompanied by non-caseating granulomatous lesions. A 
granulomatous inflammatory reaction also was observed in the primary 
draining iliac lymph nodes of the bladder but seldom in the lymph 
nodes stations beyond the primary nodes. Occasionally granulomas were 
found in the liver, lung and spleen, indicating that a generalized 
inflammatory response against BCG can occur. In these animals 
granulomas also were observed in distant lymph nodes. Such generalized 
inflammatory reactions are generally thought to be allergic in 
nature. From other experiments (5) it is known that attachment of BCG 
to the bladder wall is far more better when the bladder epithelium has 
been damaged e.g. by electrocautery. Our results, however, indicate 
that BCG is able to exerts its activity throughout an intact 
epithelial layer, thus inducing granulomatous lesions but also a 
systemic immunological reaction to BCG. 
To assess its toxicity, the local and general side effects of intra-
vesical and intradermal application of BCG-RIVM were evaluated in the 
dog. In chapter IV it is reported that intravesical and intradermal 
application of BCG-RIVM during six consecutive weeks, causes no 
serious local and systemic side effects. There was no significant rise 
in body temperature and haematological and chemical parameters 
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including renal and hepatic functions remained within the normal range 
in all animals. Small granulomas were observed in the subepithelial 
layer of the bladder wall. In contrast to the observations made in the 
guinea pig, no granulomas or signs of active inflammation were seen in 
the iliac lymph nodes, spleen and liver of the dogs. The difference, 
especially with regard to the histomorphological changes in the 
bladder wall and in the iliac lymph nodes between the guinea pig and 
the dog are problably due to the difference in susceptibility for 
mycobacteria between these animals (Θ). The DTH-reaction in the dogs 
remained negative, even after repeated intradermal and intravesical 
administration of BCG. 
After the assessment of the minor toxicity in the dog, the local and 
systemic side effects of BCG-RIVM were evaluated in a phase I study. 
In chapter V the results of 3D selected patients, who had a history of 
strongly recurrent superficial bladder tumors and who had been treated 
previously with different intravesical chemotherapeutic agents 
unsuccesfully, are reported. Our results indicate that intravesical 
and intradermal administration of BCG-RIVM, once a week for 6 
consecutive weeks was reasonably well tolerated. No severe local or 
systemic side effects were observed. Seven patients (24л) showed 
symptoms of malaise. In 1 out of 30 patients a local (inguinal region) 
lymph node enlargement was noted, due to the intradermal scarification 
on the upper thigh. In general, haematological and blood chemistry 
parameters remained within normal ranges during and after BCG 
therapy. At a total of 180 instillations, θ times mycobacteria were 
found in the urine of patients at 7 days after instillation. The 
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highest concentration of bacilli in the urine found at 7 days after 
instillation was 5x10^ c.p. Evaluating the systemic and local 
toxicity, we concluded that BCG-RIVM is a preparation with minor local 
and systemic side effects. It is likely that this limited toxicity is 
not due to the dose of BCG used (± 1χ1θ9 c.p.), which has been in the 
same range as in other reported clinical trials, but probably to the 
intrinsic properties of the BCG-RIVM preparation. 
In chapter VI the immune reactions in guinea pigs after intravesical 
administration of BCG-RIVM in an intact bladder are reported. Both 
specific immune responses against BCG itself and non specific immune 
responses e.g. mitogenic lymphocyte stimulation (ConA, PHA and LPS) as 
well as spontaneous cytotoxic activity (NK- and LAK-cell) were 
determined in the primary draining lymph nodes of the bladder and in 
the spleen. Even in low doses (1Cß c.p.) of BCG a PPD skintest 
conversion from negative to positive was observed after repeated 
instillations in the intact bladder. BCG immune lymphocytes were 
present locally both in the regional lymph nodes and in the spleen. No 
differences in mitogenic responses to ConA, PHA and LPS, nor 
spontaneous cytotoxic (NK-activity) were observed in the lymph nodes 
and/or in the spleen between BCG and placebo treated animals. Both in 
the lymph nodes and to a lesser degree in the spleen cells, lymphokine 
activated killer (LAK) cell activity could be induced. 
In patients treated with BCG, it is important to search for tools in 
order to predict which patient will be a responder or a non responder 
to BCG therapy. Therefore in the patients involved in the toxicity 
- 216 -
study (described in chapter V) the skin reactivity to PPD was tested. 
Furthermore, sera and PBL's of these patients were investigated in a 
range of immunological assays to study the immune response after BCG 
treatment and to evaluate the possible prognostic value of these 
tests. The results are reported in chapter VII. The absence of PPD 
skin test conversion or a transient reaction to tuberculin PPD was 
correlated with a recurrence of bladder tumors. Patients with a 
longlasting positive PPD skin test remained free of tumor recurrences 
for a significant longer period. Cytotoxicity of PBL's from patients 
to the bladder carcinoma cell line T24 and to the NK-sensitive K562 
cell line was increased in some of the patients, but this increase was 
not significant. The reactivity of PBL's to mitogens and subset 
distribution (ratio T-helper/T-suppressor cells) were not influenced 
by the BCG treatment. Antibody response to mycobacterial antigen after 
intravesical and intradermal BCG therapy was observed about h0% of the 
patients and most of these patients showed recurrent tumors within 6 
months. These observations are in contrast with the results obtained 
by Lamm (2), who suggested that measuring the antibody response to BCG 
is as useful as measuring PPD skin tests. Further investigations and a 
larger number of patients are needed to decide whether or not the use 
of immunological parameters in the peripheral blood are suitable as a 
diagnostic or prognostic tool during and after BCG therapy. 
Finally, to test the local and systemic side effects and particularly 
the antitumor activity of BCG-RIVM in a sufficient number of patients, 
a prospective randomized clinical trial was conducted to compare 
BCG-RIVM with Mitomycin-C, an intravesically used chemotherapeutic 
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drug in patients with primary or recurrent superficial bladder tumors, 
including carcinoma in situ. In chapter VIII the incidence of side 
effects of 165 patients and the recurrence rate of tumors in ЗОВ 
patients are reported after a follow-up period of twelve months. Drug 
induced or chemical cystitis was observed in 13 (16.755) of 7Θ BCG-RIVM 
treated patients and in 12 (13.8л) of 87 Mitomycin-C treated 
patients. In the same group bacterial cystitis occured in 17 (21.BK) 
patients and in 16 (18.45») patients respectively. In the BCG group 
(N= 148), 44 (29.85») had recurrent tumors, while in the Mitomycin 
group (N= 160), 40 (25.05») had a recurrence. The recurrence rate for 
BCG treated patients was 0.33 and for Mitomycin treated patients the 
rate was 0.29 (p= 0.560, not significant). 
These preliminary data demonstrate no statistically significant 
difference between the two arms with regard to toxicity and recurrence 
of tumors. It is expected that the results of local and systemic 
toxicity will not change anymore in the patients enrolled in the 
trial, since the accrual of patients had been closed on October the 
first 1986. This means that there have not been BCG instillations 
performed in patients randomized in this study after January the first 
1987. At this moment it is not passible to answer the question whether 
BCG-RIVM or Mitomycin-C is more effective as an adjuvant treatment in 
superficial bladder cancer. Therefore a longer follow-up period, at 
least 3 years, is warranted. 
In conclusion, the studies described in this thesis show several 
features of BCG-RIVM. In guinea pigs the BCG preparation was able to 
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induce both, at the application side itself (the bladder wall) and in 
the draining lymph nodes granulomatous reactions. Granulomas were also 
found in the bladder cold cup biopsies after BCG-RIVM treatment in 
patients (unpublished data). Immunologically, in guinea pigs a 
systemic reaction to BCG was induced as indicated by the PPD skin test 
conversion and the antigenic stimulation of spleen cells. Other non 
BCG related immune reactions such as mitogen reactivity and NK cell 
activity were not found increased. Similar results were obtained in 
patients with superficial bladder cancer. Regarding the immunological 
parameters investigated, only the PPD skin test was indicative for the 
clinical result. However, more studies are needed. BCG-RIVM induced 
minor local and systemic toxicity and equal antitumor efficacy 
compared to Mitomycin-C after a follow-up period of one year. 
PROSPECTS 
Regarding the conclusions of this thesis, the clinical use of BCG-RIVM 
for superficial bladder cancer has to be tested more intensively, 
especially in comparison with other BCG preparations. Therefore in 
April 19Θ7 a comparative study of intravesical instillation of 
Mitomycin-C, of BCG-RIVM and of BCG-Tice in pTa-pT1 papillary 
carcinoma and primary carcinoma in situ of the bladder was started. It 
is expected that this prospective randomized study will bring two 
important answers: 
1. Is the antitumor activity of BCG-RIVM, known as a safe strain with 
minor toxicity, comparable to BCG-Tice, a BCG preparation with 
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proven antitumor activity but sometimes marked toxicity. 
2. What is the efficacy of a well known BCG preparation (BCG-Tice) 
compared to the efficacy of one of the most potent chemotherapeutic 
drugs (Mitomycin-C) against superficial bladder tumors. 
More data are needed to evaluate which is the best therapeutic 
scheme. The six week course used initially, is an empirical one and 
until now there is insufficient data which instillation scheme is the 
most appropriate: a six week course, a repeated six week course or a 
six week course followed by monthly instillations (maintenance 
therapy). 
The intradermal BCG administration has been abandonned in the past but 
a possible additive influence of this route of administration on the 
antitumor activity has been investigated insufficiently in a 
prospective way. Therefore the efficacy of maintenance therapy with or 
without intradermal application using BCG-RIVM is tested currently in 
a clinical trial in which selected patients are enrolled who have 
strongly recurrent tumors and who have been treated unsuccessfully 
with intravesical chemotherapeutic agents. 
As far as the experimental plans for the future concerns, the 
following issues have to be considered. Few immunological studies, 
primarily in the peripheral blood of patients treated with BCG, have 
been performed. Anecdotal and also equivocal results have been 
encountered. More systemic studies are needed for the investigation of 
immunotherapeutic mechanisms in humans. The potential immune 
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mechanisms to be explored can be devided in two directions. First, the 
development of an antigen specific response to BCG may initiate a 
cascade of largely non specific immunological events, ultimately 
leading to tumor elimination. Secondly, BCG may have an adjuvant 
effect on the induction of tumor specific immunity. 
Killing of tumor cells may be mediated by cell mediated mechanisms 
e.g. natural killer cells, antibody dependent cell mediated 
cytotoxicity, lymphokine activated killer cells (LAK-cells), cytotoxic 
T-lymphocytes and macrophages. 
Soluble factors such as interferon, interleukin-2 and lymphotoxin / 
tumor necrosis factor may directly or indirectly kill tumor cells as 
well. The presence of interleukin-2 (IL-2) in the urine of patients 
treated with BCG has been reported (4). Also for BCG-RIVM the 
induction of IL-2 production was observed after the third and 
following BCG-RIVM instillations (unpublished data). The association 
between the presence of IL-2 and response to intravesical BCG therapy 
has not been proved yet but deserves more investigation. 
The induction of a local inflammatory response in the bladder wall and 
primary lymph nodes is correlated with an antitumor response (1). 
Characterization of these infiltrates, using monoclonal antibodies, 
could lead to more knowledge about what kind of cells are involved, 
and whether or not there is a possible difference between the 
composition of infiltrates of BCG responding and BCG non responding 
patients. 
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It has been shown that the glycoprotein fibronectin plays a crucial 
role in the attachment of BCG to the murine bladder wall (5). 
Quantitative studies revealed that BCG attachment is far more better 
in murine bladders damaged by electrocautery than in non damaged 
bladders. Attachment of BCG is possibly the requisite first step in 
the initiation of the antitumor response. It has been suggested that 
the culture method of BCG may influence the attachment capacity of BCG 
to fibronectin and by that to the bladder wall (7). The presence of a 
detergent in strains produced as a homogeneously dispersed culture was 
suggested to lead to a reduced binding capacity. In our laboratory 
preliminary studies were performed to test the binding capacity of 
BCG-RIVM, a homogeneously dispersed culture, BCG-Tice and BCG-Armand 
Frappier which both latter preparations are surface cultured 
preparations, not containing detergents. Using different 
concentrations of BCG the results did not show a significant 
difference of BCG particles in vitro on fibronectin coated coverslips 
between the three different preparations. Ratliff, however, observed a 
reduced binding capacity of strains containing detergents (6) in vitro 
and in the murine bladder. It is not known whether data obtained in 
the murine bladder are comparable to the human bladder. This question 
raises because a major difference in susceptibility was encountered by 
us investigating the immunological and histological reactions after 
intravesical BCG administrations in the dog and in the guinea pig. 
Furthermore, it is not known whether or not a tumor specific immunity 
occurs after BCG administration in patients with superficial bladder 
cancer. Particularly in this field more research has to be performed. 
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Finally it is expected that surface and transmission electronmicro-
scopy possibly may contribute to the mechanism how BCG reacts with the 
mucosa cells of the bladder and if and how it may penetrate the 
epithelial cells (3). Much is expected form collaborative efforts from 
urologists and research workers and step by step the intruiging puzzle 
will be unraveled. 
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Dit proefschrift behandelt de histologische immunologische en thera-
peutische aspecten van BCG-RIVM, toegepast als een vorm van niet 
specifieke immunothérapie bij oppervlakkig blaascarcinoom. Dit 
Nederlandse BCG-preparaat wordt geproduceerd door het Rijksinstituut 
voor Volksgezondheid en Milieuhygiëne (RIVM), Bilthoven, Nederland. 
In hoofdstuk I worden de karakteristieken en behandeling van opper-
vlakkig blaascarcinoom besproken. Na chirurgische therapie van de 
oppervlakkige tumoren (endoresectie) wordt een adjuvante behandeling 
geadviseerd om recidief tumoren te voorkomen en/of progressie tot 
invasieve tumoren te verhinderen. Tot recent werden hoofdzakelijk 
intravesicaal geïnatilleerde chemotherapeutica gekozen om dat doel te 
bereiken, maar sinds 1976 ia ook BCG gebruikt als een adjuvante anti-
tumor therapie. De voorwaarden, nodig voor een succesvolle antitumor 
therapie in dieren, zoals beschreven door Zbar en Rapp (9), zijn even-
eens aanwezig in patiënten die lijden aan oppervlakkige blaascarcino-
men. Dit zou de reden kunnen zijn waarom BCG effectief is tegen deze 
ziekte, terwijl geen overtuigende effectiviteit is vastgesteld tegen 
de meeste andere humane tumoren. 
Hoofstuk II geeft een overzicht van BCG immunothérapie voor oppervlak-
kig blaascarcinoom. De gemiddelde complete response rate na BCG thera-
pie bedraagt ongeveer 70% in de literatuur. Hoewel BCG gedurende meer 
dan 10 jaar wordt gebruikt, is er geen overeenstemming bereikt over 
het behandelingsschema, de optimale dosis en het meest geschikte 
BCG-preparaat. Hoe BCG zijn antitumor activiteit ontplooit, is nog 
steeds niet precies bekend. Dit betekent dat een aantal problemen nog 
moeten worden opgelost. 
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De histomorphologische effecten na intraveslcale BCG-RIVM toediening 
in de intacte blaas van de cavia, worden beschreven in hoofdstuk III. 
De resultaten geven aan dat BCG in staat is ontstekingsinfiltraten te 
induceren in de subepitheliale laag van de blaaswand, terwijl de 
mucosa ogenschijnlijk in tact is. Deze infiltraten bestaan uit mono-
nucleaire Infiltraten, die in ongeveer 50S der gevallen vergezeld gaan 
van niet verkazende granulomateuze lesies. Een granulomateuze ontste-
kingsreactie werd ook waargenomen in de primaire drainerende iliacale 
lymfklieren van de blaas, maar zelden in de lymfklieren voorbij de 
primaire stations. In enkele gevallen werden ook granulomata gevonden 
in de lever, long en milt hetgeen betekent dat een gegeneraliseerde 
ontstekingsreactie gericht tegen BCG kan voorkomen. In deze dieren 
werden ook granulomata gevonden in de lymfklieren voorbij de primaire 
stations. Deze gegeneraliseerde ontstekingsreacties worden beschouwd 
als een allergische reactie tegen BCG, aangezien geen mycobacteriën 
kunnen worden gekweekt uit de granulomata. Uit andere experimenten 
(15) is gebleken dat hechting van BCG aan de blaaswand sterk toeneemt 
als de blaaswand is beschadigd, bijvoorbeeld door electrocoagulatie. 
Onze resultaten echter geven aan dat BCG werkzaam is door een intacte 
epitheliale laag heen. Niet alleen granulomateuze lesies worden geïn-
duceerd maar ook ontstaat er een systemische immunologische reactie 
tegen BCG-RIVM (PPD conversie). 
Om de toxiciteit van BCG-RIVM zowel locaal als systemisch vast te 
stellen werden de bijverschijnselen onderzocht na intraveslcale en 
intradermale toediening bij de hond. In hoofdstuk IV wordt beschreven 
dat intraveslcale en intradermale toediening van BCG-RIVM gedurende 6 
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opeenvolgende weken geen ernstige locale en systemische bijwerkingen 
veroorzaakt bij de hond. Er werd geen significante stijging in de 
lichaamstemperatuur geconstateerd en de haematologische en chemische 
parameters, inclusief de lever- en nierfuncties bleven binnen de 
normale grenzen in alle dieren. Kleine granulomen werden gevonden in 
de submucosa van de blaaswand. In tegenstelling tot de observaties 
gedaan bij de cavia's werden geen granulomata of tekenen van actieve 
ontsteking gevonden in de iliacale lymfklieren, milt en lever van de 
honden. De histomorfologische verschillen aangetroffen in de blaaswand 
en de iliacale lymfklieren bij cavia en hond worden waarschijnlijk 
veroorzaakt door een verschil in gevoeligheid voor mycobacteriën van 
deze twee diersoorten (B). De DTH reactie in de honden bleef negatief, 
zelfs na herhaalde intradermale en intravesicale BCG toediening. Na de 
vaststelling van de minimale toxiciteit in de hond werden vervolgens 
de locale en systemische bijwerkingen van BCG-RIVM geëvalueerd in een 
fase I studie. 
In hoofdstuk V worden de resultaten van 30 geselecteerde patiënten 
beschreven die allen bekend waren met sterk recidiverende multipele 
oppervlakkige blaascarcinomen en die voorafgaand intravesicaal waren 
behandeld met meerdere chemotherapeutische middelen, zonder succes. 
Onze resultaten geven aan dat intravesicale en intradermale toediening 
van BCG-RIVM éénmaal per week gedurende 6 opeenvolgende weken, goed 
werd getolereerd. Er werden geen ernstige locale of systemische bij-
werkingen vastgesteld. Zeven patiënten (248) vertoonden symptomen van 
algemene malaise. Bij 1 patiënt werd een vergroting van de inguinale 
lymfklieren geconstateerd, veroorzaakt door de intradermale scarifica-
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tie op het bovenbeen. In het algemeen bleven de hematologische en 
chemische parameters in het bloed binnen normale grenzen tijdens en na 
BCG therapie. Op een totaal van 180 instillaties werden in В gevallen 
mycobacteriën gevonden in de urine van patiënten, tot 7 dagen na 
instillatie. De hoogste concentratie bacillen in de urine, 7 dagen na 
instillatie, bleek 5x10' c.p. te zijn. Wij concludeerden dat BCG-RIVM 
een BCG-preparaat is met minimale locale en systemische bijwerkingen. 
Het is aannemelijk dat deze beperkte toxiciteit niet veroorzaakt wordt 
door de dosis BCG (± 1x10^ c.p.) hetgeen ongeveer dezelfde dosis is, 
als die wordt gerapporteerd in andere klinische trials. Waarschijnlijk 
is de verminderde toxiciteit het gevolg van de intrinsieke eigenschap-
pen van het BCG-RIVM-preparaat. 
In hoofdstuk VI worden de immunologische reacties beschreven welke 
optreden bij cavia's na intravesicale toediening van BCG-RIVM in een 
intacte blaas. Zowel specifieke immuun reacties tegen BCG en niet spe-
cifieke immuun reacties zoals mitogene lymfocyten stimulatie (Con A, 
PHA en LPS) en spontane cytotoxische activiteit (NK- en LAK-cel) wer-
den bepaald in de primaire lymfklieren die de blaas draineren en in de 
milt. Zelfs in lage dosering (10^ c.p.) BCG, leverde een PPD huidtest 
conversie op van negatief naar positief, wanneer instillaties worden 
herhaald in de intacte blaas. Tegen BCG geïmmuniseerde lymfocyten wer-
den aangetroffen zowel, in de regionale lymfklieren van de blaas als 
in de milt. De mitogene respons tegen Con A, PHA en LPS en de spontane 
cytotoxische activiteit (NK-activiteit) bleken niet verschillend te 
zijn in dieren die met BCG dan wel met placebo waren behandeld. Zowel 
in de lymfklieren en in mindere mate in de miltcellen, kon lymphokine 
activated killer cell activity (LAK) worden geïnduceerd. 
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lymphokine activated killer cell activity (LAK) worden geïnduceerd. 
Bij patiënten die behandeld worden met BCG, is het belangrijk naar 
factoren te zoeken die zouden kunnen voorspellen welke patiënt een 
responder of niet-reponder voor BCG therapie zal zijn. Daarom werd in 
de patiëntengroep uit de fase II studie (zie hoofdstuk V) de PPD huid-
reactie onderzocht. Bovendien werden sera en perifere bloedlymfocyten 
van deze patiënten getest voor wat betreft hun immuunrespons na BCG 
behandeling. Beoordeeld werd of de resultaten een mogelijke prognosti-
sche waarde hadden met betrekking tot de lengte van het tumor-vrij 
interval. De gegevens worden gerapporteerd in hoofdstuk VII. Het ont-
breken van een PPD huidtest conversie of een slechts kort aanhoudende 
conversie bleek een correlatie te vertonen met het optreden van reci-
dief blaastumoren. Patiënten met een langdurige positieve PPD huidtest 
bleven langer vrij van tumorrecidief. Cytotoxiciteit van perifere 
bloedlymfocyten van patiënten tegen de blaascarcinoom cellijn T24 en 
tegen de NK-sensitieve K562 cellijn bleek te zijn toegenomen in 
sommige patiënten, maar deze toename was niet significant. De reacti-
viteit van perifere bloedlymfocyten tegen mitogenen en de onderlinge 
verdeling (ratio-T-helper/T-suppressor cel) werden niet beïnvloed door 
de BCG behandeling. Productie van antilichamen tegen mycobacteriële 
antigenen, na intravesicale en intradermale BCG therapie, werd gevon-
den in ongeveer 40S van de patiënten. Een meerderheid van deze patiën-
ten kregen een tumorrecidief binnen 6 maanden. Deze observaties zijn 
in tegenstelling met de resultaten verkregen door Lamm (2) die sugge-
reerde dat het meten van antilichaam respons tegen BCG even bruikbaar 
is als het meten van PPD huidreacties. Meer onderzoek en een groter 
- 231 -
aantal patiënten zijn nodig om te besluiten of de immunologische 
parameters in het perifere bloed bruikbaar zijn als diagnostische of 
prognostische factoren tijdens en na BCG therapie. 
Teneinde de locale en systemische bijverschijnselen en vooral de anti-
tumor activiteit van BCG-RIVM in een voldoende aantal patiënten te 
onderzoeken werd een prospectieve gerandomiseerde klinische trial 
gestart waarbij BCG-RIVM werd vergeleken met Mitomycine-C, een intra-
vesicaal toegepast chemotherapeuticum, bij patiënten met primair of 
recidief oppervlakkig blaascarcinoom, inclusief carcinoma in situ. In 
hoofdstuk VIII wordt de incidentie gemeldt van de bijverschijnselen 
van 165 patiënten, alsmede de recidieffrequentie van tumoren in 308 
patiënten na een follow-up periode van 12 maanden. Chemische cystitis 
(drug-induced) werd gezien in 13 (16,7K) van 78 BCG-RIVM behandelde 
patiënten en in 12 (13,8S) van 87 Mitomycine-C behandelde patiënten. 
In dezelfde groep trad bacteriële cystitis op in 17 (21,8%) en in 16 
(18,4X) van de respectievelijke patiënten. In de BCG groep (N= 148), 
vertoonden 44 (29,8%) recidieftumoren terwijl in de Mitomycine groep 
(N= 160), 40 patiënten (25,0SS) een recidief kreeg. De recidieffrequen-
tie voor BCG behandelde patiënten was 0.33 en voor Mitomycine behan-
delde patiënten 0.29 (p= 0.560, niet significant). Deze voorlopige 
resultaten laten geen statistisch significant verschil zien tussen de 
twee armen met betrekking tot de toxiciteit en de recidieffrequentie 
van tumoren. Het is te verwachten dat de resultaten van locale en 
systemische toxiciteit niet meer zullen veranderen bij de patiënten 
gerandomiseerd binnen deze trial, aangezien de aanmelding van patiën-
ten werd gesloten op 1 oktober 1986. Dit betekent dat er geen BCG-
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instillaties meer zijn uitgevoerd na 1 januari 19Θ7 in deze patiënten-
groep. Het ia niet mogelijk de vraag te beantwoorden of BCG-RIVM dan 
wel Mitomycine-C effectiever is als adjuvante behandeling van opper-
vlakkig blaascarcinoom. Hiervoor is een langere follow-up periode 
nodig, tenminste 3 jaar. 
CONCLUSIE 
De studies in dit proefschrift beschrijven verschillende aspecten van 
BCG-RIVM. In cavia's was BCG-RIVM instaat zowel in de blaaswand als in 
de drainerende lymfklieren granulomateuze reacties te induceren. 
Granulomata werden ook aangetroffen in blaasbiopsieën van patiënten na 
BCG-RIVM behandeling (niet gepubliceerde gegevens). Immunologisch werd 
een systemische reactie tegen BCG geïnduceerd in cavia's, hetgeen 
bleek uit een PPD huidtest conversie en de antigene stimulatie van 
miltcellen. Andere, niet BCG gerelateerde immuunreacties zoals de 
mitogene reactiviteit en NK-cel activiteit waren niet toegenomen. 
Dezelfde resultaten werden verkregen bij patiënten met oppervlakkig 
blaascarcinoom. Met betrekking tot de immunologische parameters die 
werden onderzocht, bleek alleen uitkomst van de PPD huidreactie te 
correleren met de lengte van het tumor-vrij interval. Meer studies 
zijn echter nodig. BCG-RIVM induceerde minimale locale en systemische 
toxiciteit. De antitumor activiteit van BCG-RIVM bleek gelijk te zijn 
aan die van Mitomycine-C na een follow-up periode van 1 jaar. 
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TOEKOMSTPERSPECTIEVEN 
Gelet op de conclusies van dit proefschrift zal de klinische toepas­
sing van het BCG-RIVM voor oppervlakkig blaascarcinoom uitvoeriger 
moeten worden onderzocht vooral in vergelijking met andere BCG-prepa-
raten. Daarom is er in april 19B7 een prospectieve gerandomiseerde 
3-armige studie gestart waarin Mitomycine-C, BCG-RIVM en BCG-Tice 
onderling worden vergeleken in de toepassing voor pTa-pTI papillair 
urotheelcelcarcinoom en primair carcinoma in situ van de blaas. Het is 
te verwachten dat deze prospective gerandomiseerde studie 2 belang­
rijke antwoorden zal brengen. Ten eerste: Is de antitumor activiteit 
van BCG-RIVM, bekend als een veilig preparaat met minimale toxiciteit, 
vergelijkbaar met BCG-Tice, een BCG-preparaat met bewezen antitumor 
activiteit, maar met soms aanzienlijke bijwerkingen. Ten tweede: Із de 
effectiviteit van een bekend BCG-preparaat (BCG-Tice) vergelijkbaar 
met de effectiviteit van een van de meest werkzame chemotherapeutica 
(Mitomycine-C) voor oppervlakkige blaastumoren. 
Meer gegevens zijn nodig om te evalueren welk therapeutisch schema het 
meest optimaal is. De 6-weekse cyclus is een empirisch schema en tot 
op dit moment zijn er onvoldoende gegevens welk instillatieschema op­
timaal is: een 6-wekelijkse cyclus, een herhaald 6-wekelijkae cyclus, 
of een 6-wekelijks schema gevolgd door maandelijkse instillaties 
(onderhoudstherapie). 
De intradermale BCG toediening is verlaten in het verleden maar een 
mogelijke additieve invloed van deze toedieningsweg op de antitumor 
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activiteit is onvoldoende onderzocht op prospectieve wijze. Daarom 
wordt de effectiviteit van onderhoudstherapie met of zonder intrader-
male toepassing momenteel getest in een klinische trial, waarin 
geselecteerde patiënten zijn opgenomen, die sterk recidiverende opper-
vlakkige blaastumoren hebben en die zonder succes met intravesicale 
chemotherapeutica zijn behandeld. 
Voor wat betreft de experimentele plannen voor de toekomst kan het 
volgende worden gezegd. Slechts weinig immunologische studies uitge-
voerd in het perifere bloed van patiënten behandeld met BCG zijn tot 
nu toe verrricht. Anecdotische en ook tegenstrijdige resultaten waren 
hiervan het gevolg. Meer systemiache studies zijn nodig om het immuno-
therapeutische mechanisme in de mens te onderzoeken. Potentieel kunnen 
de immuunmechanismen die moeten worden onderzocht, in twee richtingen 
worden verdeeld. Ten eerste kan de vorming van een antigeen specifieke 
respons tegen BCG een cascade van hoofdzakelijk niet-specifieke 
immunologische gebeurtenissen opgang brengen, uiteindelijk leidend tot 
eliminatie van de tumor. Ten tweede kan het BCG een adjuvant effect 
hebben op de inductie van tumor specifieke immuniteit. Eliminatie van 
tumorcellen kan plaatsvinden via mechanismen door cellen teweegge-
bracht zoals door natural killer cells, antibody dependent cell 
mediated cytotoxicity, lymphokine activated killer cells (LAK cells), 
cytotoxic T-lymphocytes en macrophagen. Humorale factoren zoals 
Interferon, Interleukine-2, Lymphotoxine/Tumor Necrosis Factor kunnen 
eveneens tumorcellen doden. De aanwezigheid van Interleukine-2 in de 
urine van patiënten behandeld met BCG is bekend (4). Ook na BCG-RIVM 
instillatie werd 11-2 productie aangetroffen, na de derde en volgende 
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BCG instillaties (niet gepubliceerde gegevens). De associatie tussen 
de aanwezigheid van 11-2 en de antitumor respons na intravesicale BCG 
therapie is nog niet bewezen, maar verdient meer aandacht. 
De inductie van een locale ontstekingsreactie in de blaaswand en pri-
maire lymfklieren wordt gecorreleerd met een antitumor respons (1). De 
karakterisering van deze Infiltraten met behulp van monoclonale anti-
lichamen zou kunnen leiden tot meer kennis omtrent de aard van de cel-
len die hierbij betrokken zijn, zowel bij patiënten die een gunstige 
en een niet-gunstige antitumor respons vertonen na BCG therapie. 
Ratliff heeft vastgesteld dat het glycoproteïne fibronectine een 
belangrijke rol speelt bij de hechting van BCG aan de blaaswand bij de 
muis (5). Kwantitatieve studies hebben aangetoond dat de hechting van 
BCG aanzienlijk beter verloopt in blazen die zijn beschadigd door 
middel van electrocoagulatie. De hechting van BCG aan de blaaswand is 
mogelijk een belangrijke factor in de initiatie van de antitumor 
respons. Mogelijk beïnvloedt de kweekmethode van het BCG-preparaat de 
hechtingscapaciteit van BCG aan fibronectine en hierdoor aan de 
blaaswand (7). De aanwezigheid van een detergens in preparaten 
geproduceerd als een homogene cultuur zou mogelijk een gereduceerde 
bindingscapaciteit teweegbrengen. In ons laboratorium werd de 
bindingscapaciteit getest van BCG-RIVM, een homogene cultuur, en van 
BCG-Tice en BCG-Armand Frappier, welke beide oppervlakculturen zijn 
die geen detergens bevatten. Gebruikmakend van verschillende 
concentraties BCG konden wij geen significant verschil aantonen in de 
hechtingscapaciteit van de verschillende BCG-preparaten in vitro op 
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fibronectine gecoate dekglaasjes. Ratliff echter vond een gereduceerde 
bindingscapaciteit van preparaten die detergena bevatten (6) in vitro 
en in de blaas van de muis. Het is onbekend of de resultaten verkregen 
in de blaas van de muis vergelijkbaar zijn met de humane blaas. Er is 
immers een groot verschil in gevoeligheid voor mycobacteriën tussen de 
verschillende diersoorten zoals door ons werd waargenomen bij de 
bestudering van de immunologische en histologische reacties, na 
intraveaicale BCG toediening in de hond en de cavia. 
Het is niet bekend of er een tumorspecifieke immuniteit ontstaat na 
BCG toediening in patiënten met oppervlakkig blaascarcinoom. Vooral op 
dit terrein is meer onderzoek nodig. Tenslotte is het te verwachten 
dat oppervlakte- en transmissie-electronenmicroscopie mogelijk kan 
bijdragen tot opheldering van het mechanisme hoe BCG reageert met de 
mucosacellen van de blaas en hoe BCG instaat is de epitheliale cellen 
te penetreren (3). Veel kan worden verwacht van de gezamelijke inspan-
ningen van urologen en onderzoekers en stap voor stap zal de intrige-
rende puzzle worden opgelost. 
Nijmegen, september 19ΘΘ. 
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B.C.G.-RIVM bacilli at the surface of a guinea pig bladder. 
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STELLINGEN BEHORENDE BIJ HET PROEFSCHRIFT: 
NON SPECIFIC IW4UNOTHERAPY NITH BCG-RIVM IN SUPERFICIAL BLADDER 
CANCER: HISTOLOGICAL, IIMMOLOGICAL AND THERAPEUTIC ASPECTS. 
A.P.M, van der Heijden 
1. Patiënten waarvan de PPD huidtest tijdens intravesicale BCG thera-
pie conversie vertoont van negatief naar positief blijven langer 
vrij van oppervlakkig blaascarcinoma als deze conversie langdurig 
aanhoudt. 
2. Aan immunologische reacties in het perifere bloed van patiënten 
die behandeld worden met intravesicale BCG-therapie kan geen voor-
spellende waarde worden toegekend met betrekking tot de effectivi-
teit van deze therapie. 
3. Voor de adjuvante behandeling van het oppervlakkig blaascarcinoma 
na transurethrale resectie is de effectiviteit en toxiciteit van 
intravesicaal BCG-RIVM vergelijkbaar met die van intravesicaal 
Mitomycine-C. 
4. De vrees voor frequente ernstige bijwerkingen van intravesicale 
BCG therapie is ongegrond,' maar urologen die BCG toepassen moeten 
op de hoogte zijn van tuberculostatische therapie. 
5. Gezien het histologische karakter en de localisatie verdient het 
aanbeveling de antitumor werking van BCG te onderzoeken bij het 
door Schistosomia haematobium veroorzaakte plaveiselcelcarcinoma 
van de blaas. 
6. Bij het optreden van microscopische haematurie dient de uroloog 
door middel van zorgvuldig sedimentsonderzoek de aanwezigheid van 
erythrocyten celcilinders uit te sluiten, vóórdat hij cystoscopie 
verricht. 
7. De chirurgische behandeling van het niercelcarcinoom in de 
solitaire nier kan beter geschieden door middel van een partiële 
nierresectie dan door enucleatie van de tumor. 
θ. Bevoogding van de derde geldstroom door overheid, faculteit of 
ziekenhuisdirectie leidt binnen het academische ziekenhuis tot 
afbraak van hoogwaardige research. 
9. De vooruitgang van het klinische onderzoek betreffende urologische 
maligniteiten hangt grotendeels af van de medewerking van niet 
universitair werkende urologen aan prospectief gerandomiseerde 
trials. 
10. De beste onderzoeksmethode ter detectie van een urologische afwij­
king in het scrotum is de transscrotale echografie. 
11. Voor de detectie van prostaatcarcinoom stadium A of В is het meten 
van prostatic specific antigen (PSA) in het serum niet zinvol. 
12. Patiënten met een ingewikkelde vorm van incontinentia urinae 
worden voor deze aandoening te vaak geopereerd. 
13. Door de toenemende toepassing van systemische chemotherapie bij 
infiltratief blaascarcinoma, zullen hersenmetastasen van deze 
maligniteit vaker worden gezien dan voorheen. 
14. De coördinatie van de waarschuwingslichten en de spoorwegbomen bij 
bewaakte spoorwegovergangen kan tot verwarring leiden bij de 
weggebruiker. Veel beter ware het de spoorwegbomen pas dan omhoog 
te laten gaan wanneer er zeker géén trein meer in aantocht is. 



